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CHAPTER I 
INTRODUCTION AND REVIEW OF THE LITERATURE 
I. INTRODUCTION TO HEPARIN 
A. History 
Heparin is a commonly used anticoagulant drug 
indicated for the prophylaxis and treatment of thrombo-
embolic disorders. Although it has been investigated for 
almost 70 years and been in clinical use for over thirty 
years, many questions remain relative to its pharm-
acodynamic actions (Jaques, 1979). 
The discovery of heparin is attributed to the 
serendipitous observations of Jay Mcclean, a medical 
student at Johns Hopkins working under the direction of 
professor W.H. Howell. Howell's inte~ests were in the 
investigation of natural thromboplastins. He assigned 
Mcclean the task of extracting and observing the activity 
of various phosphatides such as cephalin and a hepatic 
extract termed heparophosphatide. During these studies 
Mcclean noticed that the thromboplastic activity of the 
phosphatide was not only lost after prolonged storage, but 
actually prolonged coagulation times in his assay system. 
Further investigations by Howell and Holt, (1918) demon-
strated that these substances were also active after 
intravenous administration in dogs. Since these 
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substances were especially abundant in the liver, Howell 
named them heparins. Further characterization revealed 
that these substances contained no phosphorus and were not 
actually phosphatides, but rather sulfur containing carbo-
hydrates (Howell & Holt, 1928). These heparins demon-
strated weak anticoagulant activity and were to toxic for 
therapeutic use. 
using a different extraction method, Scott and 
Charles, (1933) reported that a relatively pure high yield 
of heparin could be obtained from beef lung. In this 
system, purification by tryptic digestion and alcohol 
precipitation removed protein and fatty contaminants. 
Additional work by Scott and Charles, (1936) resulted in 
the preparation of a crystalline form of heparin as either 
a barium or sodium salt. The enhanced efficiency of these 
• 
extraction and purification processes resulted in suf-
ficient quantities of suitable material for clinical 
evaluation. 
B. The Chemistry of Heparin 
Chemically heparin is best characterized as a family 
of linear anionic polysaccharide chains with a highly 
heterogeneous distribution of molecular weights. The 
molecular weights of the individual components generally 
range from 1,000 through 50,000 daltons. The mean 
molecular weight is usually between 9,000 and 15,000 
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daltons, however these figures vary with both the source 
and method of extraction. It has been shown that beef 
lung heparin has different molecular weight character-
istics compared to porcine mucosal heparin (Cifonelli & 
King, 1970 ; Bianchini et al., 1976). 
Reports from various investigators have shown that 
commercial heparin preparations contain at least 21 
discrete molecular species identifiable by electro-
focusing (Mc Duffie et al., 1975; Dietrich et al., 1975). 
Most likely twenty-one is the minimal number since the 
separation loses resolution at the longest chains. For 
this reason the number may be as high as 23 or 24. These 
molecular species vary in molecular weight, net charge, 
charge density and ratio of hexose residues. The 
heterogeneity within the components of heparin has been 
• 
shown to be a consequence of the natural synthetic process 
rather that an artifact of preparation (Cifonelli, 1974). 
A conceptual representation of the diversity of heparin is 
seen in appendix I. Recently, heparin preparations have 
also been shown to vary in terms of the proportion of 
individual molecular weight components (Barlow, 1983, 
1985) . Not only are heparins heterogeneous in terms of 
their composition of molecular weight components, but also 
in the distribution of these components. Thus, it is 
possible that heparins with similar mean molecular weights 
may differ in the relative proportion of individual 
3 
components. 
The polysaccharide chains of heparin are constructed 
with alternating residues of uronic acid (either L idur-
onic or o-glucuronic acid) and D-glucosamine monosac-
charide units joined via alpha 1-4 glycosidic linkages. 
These residues are sulfated and acetylated to a varying 
degree, however most glucosamine units possess an o-
sulfate at carbon six, while most iduronic acid residues 
are sulfated at carbon two. An o-sulfate group at carbon 
three is thought to be critical to the anti thrombin III 
binding sequence (Lindahl et al., 1980). A drawing 
representing the chemical structure of heparin is seen in 
appendix II. 
Commercial heparin is generally extracted from 
either bovine lung or porcine~ intestinal mucosa and 
• prepared as either a sodium or calcium salt. However, 
barium and potassium salts are also prepared. These 
metals are usually present at concentrations of about 12 
%. No difference has been observed in the pharmacologic 
properties between any of the different salt preparations 
and it is generally assumed that they are equivalent 
(Cocchetto and Bjornsson, 1984). 
C. Standardization of Heparin 
Due to the inherent variability within the sources 
and methods of manufacturing, it is necessary to standard-
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ize commercial heparin preparations in terms of biological 
actions. These actions are quantified in units of anti-
coagulant activity. 
The first unit was defined by Howell as the amount 
of heparin that would prevent the clotting of one ml. of 
freshly drawn cat blood overnight in the cold (Howell, 
1928). The Connaught unit was essentially similar to the 
Howell unit, however the potency was determined by 
comparison to a defined reference heparin preparation 
(Scott & Charles, 1933). The need for international 
standardization of heparin resulted in the establishment 
of the first international standard and unit of heparin in 
1942. The unit was defined as 1/130 mg of the inter-
national standard heparin preparation (prepared for and 
held by the World Health Organization Division of 
Biological Standards Geneva, Switzerland) • Since its 
origin, the international standard has been successively 
modified such that currently the fourth international 
standard is utilized. Unfortunately, no specific assay 
was described for use with the international standards. 
Consequently these standards have been used in a variety 
of assays for heparin's potency evaluation. Since the 
values of the international standards vary in different 
assay systems, the international standards have proven an 
unreliable method for the standardization of heparin 
(Brozovic & Bangham, 1974). 
5 
The U. s. Pharmacopeial Unit (USP) was originally 
defined as the amount of activity present in 1/130 mg of 
the second international standard heparin. Unlike the 
international unit, the USP unit utilizes a specific 
coagulant method to evaluate the potency of heparin. The 
assay measures heparin's inhibition upon recalcified 
activated sheep plasma (U.S. Pharmacopeia XX, 20th 
revision). Although this method relies on a semi-
quantitative visual evaluation of the clot endpoint, it 
has proven to be very reproducible among individual 
heparin preparations. 
The British Pharmacopeial (BP) assay has also been 
widely used for heparin potency evaluation and standard-
ization. This assay is based upon the inhibition of 
thromboplastin activated oxalatea ox blood by heparin. 
. . . When compared to USP standardized heparins, this assay 
gives higher results for lung heparins but lower values 
for mucosal heparins (Brozovic & Bangham, 1974). 
Recently, the USP has established an assay for 
standardizing heparin in terms of anti Xa uni ts. This 
assay measures the inhibition of standardized bovine 
factor Xa in the presence of heparin using a Xa specific 
chromogenic substrate. The amount of anti factor Xa 
activity per mg in USP units must not be less than 80 % 
nor more than 120 % of the potency of heparin in USP 
heparin uni ts per mg as determined by the assay 
6 
(Pharmacopeial Forum, 1984). 
o. overview of Coagulation 
In order to understand the mechanisms and sites of 
action of heparin, a basic comprehension of the coag-
ulation network is helpful. 
Blood coagulation occurs through a series of complex 
interactions between at least 15 distinct plasma glyco-
proteins. A description of the names, functions, approx-
imate molecular weights and normal plasma concentrations 
is listed in appendix III. With the exception of 
fibrinogen these glycoproteins are classified as either 
protein cofactors or enzyme precursors. The precursors 
circulate as non-activated zymogens and are converted to 
active enzymes upon proteolytic activation. Most of these 
enzymes are serine proteases • • which produce limited 
proteolytic cleavage at peptide bonds on the carboxyl side 
of arginine. 
In its most simplified form, the coagulation network 
can be represented as two distinct, but interacting 
pathways which result in the generation of thrombin. 
These pathways, the intrinsic and extrinsic are so 
designated based upon their mechanism of activation and 
are conceptually illustrated in appendix IV. 
Intrinsic activation is a surface mediated reaction 
which results when the contact factors (prekallikrein and 
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factor XII) are adsorbed to a negatively charged surface. 
such a negatively charged surface is provided in vitro by 
glass or kaolin and in vivo by collagen. The interactions 
between the contact factors and a negatively charged 
surface result in a conformational change which exposes 
the active serine site of the molecule. During this 
process, the contact factors are activated to the 
proteases kallikrein and factor XIIa. In the presence of 
the protein cofactor high molecular weight kininogen, 
factor XII a activates factor XI to XI a. A intermediary 
stage of intrinsic activation is then initiated when 
factor XIa activates factor IX. This is the first calcium 
and phospholipid dependent phase of intrinsic activation. 
Calcium and phospholipid are also necessary for the next 
step where factor IX a converts ~ factor X to Xa. The 
protein cofactor factor VIII is also required for this 
process. Factor X activation is also the first step of. 
the common pathway so designated because it is at this 
point that both intrinsic and extrinsic pathways converge. 
After the generation of factor Xa, factor II (prothrombin) 
is converted by Xa in the presence of the protein co-
factor, factor V, to IIa (thrombin). Finally, factor IIa 
converts f ibrinogen into soluble fibrin monomers and 
fibrinopeptides A and B. At this point the fibrin 
monomers are able to spontaneously polymerize, however 
they remain soluble (in 5 M urea) until acted upon by the 
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transaminase, factor XIIIa. 
Extrinsic activation results when factor VII comes 
into contact with the intracellular lipoprotein, tissue 
thromboplastin. Since this lipoprotein normally resides 
within cells, it is extrinsic to plasma. For this reason, 
initiation of coagulation by this mechanism has been 
termed extrinsic activation. 
Unlike other precursors of the coagulation enzymes, 
factor VII has been demonstrated to possess proteolytic 
activity (Zur, 1978). When tissue thromboplastin enters 
the blood, the proteolytic activity of factor VII is 
enhanced sufficiently to activate factor X (Nemerson, 
1983) • The activated factor X then catalyzes the 
conversion of VII to VIIa, thus creating an amplification 
loop. Factor VII-thromboplastin"' has also been shown to 
• 
activate factor IX, and by this mechanism may further 
amplify the initiation of coagulation by contributing to 
factor X activation (Osterud & Rapaport, 1977). Because 
of the powerful amplification mechanisms surrounding 
factor VII activation, it has been suggested that factor 
VII may be the key enzyme for the initiation of 
coagulation (Nemerson, 1983). 
Al though most of the proteins of the coagulation 
network are procoagulant, a variety of enzymes and 
protease inhibitors display some anticoagulant actions. 
Alpha-1 antitrypsin, C-1 esterase inhibitor and alpha-2 
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antiplasmin inhibit serine proteases by forming a 1:1 
stoichiometric complex which inhibits serine proteases 
upon association. Antithrombin III (discussed later in 
detail) also functions in this manner. When compared for 
their ability to inhibit thrombin, antithrombin III is the 
most potent of the aforementioned inhibitors. Alpha-2 
macroglobulin has also been shown to inhibit thrombin 
(Thompson & Harker 1983). 
Recently protein c, a vitamin K dependent protein, 
has been shown to be an important regulator of coagulation 
(Comp, 1984) • Upon activation by thrombomodulin bound 
thrombin, protein C exerts it's anticoagulant actions by 
digesting the active forms of factors V and VIII. 
A regulatory mechanism which functions after the 
formation of a clot, involves tlte enzyme plasmin. This 
• protein circulates as the zymogen plasminogen and can be 
activated to plasmin during contact activation or by the 
activity of various tissue plasminogen activators. After 
activation, plasmin can dissolve insoluble fibrin monomers 
and produce in clot lysis. The activity of plasmin is 
regulated by the inhibitors alpha2 antiplasmin and alpha2 
macroglobulin. 
E. Mechanism of Heparin's Action CAntithrombin III 
Dependent) 
It has been recognized for many years that heparin 
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requires the plasma protein antithrombin III for the 
expression of most of its anticoagulant effects. The 
initial observation of this cofactor was made by Howell, 
(1928) and Quick, (1938). It was observed that heparin 
tested against pure thrombin and fibrinogen had little 
effect. However when heparin was tested against thrombin 
in plasma, it was an extremely potent anti-thrombin agent. 
since this antithrombin activity of heparin in plasma 
could be destroyed by heating, it was hypothesized that 
the components necessary for the action of heparin were 
probably proteins (Howell, 1928 ; Quick, 1938). By 
separating the albumin and globulin fractions of plasma, 
the heparin cofactor activity was primarily found in the 
albumin fraction (Quick, 1938). These observations led to 
the hypothesis that components of the albumin fraction 
• 
contained anti thrombin activity and that the addition of 
heparin resulted in the intensification of these actions. 
Further biochemical characterization finally 
revealed that antithrombin III is an alpha2 globulin with 
a molecular weight of about 64, ooo (Abligaard et al., 
1967) . 
The observation that factor Xa as well as thrombin 
could be inhibited by a plasma protein and that this 
process was accelerated by heparin was reported by Biggs 
et al., (1970) and Yin et al., (1971). They concluded 
that the heparin accelerated factor inhibiting factor Xa 
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and thrombin were the same protein. These observations 
were confirmed by the studies of Rosenberg & Damus, (1973) 
and oamus et al., (1973) who offered the first mechanistic 
analysis of the actions of antithrombin. Using an extract 
of anti thrombin judged homogeneous by disc gel electro-
phoresis, SOS gel electrophoresis and immunoelectro-
phoresis they were able to demonstrate that anti factor Xa 
and antithrombin activities reside on the same molecule. 
The proposed mechanism for the inhibition of thrombin 
involves binding between arginine residues on antithrombin 
and the active serine sites of thrombin. The binding 
occurs in a stable 1 : 1 stoichiometric complex which is 
not dissociable by denaturing or reducing agents. Heparin 
accelerates this process by binding allosteric lysyl 
residues on antithrombin which result in a conformational 
• 
change providing a more favorable orientation of one or 
more arginines for interaction at the active site of 
thrombin (Rosenberg & Damus, 1973 . I Rosenberg, 1975 . I 
Damus et al., 1973 ). A critical tryptophan residue has 
also been proposed to reside within the heparin binding 
site (Blackburn & Sibley, 1980). This proposal is based 
upon the observation that modification of a single 
tryptophan residue blocks not only the binding of heparin 
to antithrombin, but also the heparin induced enhancement 
of thrombin inactivation. Since these actions can be 
accounted for by allosteric effects, additional 
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experimentation is necessary to prove the critical role of 
tryptophan (Blackburn & Sibley, 1980). 
The reactivity between arginine and active serine 
sites led to the hypothesis that the heparin-antithrombin 
complex should inhibit all serine proteases within the 
coagulation network (Rosenberg, 1975) • Consistent with 
this view, it has been demonstrated that in vitro, the 
heparin-antithrombin complex exerts it's anticoagulant 
effects by inhibiting factors XIIa, XIa, Xa, IXa and 
thrombin (Damus et al., 1973 ; Rosenberg et al., 1975 ; 
Snead et al., 1976 and Yin et al., 1971). The possible 
exception to this theory is the serine protease factor 
VIIa (Rosenberg et al. , 1977 & Jesty, 1978) • Although 
some investigators have reported inhibition of factors VII 
or VIIa by heparin-antithrombin.,. (Godal et al., 1974 
Broze & Majerus, 1980) I these observations are 
controversial and currently the subject of investigation. 
The heparin-antithrombin complex has also been shown 
to inhibit the serine protease plasmin (Highsmith et al., 
197 4) • 
F. Mechanisms of Heparin's Action 
Independent) 
CAntithrombin III 
Many investigators studying the anti thrombotic 
actions of heparin have reported that the in vitro 
anticoagulant actions of heparin are not always 
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quantitatively related to the in vivo antithrombotic 
actions. Furthermore, antithrombotic activity often shows 
poor relationship to antithrombin III affinity (Merton et 
al., 1984 ; Barrowcliffe et al., 1984). Consistent with 
these observations, Ofosu et al., (1982) have shown 
anticoagulant actions by low antithrombin affinity 
fractions. Using fractions prepared by antithrombin 
affinity chromatography methods, low affinity heparin 
inhibited activation of prothrombin, but did not inhibit 
factor Xa or IIa. Unlike the anticoagulant actions of 
high affinity heparin, this inhibition was not dependent 
upon the presence of antithrombin. The mechanism of the 
low affinity component in this action was attributed to 
disruption of the binding of factor Xa to phospholipid, 
ca++ and factor II by low affinity heparin. It was 
• 
concluded that the contribution by the low affinity 
component in terms of the overall antithrombotic effect of 
heparin was probably insignificant (Ofosu et al., 1982). 
Using similar affinity chromatographic methods it 
has been shown that about one third of commercial heparin 
binds with high affinity to antithrombin III (Holmer et 
al., 1981). If antithrombin III dependent mechanisms are 
solely responsible for heparins anticoagulant actions, 
then it would appear that almost two-thirds of the heparin 
mixture is inactive. In support of this view, removal of 
the high antithrombin III affinity fraction from· heparin 
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results in almost complete loss of the in vitro anti-
coagulant activity. Based on these observations, it was 
predicted that high antithrombin III affinity fraction of 
heparin would be a more effective in vivo antithrombotic 
agent than conventional heparin. Recently, several 
investigators have shown this not to be true. Merton et 
al., (1984) compared high affinity with unfractionated 
heparin for their ability to inhibit stasis induced 
thrombosis in a rabbit model. Although similar circulat-
ing anti Xa and clotting activity was observed, the 
unfractionated heparin provided greater protection from 
thrombosis that the high affinity fraction. The greater 
antithrombotic response of the unfractionated heparin was 
attributed to its content of low antithrombin affinity 
components. Further proof of th~ antithrombotic effects 
• 
of low affinity heparin was demonstrated by mixing low 
affinity with high affinity heparin. The addition of low 
affinity components restored antithrombotic potency to the 
high affinity fraction equivalent to unfractionated 
heparin (Merton et al., 1984 ; Barrowcliffe et al., 1984). 
These observations clearly indicate that at least a part 
of heparins antithrombotic effects are mediated through 
non anti thrombin III dependent mechanisms. Speculation 
about the nature of these mechanisms has included effects 
on endothelial cells, pro-fibrinolytic actions, anti-
coagulant actions mediated through heparin cofactor II, 
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effects upon blood viscosity and interactions with 
cellular components of the blood. 
1 • Heparin's Action on Endothelial Cells 
It has been demonstrated that heparin binds to 
endothelial cells both in vitro and in vivo (Mahadoo et 
al., 1977 ; Barzu et al., 1984). Because of their 
critical role in hemostasis, binding of heparin to endo-
thelial cells is thought to play an important anti-
thrombotic role which is indirectly independent of the 
antithrombin III mechanism. Recently, several inves-
tigators have shown that heparin like molecules exist on 
the surface of endothelial cells and are important 
determinants of the anticoagulant nature of these cells 
(Rosenberg, 1985). It is thought that anti heparin 
.. 
proteins such as platelet factor - 4 and histidine rich 
glycoprotein, constantly compete with anticoagulant 
proteins for the limited number of binding sites on these 
heparin like molecules. The binding of exogenous heparin 
to endothelial cells would alter this competition simply 
by creating additional binding sites (Rosenberg, 1985) . 
These additional binding sites could contribute to 
heparin's overall antithrombotic actions by increasing the 
difficulty for neutralizing the natural antithrombotic 
characteristics of endothelial cells by anti heparin 
proteins. 
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2 • Heparins Effect on Fibrinolysis 
A profibrinolytic action, resulting from heparin-
endothelial interactions may also contribute to overall 
antithrombotic effects. Heparin administration has been 
associated with an increase in fibrinolytic activity as 
demonstrated by decreased euglobulin lysis times, 
increased fibrin plate activity, increased circulating BB 
15-42 related peptides and increased circulating 
immunoreactive tissue plasminogen activator (t-PA) 
(Gaffney et al., 1982 ; Variel et al., 1983 ; Vinazzer et 
al., 1982 . 
' 
Fareed, 1985) • Although the mechanisms 
resulting in the increased fibrinolytic activity are not 
well understood, it is likely that several mechanisms are 
involved. Among the possible profibrinolytic mechanisms 
of heparin are direct release o'f t-PA from endothelial 
... 
cells, an increased synthesis of t-PA and inhibition of 
plasmin or plasminogen activator inhibitors (Fareed, 
1985). 
3. Heparin Cofactor II 
An additional heparin cofactor, similar to 
antithrombin III in composition and molecular weight has 
been recently identified (Griffith et al., 1983 . 
' 
Tollefsen et al., 1982) • This cofactor has been termed 
heparin cofactor II. Unlike antithrombin III, it is 
thought to inhibit only thrombin and not the other 
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proteases of the coagulation network inhibited by 
antithrombin III (Tollefsen et al., 1984). Like anti-
thrombin III, heparin cofactor II binds heparin and other 
sulfated polysaccharides in a 1 : 1 stoichiometric manner. 
The binding of heparin, chondroitin sulfate, dermatan 
sulfate, pentosan polysulfate or dextran sulfate results 
in a dramatic increase in the rate at which thrombin is 
neutralized (Yamagishi et al., 1986) •• 
Although in vitro, the heparin-heparin cofactor II 
complex inhibits thrombin, it's role as a physiological 
mediator of heparins anticoagulant actions is question-
able. Heparin cofactor II's concentration in the plasma 
is only about 1.0 micro molar, approximately half that of 
antithrombin III. Also, heparin cofactor II requires a 
two fold greater concentration of ileparin to neutralize an 
• 
equivalent amount of thrombin when compared to anti-
thrombin III. Consistent with these observations, animal 
studies indicate that after intravenous injection, 
thrombin is exclusively neutralized by antithrombin III 
(Tollefson, 1984). Thus it seems unlikely that under 
normal physiologic conditions, heparin cofactor II is a 
significant contributor to heparins anticoagulant actions. 
4. Heparin's Effect on Blood Rheology 
It is thought that anti thrombotic actions can be 
produced by agents which affect the rheology of blood 
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(Angelkort et al., 1979). Consistent with this, it has 
been suggested that a lowering in blood viscosity by 
heparin may contribute to it's overall antithrombotic 
effects (Kitsos et al., 1986 ; Reggiero et al., 1983 . I 
Copley and King, 1984). Preliminary reports by Kitsos et 
al., (1986) have demonstrated some reduction in whole 
blood viscosity by heparin and heparin fractions. These 
effects were only detectable using an extremely sensitive 
controlled stress rheometer. 
currently, the mechanism involved in heparin's 
effect on viscosity is not well understood, however it 
seems likely that cell membrane characteristics and plasma 
protein levels are altered. It has been hypothesized that 
both a reduction in plasma fibrinogen levels, as well as a 
direct effect on f ibrinogen may be responsible for 
• 
heparin's decrease in plasma viscosity (Ruggiero et al., 
1983 ; Copley and King, 1984). 
5. Cellular Interactions 
Several investigators have suggested that actions by 
heparin on cellular components of the blood may contribute 
to it's overall antithrombotic effects. Most reports have 
identified platelets and leukocytes as the components 
involved in these actions (Zucker, 1977 ; czarnetzki et 
al., 1980). 
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a. Platelets 
Platelets plays an important role in the development 
of both arterial and venous thrombosis. The former being 
more dependent on the activity of platelets than the 
latter. It seems likely that heparin affects this role 
since it is known to produce effects upon platelets both 
in vitro and in vivo. The exact nature of heparins 
influence on platelets and the resulting contribution to 
hemostasis is unclear at this time. Both stimulation and 
inhibition of in vitro platelet aggregation have been 
reported by heparin (Salzman et al., 1980 ; Gillett & 
Besterman, 1973). These effects appear to be dependent on 
the source of heparin, the individual platelets and the 
method of aggregation. 
Heparin has been suggested "'to exert anti thrombotic 
actions by inhibiting the adherence of platelets to 
subendothelial connective tissue. Evidence for this comes 
from experiments using heparin coated arterio-venous 
shunts in dogs . In these studies, heparin coated shunts 
remained patent longer and displayed a reduced 
accumulation of platelets (Zucker, 1977). 
b. Leukocytes 
Leukocytes have been suggested to play a role in 
blood coagulation. Although both anticoagulant and 
procoagulant activities have been reported, it seems 
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likely that leukocytes act in a procoagulant manner by 
stimulating thromboplastin production (Niemetz, 1972 
Lerner et al., 1977). Heparin has been shown to inhibit 
chemotactic factors involved in the migration of 
leukocytes (Czarnetzki et al., 1980). This inhibition may 
result in reduced thromboplastin production and by this 
action contribute to the overall anticoagulant action. 
G. The Pharmacokinetics of Heparin 
Heparin has been used clinically for almost 30 
years, yet its pharmacokinetics remain poorly understood. 
The difficulty in studying this complex problem originates 
from heparin's polycomponent nature (Estes, 1980) • 
Because heparin is not one molecule but rather a mixture 
of diverse molecules, a suitable method for measuring the 
• 
kinetics of all components does not exist. 
In an attempt to study the pharmacokinetics of 
heparin several investigators have utilized radio-
labelled heparin. The use of this method is questionable 
since it appears that the radioactive label may not 
distribute identically to the individual components of 
heparin. A greater proportion of label may bind to low 
molecular weight heparin species. This is suggested by 
results from radio-labelled studies which demonstrate a 
slightly larger volume of distribution (Estes, 1980). The 
larger distribution volume may also be explained by free 
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label resulting from migration off the heparin or 
metabolic degradation. 
In the absence of accurate direct kinetic 
measurements, a variety of bio-assays have been used to 
estimate the pharmacokinetics of heparin. These bio-assay 
methods utilize calibration curves to determine the plasma 
concentration of heparin. Most commonly, various 
activated clotting time assays are used in these studies. 
A brief review of the various bio-assays for heparin has 
been provided by Wessler and Gitel, (1979). 
comparison of pharmacokinetic studies using dif-
ferent bio-assays has demonstrated great variation. 
Results about absorption, volume of distribution (Vd) and 
clearance (Cl) vary significantly and are dependent upon 
the method of assay. 
.,, 
• 
In reviewing the pharmacokinetics of heparin it is 
important to mention some of the components with which it 
is likely to react in vivo. In the blood, heparin not 
only binds to antithrombin III, but also to many 
constituents of the plasma including fibronectin, albumin, 
fibrinogen, platelet factor-4 and histidine rich glyco-
protein (Dawes et al., 1985; Estes, 1980). The effect of 
binding by heparin to these plasma components upon the 
pharmacokinetics and pharmacodynamics is largely unknown. 
Heparin has also been shown to bind and be taken up by 
endothelial cells (Barzu et al., 1984 ; van Rijn et al., 
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1987)· 
1 • ,Absorption 
Because the molecules of heparin are so highly 
charged, it is not well absorbed from all routes of 
administration. Generally heparin is administered by 
either subcutaneous or intravenous routes. Intra-
pulmonary administration has also been shown to be a 
useful method (Bick and Ross, 1985). More recently, 
absorption of orally administered heparin has been 
reported (Ueno et al., 1982 ; Lasker, 1985 ; Larsen et 
al., 1986). Although there is wide variation in both the 
rate and extent of absorption after various routes of 
administration, the total amount of heparin required to 
achieve the same anticoagulant effect over equivalent time 
periods has been reported to be ·similar for intravenous, 
• 
subcutaneous and intrapulmonary routes (Cocchetto and 
Bjornsson, 1984). Similar data following oral adminis-
tration of heparin is not available, however preliminary 
data indicates that only low molecular weight molecules 
displaying anti Xa activity are recovered from the plasma 
(Larsen et al., 1986). 
2. Distribution 
Most studies have reported the Vd of heparin to be 
about 0.07 L/Kg (Estes, 1980). This volume approximates 
distribution to the plasma compartment, however slightly 
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larger distribution volumes have been reported depending 
on the method of assay. Bjornsson et al., (1982) demon-
strated the differences in Vd calculated from three assay 
methods. Significant differences were obtained, with the 
values obtained from chemical methods being slightly 
greater than those based upon coagulant assays. It should 
be mentioned that when 35s labelled heparin has been used 
to estimate Vd, volumes between those of extracellular and 
total body water are reflected (Estes, 1980). This is not 
an accurate reflection of heparins distribution volume and 
illustrates the inadequacy of radiolabelled heparin for 
such studies. The large Vd is explained by the loss of 
the radioactive label from the heparin molecule. 
Cellular uptake of heparin has been reported by 
several investigators (Mahadoo ana Jaques, 1979 ; Barzu et 
al., 1984). If these observations are true, they may 
explain reports indicating a volume of distribution for 
heparin which slightly exceeds the plasma compartment. 
The major cell populations responsible for heparin uptake 
were reported to be macrophages and endothelial cells. 
3. Half-life and Clearance 
Unlike many drugs, heparin exhibits dose dependent 
pharmacokinetics (Estes, 1980 ; Bjornsson et al., 1982 ; 
Raasch, 1980 ; Cocchetto and Bjornsson, 1984). Half-life 
increases with increasing dose in humans and animals with 
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no Michaelis-Menton type kinetics being apparent 
(Cocchetto and Bjornsson, 1984). After administration to 
normal volunteers, the half-life of heparin is about 1.5 
hours, however reports have ranged from 23 minutes to 2.48 
hours depending on the dose and method of assay (McAvoy, 
1978). Clearance rates have been reported at about 0.5 to 
o.6 ml/min/Kg (Estes, 1980). Most investigators have 
emphasized the many variables affecting heparins half-life 
and clearance, thus estimates of its true values are 
difficult. 
Recently it has been shown that different delivery 
systems may affect the half-life of heparin. Using 
heparin encapsulated in liposomes, a half-life up to three 
times that of non-encapsulated heparin was observed after 
intravenous administration (Kim., et al., 1986). The 
• 
prolonged half-life was attributed to gradual release of 
the heparin from liposomes trapped within the reticulo-
endothelial system. 
4. Metabolism and Elimination 
The metabolism and elimination of heparin are rather 
poorly understood due to heparins polycomponent nature. 
Unlike more conventional drugs, metabolites of heparin are 
not readily identifiable. Heparin metabolism involves 
depolymerization and desulfation by a variety of heparin-
ases, desulfatases and endoglycosidases. Thus during 
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metabolism, high molecular weight components may be 
metabolized to molecules resembling non-metabolized low 
molecular weight species. 
Heparin is primarily eliminated by the reticulo-
endothelial system, liver and kidneys. Evidence for this 
is found in the prolonged anticoagulant effects observed 
in nephrectomized and hepatoectomized animals (Cocchetto 
and Bjornsson, 1984). The reticuloendothelial system has 
been associated with this process largely because it is 
the only system which can account for the reports of 
variation and dose dependent nature of heparins half-life 
(Estes, 1980). 
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II· THE MOLECULAR WEIGHT DEPENDENT EFFECTS OF HEPARIN 
A. Fractionation 
As previously discussed, there are a variety of 
oligosaccharide chains of differing molecular weight 
within any given heparin preparation. Assuming that 
individual molecular weight components differ in their 
biological function, many investigators have studied the 
biologic actions of heparin as a function of molecular 
weight. To accomplish this task, various fractionation 
techniques have been employed to create molecular weight 
fractions. The most commonly employed fractionation 
techniques have been gel-filtration chromatography or 
depolymerization with either nitrous acid or heparinase. 
The depolymerization methods typically result in end 
residues which are characteristic of the process (Casu, 
1984) • Heparinase an enzyme from Flavobacterium 
heparinum, splits glycosidic bonds between N - sulfated 
glucosamine and iduronic acid 2 - sulfate. This process 
results in fragments which terminate with 4 , 5 - un-
saturated iduronic acid at the non reducing end and N-
sulfated glucosamine at the reducing end. Using heparin-
ase, more that 90 % of a commercial heparin has been shown 
to be digested to a hexasaccharide (Jaques, 1978, 1978). 
Nitrous acid is less specific than heparinase 
digestion and splits glycosidic bonds between N - sulfated 
glucosamine and any kind of uronic acid. This results in 
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fractions with 2, 5 - anhydromannose at the reducing end 
ccasu, 1984). 
under carefully controlled conditions, the use of 
both heparinase and nitrous acid results in the production 
of low molecular weight compounds without major deviation 
from the original glycosaminoglycan structure (Coyne, 
l985). Because of these characteristics, both depolymer-
ization techniques have been utilized in studies on the 
molecular weight dependent effects of heparin. 
Unlike heparinase and nitrous acid digestions, gel 
filtration chromatography does not in any way alter the 
native chemical composition or structure of heparin. For 
the separation of various molecular weight components, gel 
filtration depends on a size exclusion principal. During 
the gel filtration process, the individual heparin 
• 
molecules elute at a rate dependent upon their size. High 
molecular weight species elute at a faster rate than those 
of low molecular weight. Thus depending upon the size 
exclusion properties of the gel, an effective separation 
based upon molecular weight can be achieved. Using this 
technique, only natural fractions are separated from the 
original preparation. These characteristics contribute to 
the effectiveness of gel filtration a fractionation 
technique for studying the molecular weight dependent 
effects of heparin. 
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In Vitro Studies B· 
Molecular Weight Dependent Inhibition of Thrombin 1. 
Initial studies largely utilized gel filtration 
techniques to fractionate a single source of heparin into 
molecular weight fractions (Scott et al., 1957 ; Laurent, 
1961 and Lasker, 1966). 
using gel filtered molecular weight fractions in 
whole blood or plasma clotting assays, some correlation 
was observed between molecular weight and heparin's 
anticoagulant activity (Laurent, 1961). Generally, 
higher molecular weight heparins were more potent than 
those of lower molecular weight, however variation was 
observed with both the source of heparin and the assay 
utilized. Correlations between molecular weight and 
anticoagulant activity were consistent only between 
molecular weights of 11,000 - 4,000 daltons (Scott et al., 
1957; Laurent, 1961; Lasker and stivala, 1961). 
Additional studies by Laurent et al., (1978) and 
Shen et al., (1978) utilized gel matrices with differing 
size exclusion properties to study molecular weight 
dependent effects over a greater range of molecular 
weights. Fractionation of single sources of porcine 
mucosal and beef lung heparin yielded fractions ranging 
from 36,000 - 5,600 daltons. Using these gel filtered 
fractions, anticoagulant activity determined by both a 
whole blood clotting and a amidolytic antithrombin assay 
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demonstrated a molecular weight dependence in ranges from 
7 , soo through about 16, 500 dal tons. Molecular weights 
above 16,500 did not exhibit an increase in anticoagulant 
activity with increasi.ng molecular weight. Both inves-
tigators reported that the lowest molecular weight 
fractions (< 5,600 & < 6,200) did not show any significant 
anticoagulant activity. It is interesting to note that a 
molecular weight of about 5,600 correlates well with the 
minimum size of heparin necessary to accelerate thrombin 
inhibition in the presence of antithrombin (Costa et al., 
1981) • This observation, along with reports of anti Xa 
activity at even lower molecular weights, suggest that the 
molecular weight dependent effects reported by Laurent et 
al., (1978) and Shen et al., (1978) largely reflected the 
molecular weight dependent effects of heparin upon 
thrombin. 
The relationship of molecular weight to thrombin 
inhibition was thought to relate to the necessity of 
heparin binding simultaneously to both anti thrombin III 
and thrombin for maximal inhibition (Nordenman et al. , 
1978 ; Porter et al., 1976 ; Wilson-Gentry and Alexander, 
1973) . Since heparin is a linear polysaccharide, higher 
molecular weights are equated with longer chains. With 
increasing chain length, there is also increased prob-
ability that the chain will be of sufficient length to 
bind both anti thrombin III and thrombin. More recently 
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oosta et al., (1981) have shown that heparin fragments of 
about 14 monosaccharide residues are capable of catalyzing 
thrombin inactivation. Using heparin fragments of various 
length, the kinetic rate constants for the inactivation of 
thrombin by antithrombin heparin were studied as a 
function of the length of the heparin fragment. Hexasac-
charide, octasaccharide and decasaccharide sequences 
displayed no effect on the rate of thrombin inactivation 
although they were found to bind tightly to antithrombin 
III. Heparin fragments of longer length ( 14 residues) 
bound to antithrombin with equal affinity, but were 
capable of catalyzing thrombin inactivation. Using a 
slightly longer heparin fragment, additional rate 
enhancement of thrombin inactivation was observed. These 
findings suggested that both fragments possessed similar 
ability to activate antithrombin relative to thrombin 
inactivation, however the larger fragment possessed an 
additional structural element which may have contributed 
in approximating free enzyme with protease inhibitor 
(Oosta et al., 1981). 
The direct binding of heparin to thrombin provided a 
partial explanation of the molecular weight dependent 
effects of heparin. Additional explanations of the 
molecular weight dependent actions of heparin upon 
thrombin were thought to involve binding to antithrombin 
III. It has been proposed that molecular weight dependent 
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effects may relate to the probability of finding the 
antithrombin III binding site (Laurent et al., 1978). If 
a specific sequence of heparin is required to bind to 
anti thrombin III, then the anticoagulant activity should 
be related to the probability of finding that sequence on 
the heparin molecules. This theory assumed equal prob-
ability of these sequences occurring along the heparin 
chains. Al though these assumptions provided an explan-
ation of the molecular weight dependent effects of 
heparin, additional factors were thought to be involved 
based on studies using high antithrombin III affinity 
heparin. Since these fractions were already selected for 
their ability to bind antithrombin III, it was proposed 
that they should no longer display molecular weight 
dependent effects. However, a high correlation between 
• 
molecular weight and anticoagulant activity was still 
observed in these fractions. 
2. Molecular Weight Dependent Inhibition of Xa 
A molecular weight dependence to the inhibition of 
factor Xa has also been reported (Lane et al. , 1978 ; 
Andersson et al., 1978 ; Thunberg et al., 1979). As with 
investigations involving thrombin, gel filtered fractions 
of heparin were utilized in these studies along with 
specific anti Xa assays. Unlike the antithrombin effects 
of heparin, the specific activity per unit weight of 
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heparin increased with decreasing molecular size in both 
amidolytic and clot based assays (Andersson et al., 1979 ; 
Lane et al., 1978 ; Graham and Pomeroy, 1979). Interest-
ingly, this negative correlation between molecular weight 
and anti Xa activity was observed in plasma but not in 
purified systems (Andersson et al., 1979). In the 
purified system, the molecular weight dependence resembled 
that of thrombin where higher molecular weights resulted 
in greater inhibition (Andersson et al., 1979 and Ellis et 
al., 1987). Investigation of this discrepancy between 
plasma and purified systems revealed that the high 
molecular weight anti Xa components were preferentially 
neutralized in plasma (Anderssom et al., 1979). Ellis et 
al., ( 1987) speculated that this effect may be due to 
interactions with lipoproteins. - This neutralization 
• 
sharply decreases at low molecular weights, thus the 
increased anti Xa potency of low molecular weight heparin 
is primarily due to a decreased neutralization of this 
component in plasma. These observations are also 
consistent with reports of differential neutralization of 
various molecular weight heparins by protamine (Hubbard 
and Jennings, 1985 . 
' 
Holmer and Soderstrom, 1983 . 
' 
Racanelli et al., 1985). All investigators observed 
resistance by the anti Xa component of heparin to 
neutralization by protamine. Al though the addition of 
protamine to heparin did result in a measurable reduction 
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of the anti Xa activity, complete neutralization was never 
observed (Holmer and Soderstrom, 1983) • Similar 
observations were reported for the ability of platelet 
factor - 4 to neutralize the anti Xa activity of heparin 
(Lane et al., 1984). 
The observation that low molecular weight heparin 
displays such high anti factor Xa activity also suggests 
that unlike thrombin, direct binding of heparin to factor 
xa is not necessary for maximal inhibition (Andersson et 
al., 1979 ; Thunberg et al., 1979). This speculation has 
been confirmed by kinetic studies on the rate of 
enhancement of factor Xa inhibition in the presence of 
antithrombin and low molecular weight heparin (Jordan et 
al o I 1980) o These studies demonstrated that the heparin 
induced acceleration of Xa inhibition by antithrombin III 
• is solely dependent upon the binding of heparin to this 
inhibitor. 
The effects of specific heparin fragments from the 
same source of unfractionated heparin on factor Xa 
inhibition were reported by Oosta et al., (1981). Hexa-
saccharide, octasaccharide and decasaccharide displayed a 
significant capacity to accelerate factor Xa inhibition in 
the presence of antithrombin. A distinct relationship 
between the molecular size of these fragments and their 
biologic activity was observed. Increasing chain length 
resulted in increasing activity. This relationship was 
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consistent from the hexasaccharide to a sequence 
containing about 16 monosaccharide residues. Interest-
ingly, the affinity of these fragments to antithrombin as 
determined by a competitive binding assay also increased 
as a function of molecular size. (Costa et al., 1981). 
3. Molecular Weight Dependent Effects on Other Coagulation 
Factors 
The majority of studies investigating the molecular 
weight dependence of heparin utilized global clotting 
assays such as the APTT or the British Pharmacopoeia 
assay. These tests reflected multiple effects upon the 
coagulation system and did not demonstrate actions upon 
individual proteases. When factor specific amidolytic 
assays were used to investigate the molecular weight 
... 
dependent effects of heparin, similar effects as observed 
in the global assays were reported for the inhibition of 
thrombin. A different pattern of molecular weight 
dependence was observed for the inhibition of factor Xa. 
These observations led to speculation about the molecular 
weight dependent effects on the other coagulation factors 
known to be inhibited by heparin. 
Holmer et al., (1981) reported the effects of gel 
filtered molecular fractions of heparin on coagulation 
factors XIIa, XIa, Xa, IIa, and Kallikrein in amidolytic 
and clotting assays specific for these factors. As with 
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previous reports' anti IIa potency increased with 
increasing molecular weight. An inverse relationship was 
observed for anti Xa activity. Potency appeared to 
increase with decreasing molecular weight. The relation-
ships between molecular weight and potency of the other 
coagulation factors could be classified as resembling 
those of either factor Xa or thrombin (Holmer et al. , 
1981). 
Factors IXa and XIa resembled thrombin in that the 
specific activity of the heparin increased with increasing 
molecular weight. These reports were consistent with 
observations indicating that the inhibition of factor IXa 
is dependent upon binding of heparin both to antithrombin 
III and directly to the free enzyme (Jordan et al., 1980). 
Kallikrein and factor XIIa resembled factor Xa in 
• 
that the inhibition of these factors was less dependent 
upon the length of the polysaccharide chain. 
Based upon these observations, it was hypothesized 
that the molecular weight dependent effects of heparin 
upon other coagulation factors could be characterized as 
resembling either thrombin or factor Xa. In addition, it 
was suggested that the mechanisms relevant to the 
molecular weight dependent effects of heparin on 
coagulation factors in these categories would be similar 
(Holmer et al., 1981). 
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c. H..olecular Weight and Antithrombin III Affinity 
It is now well known that the anticoagulant activity 
of heparin is largely mediated by the plasma cofactor 
antithrombin III (Rosenberg et al., 1973 ; Damus et al., 
1973). Purification of antithrombin III by Miller-
Andersson in 1974 resulted in the development of several 
affinity chromatography techniques utilizing antithrombin 
immobilized to sepharose. The use of these techniques 
greatly facilitated the understanding of the requirements 
for the binding of heparin to antithrombin III. 
Hook et al., (1976) demonstrated that heparin could 
be separated into components of high and low anticoagulant 
activity based upon affinity to the immobilized anti-
thrombin. Interestingly, these affinity fractions 
appeared to have similar structures and molecular weight 
distributions. Some differences were observed in the net 
charge with the high affinity fractions tending to have a 
greater negative charge. 
Andersson et al. , (1976) performed a similar 
affinity fractionation with additional gel filtration to 
achieve molecular weight subfractions of the high affinity 
component. These subfractions demonstrated that the high 
affinity fraction of heparin was not homogeneous. Within 
the high affinity fraction there was still a variety of 
components differing in molecular weight. As previously 
indicated, the high molecular weight high affinity 
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fractions showed greater IIa inhibition, while low 
molecular weight high affinity fractions showed greater 
anti xa activity. Al though no molecular weight sub-
fractionation was performed on the low affinity fraction, 
in vitro screening in various anticoagulant assays 
revealed them to be virtually inactive (Andersson et al., 
1976). 
These observations by Andersson and Hook resulted in 
speculation about the relationship between heparins 
antithrombin affinity and molecular weight. It was 
theorized that high affinity heparin should contain a 
greater degree of binding sequences for antithrombin than 
low affinity heparin. Thus, the total number of these 
units in a heparin molecule would be proportional to 
antithrombin affinity (Laurent et al., 1978) • 
... 
Theories about the relationship between molecular 
weight and antithrombin affinity were obscured by an 
imprecise knowledge of the anti thrombin binding sequence 
of heparin. Laurent et al., (1978) proposed that a 
segment of ten disaccharides was needed for the full 
activity of heparin. Although the term specific dodecca-
saccharide was used, it was emphasized that this should 
not be interpreted as only one possible sequence but 
rather several sequences which may have in common the 
location of only one sugar unit. 
Using affinity and size fraction techniques, 
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Rosenberg et al• I (1978) reported characteristics 
essential for antithrombin affinity. Fractions of heparin 
with high affinity had a significantly higher content of 
glucuronic acid and a lower amount of N sulfated 
glucosamine per molecule compared to the low affinity 
fraction. Within both fractions, a tetrasaccharide 
sequence responsible for antithrombin affinity was 
identified. Differences in affinity were suggested to be 
due to the relative abundance of this sequence. Within 
the high affinity fraction, sufficient amounts of this 
sequence are present such that each molecule may contain 
the this structure. However, the low affinity fraction 
contains only enough tetrasaccharide for one fifth of the 
molecules to contain the sequence. Although about 20 % of 
the molecules in the low affinity fraction contain the 
... 
tetrasaccharide sequence, only about 1 % of the anti-
coagulant activity of the high affinity fraction is 
observed. This suggests that an additional structural 
feature may either be included in or missing from the low 
affinity molecules containing the tetrasaccharide sequence 
(Rosenberg et al., 1978). 
Using nitrous acid digestion followed by anti-
thrombin affinity fractionation, Lindahl et al., (1979) 
observed that the smallest fraction binding to anti-
thrombin was between six and eight disaccharide uni ts. 
Based on this observation, it was reported that the 
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antithrombin binding site was more a tetradecassacharide. 
The binding site was thought to contain both variable and 
invariable regions, with the non variable regions being of 
critical importance to antithrombin binding. The tetra-
saccharide sequence reported by Rosenberg et al., (1978) 
was thought to be essential only in that it contributed to 
a portion of the non variable region. 
Recently, strong evidence for the minimal binding 
sequence of heparin to antithrombin III has been reported 
(Choay et al., 1983). Unlike previous studies, extensive 
heparinase digestions, combined with a unique chemical 
synthesis were utilized to define the binding requirements 
of heparin to anti thrombin III. Chemical analysis of a 
hexasaccharide obtained by heparinase digestion revealed a 
4,5 unsaturated uronic acid at the· non reducing end of the 
molecule. Since this residue was not associated with 
anticoagulant activity it was speculated that the minimal 
binding sequence of heparin was a pentasaccharide. To 
prove this theory, a specifically substituted penta-
saccharide (molecular weight 1,585) was synthesized along 
with two of the possible tetrasaccharide combinations 
contained within the pentasaccharide sequence. Subsequent 
in vitro analysis in anti Xa and specific antithrombin 
binding assays revealed that neither tetrasaccharide bound 
to anti thrombin III nor did they exhibit any anti Xa 
activity (Choay et al., 1983). However, the penta-
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saccharide bound to antithrombin with an affinity constant 
of the same order of magnitude as that reported for high 
antithrombin affinity heparin (Choay et al., 1983). 
similarly, the pentasaccharide exhibited high in vitro 
anticoagulant activity in both anti Xa amidolytic and 
clotting assays however no antithrombin activity was 
observed. 
Using a similarly synthesized tetrasaccharide 
(molecular weight 1,268), Petitou (1984) reported in vitro 
anticoagulant activity. These results, and those of 
Rosenberg et al., (1978) suggest that the minimal sequence 
of heparin capable of binding to antithrombin, is a 
tetrasaccharide. This minimal tetrasaccharide sequence 
while capable of binding to antithrombin does not exhibit 
significant anticoagulant activity·· (Petitou, 1984). Thus, 
... 
it is likely that the minimal sequence of heparin capable 
of binding to antithrombin III is a tetrasaccharide. 
However, the pentasaccharide appears to be the minimal 
sequence capable of antithrombin III binding and eliciting 
significant anticoagulant activity. By subs ti tu ting the 
molecular weights of the penta and tetrasaccharides it is 
possible to determine the molecular weight dependency for 
these functions as 1,268 and 1,585 respectively. 
The structural characteristics necessary for anti-
thrombin III binding were reported by Thunberg et al. , 
(1982). Enzymatic and chemical modifications revealed 
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that three sulfate groups played key roles in antithrombin 
affinity. These sulfates were identified as the N-
acetyl - 6 - O - sulfate on D - glucosamine, the N-
sulfate in the three position on 3,6 - di - O - sulfate-
D _ glucosamine and the N - sulfate in the three position 
on N - sulfate - 6 -o - sulfate - D - glucosamine. The 
essential role of the 6 - o - sulfate and 3 - o-
sulfate groups for antithrombin III binding were reported 
by Lindahl et al., (1983) (1980). Choay et al., (1983), 
provided strong additional evidence for the essential role 
of the 6 - O - sulfate group. Using the synthetic penta 
and tetrasaccharide fragments, interactions with anti-
thrombin III were only observed with the pentasaccharide. 
The only difference between the penta and tetrasaccharides 
was the 6 - o - sulfate group on· the monosaccharide at the 
non reducing end of the pentasaccharide. The absence of 
interactions with antithrombin without this group provides 
strong evidence for it's functional role ( Choay et al. , 
1983). Interestingly, definitive proof for the essential 
role of the 3 - O - sulfate group reported first by 
Lindahl et al., (1980), could not be demonstrated in the 
pentasaccharide studies (Choay et al., 1983). Additional 
studies by Petitou, (1984) did confirm this observation. 
A pentasaccharide deficient in the 3 - o - sulfate group, 
as determined by NMR spectroscopy did not bind to anti-
thrombin III nor exhibit any anticoagulant activity 
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suggesting the critical role of this group. In these same 
studies, a tetrasaccharide deficient in both the o-
sulfate and N - sulfate groups on the residue at the non 
reducing terminal demonstrated minimal anticoagulant 
activity suggesting that their importance must be 
reconsidered. 
o. Molecular Weight Dependent Events Not Mediated By 
Antithrombin III 
Most reports investigating the molecular weight 
dependent actions of heparin have focused upon anti-
thrombin mediated anticoagulant actions. However, some 
studies have indicated molecular weight dependence to 
functions not involving antithrombin III. 
1. Lipoprotein Lipase Activation 
It is well known that administration of heparin 
results in increased lipoprotein lipase activity in the 
blood. This increase has been attributed not to effects 
upon the kinetic properties of the enzyme but rather to an 
increased bioavailability resulting from displacement from 
capillary endothelium by heparin (Olivecrona et al., 
1977) • Harenberg et al., (1985) reported a molecular 
weight dependence to these effects. Plasma lipoprotein 
lipase activity was twice as high following intravenous 
administration of low molecular weight heparin when 
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compared to unfractionated heparin in humans. The 
molecular weight dependent effects were even more dramatic 
after subcutaneous administration. These observations 
suggest that low molecular weight heparin is more 
effective in displacing lipoprotein lipase from its 
endothelial binding sites than heparin of higher molecular 
weight. 
2. Endothelial Cell Binding 
Choay et al., (1986) reported the molecular weight 
dependent properties of heparin binding to endothelial 
cells. Affinity constants were determined using a 
competitive binding assay between radioiodinated heparin 
and fractions of various molecular weight. Using this 
technique, it was shown that heparin of higher molecular 
• 
weight possessed greater affinity for cultured endothelial 
cells than lower molecular weight fractions. Similar 
observations were reported by Barzu et al. , ( 1984) • By 
increasing the sulfate content of the various fractions it 
was observed that a higher charge density could compensate 
for decreased molecular size. 
3. Heparin Cofactor II Activation 
A molecular weight dependent activation of heparin 
cofactor II has also been reported (Choay et al., 1986). 
Yamagishi et al., 1986). Using fragments of heparin 
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obtained by nitrous acid depolymerization and sized by gel 
filtration, heparin cofactor II mediated thrombin 
inhibition decreased steadily with decreasing molecular 
weight (Choay et al., 1986). This observation was 
consistent between molecular weights of 9,700 through 
6 ,200 daltons. When low molecular weight fragments were 
chemically over sulfated, it appeared to increase the 
affinity constants for these fragments. This observation 
suggested that the molecular weight dependent effects were 
likely due to an increased charge associated with the high 
molecular weight molecules (Choay et al., 1986). 
Yamagishi et al., (1986) observed similar results relating 
charge and molecular weight to dextran sulfate enhanced 
heparin cofactor II activity. 
4. Pro-fibrinolytic Actions 
Another affect of heparin which has shown some 
dependence upon molecular weight and or sulfate content, 
are it's pro-fibrinolytic actions. Vinazzer et al., 
(1982) compared high (18,000) and low (3,000) molecular 
weight fractions from the same source for their effect on 
euglobulin lysis time. A significant difference was 
observed between the two fractions. The low molecular 
weight fraction had no effect, while the high molecular 
weight fraction showed a dose dependent enhancement of the 
euglobulin lysis time. It was thought that this effect 
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was mediated through endogenous activation of factor XII 
which paralleled the effect on euglobulin lysis time. 
Although the use of the molecular weight fractions 
demonstrated the effect to be a function of molecular 
weight, a similar effect involving sulfate content was 
observed. Using a highly sulfated synthetic heparin 
analog (3, 000 molecular weight) a comparable effect to 
that of the high molecular weight heparin was observed 
(Vinazzer et al., 1982). These results suggested that the 
molecular weight dependent effect of heparin on euglobulin 
lysis time are at least in part due to charge character-
istics. Similar pro-fibrinolytic effects involving charge 
mediated binding of heparin to plasminogen activators has 
been reported by Paques et al., (1986). 
• 
5. Heparin - Platelet Interactions 
Many studies have demonstrated effects by heparin on 
platelet function, the most notable being platelet 
aggregation. A molecular weight dependence to heparin 
induced platelet aggregation has been reported by several 
investigators. Salzman et al., (1982) reported that gel 
filtered fractions of the same source of heparin differed 
in their ability to both induce and enhance aggregation 
induced by other agonists. The high molecular weight 
fraction (22,000 daltons) was more active in these actions 
than the low molecular weight fraction (7, 000 daltons). 
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similar results comparing unfractionated heparin with 
various depolymerized fractions were observed by Brace and 
Fareed, (1985) and Blockmans et al., (1986). Further 
studies by Brace and Fareed, (1986) expanded the range of 
molecular weight dependence to heparin induced platelet 
aggregation. Using molecular weight fractions of de-
polymerized heparin ranging from 6,200 - 1,800 daltons 
platelet aggregation was studied in individual human 
platelet rich plasmas. A direct correlation between 
aggregation and molecular weight was established. In all 
cases platelets which aggregated to heparin showed a 
decreased response with fractions of decreasing molecular 
weight. 
E. In Vivo Studies 
• 1. The Effect of Molecular Weight on the Pharmacokinetics 
of Heparin 
The pharmacokinetics of heparin fractions of 
different molecular weight have not been directly 
investigated, however several investigators have compared 
the pharmacokinetics of native and various commercial low 
molecular weight heparins. Like pharmacokinetic studies 
on unfractionated heparin, these studies have primarily 
calculated kinetic parameters from estimates of plasma 
heparin concentrations determined in anticoagulant assays. 
Unfortunately, many of these assays were developed .for use 
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with unfractionated heparin and are variable in their 
response to low molecular weight heparin. Consequently, 
reports comparing the pharmacokinetics of unfractionated 
and low molecular weight heparin have yielded contrasting 
values for the various kinetic parameters. 
An additional problem in comparing the pharmaco-
kinetics or other biological actions of low molecular 
weight heparins was the lack of a international reference 
preparation (recently a low molecular weight reference has 
t>een proposed Thomas, 1987). In the absence of such a 
reference, the various low molecular weight heparins were 
standardized for potency in a variety of assays which 
differed with the manufacturer. This resulted in low 
molecular weight heparins which although standardized in 
anticoagulant units, differed significantly in potency and 
• 
gravimetric amounts. Furthermore the standardized units 
of low molecular weight heparins did not correlate well 
with units of unfractionated heparin (Barrowcliffe et al. 
unpublished report). Most pharmacokinetic studies 
comparing unfractionated and low molecular weight heparins 
have used these unit dosages. Comparisons were inaccurate 
since it was likely that the various heparins were not 
compared at equigravimetric concentrations. The pharmaco-
kinetics of heparin are dose dependent and vary with the 
method of assay. For these reasons, many reports 
comparing the pharmacokinetics of native and low molecular 
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weight heparin are of little value. 
a. ,Absorption and Distribution 
Bergqvist et al., (1983) compared the absorption of 
low molecular weight fractions (obtained by gel-two 
filtration and depolymerization) with unfractionated 
heparin after subcutaneous administration. In this study, 
plasma anti Xa activity was observed over a twenty four 
hour period after a single injection of a 5, ooo 
International Unit (IU) dose. In contrast to the 
unfractionated heparin, it was reported that there was 
significantly greater absorption of both low molecular 
weight fractions. Peak absorption for both low molecular 
weight and unfractionated heparin appeared at about four 
hours post administration (Bergqvist et al., 1983). The 
activities of both low molecular weight heparins remained 
greater at 11 hours post injection than the peak activity 
of the unfractionated heparin. These differences were 
attributed to molecular weight dependent differences in 
both the rate and amount of absorption (Bergqvist et al., 
1983) . It is interesting to note that a molecular weight 
dependent difference in the rate and degree of absorption 
was also observed between the two low molecular weight 
fractions. 
Bratt et al., (1985, 1986) 
dependent change in the volume 
reported a small dose 
of distribution after 
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intravenous administration of a low molecular weight 
fraction of heparin (Kabi 2165) as determined by plasma 
anti xa activity. At a dose of 60 IU/Kg the apparent 
volume of distribution was reported to be 2.9 L. Increas-
ing the dose to 120 IU/Kg resulted in an approximate 15 % 
increase in the volume of distribution to 3. 4 L. This 
apparent dose related increase in distribution volume was 
thought to reflect a larger fraction of drug not bound to 
antithrombin III at the higher dose. The unbound drug 
would be available for binding outside the plasma perhaps 
to endothelial cells (Bratt et al., 1986). 
b. Half-life 
The half life of low molecular weight heparin 
fractions has been reported to be significantly longer 
than unfractionated heparin. In most studies, the half-
life of low molecular weight heparin is two to three times 
longer than that of unfractionated heparin (Fareed et al., 
1985 . I Lockner et al. , 1985 . I Boneu et al • , 1985 ; 
Harenberg et al., 1986). Other investigators have report-
ed the half-life of low molecular weight heparin to be up 
to 4 times that of unfractionated heparin (Bara et al., 
1985). As with unfractionated heparin, the half-life of 
low molecular weight heparin appears to be dose dependent. 
Half-life increases with increasing dose but does not 
display typical Michaelis-Menten (capacity-limited) type 
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kinetics (Bara et al., 1985 . ' Harenberg et al • , 1986 
sergqvist et al., 1983). 
c. clearance and Elimination 
The clearance of low molecular weight heparin is 
also dependent on dose (Bratt et al., 1985 1986). After a 
120 IU/Kg dose, Cl was reported to be 25 ml/min., compared 
to 15 ml/min. after a 60 IU/Kg dose. 
Recently it has been reported that the clearance of 
native and low molecular weight heparin may be different 
(Goudable et al., 1986). Native and low molecular weight 
heparin were compared for differences in half-life in 
healthy human patients and those with impaired renal 
function. No difference was observed in the half-life of 
native heparin between the healthy and renal impaired 
• individuals. However, a dramatic difference was observed 
with the low molecular weight fraction. These results 
suggest that renal mechanisms may play a greater role in 
the clearance of low molecular weight compared to native 
heparin. 
d. Bioavailability 
Several reports have demonstrated that low molecular 
weight heparins are more efficiently absorbed after sub-
cutaneous administration than unfractionated heparin 
(Fareed et al., 1985 ; Bergqvist et al., 1983 ; Harenberg 
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et al.' 1986). In an attempt to quantify the extent of 
these differences in absorption, investigators have 
evaluated the relative bioavailability after subcutaneous 
and intravenous administration. It must be kept in mind 
that such a comparison is only acceptable when the rate 
constant of elimination (Ke) is constant with respect to 
drug plasma concentration. Since the Ke of unfractionated 
and low molecular weight heparin has been reported to be 
dependent upon concentration, the validity of such studies 
is questionable. 
By comparing the area under the plasma concentration 
time curve (AUC) for both intravenous and subcutaneous 
routes of administration, several investigators have 
reported higher bioavailability with low molecular weight 
compared to unfractionated heparin. Bara et al., (1985) 
reported 91 % bioavailability in • terms of anti Xa 
activity, for low molecular weight heparin in contrast to 
28 % for unfractionated heparin. The greater bioavail-
ability seen with the low molecular weight heparin was 
dependent upon the method of assay. When the same agents 
were compared in an anti IIa assay, no significant 
difference between the low molecular weight or un-
fractionated heparin was observed. 
Increased relative bioavailability of low molecular 
weight heparin, as measured by anti Xa methods have been 
reported by Bratt et al., (1986) and Harenberg et al., 
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(1986)· 
The Effect of Molecular Weight on Antithrombotic 
Actions 
The antithrombotic actions of unfractionated and low 
molecular weight heparins in both clinical and animal 
studies have been reviewed (Thomas et al., 1981 ; Fareed 
et al., 1985 . I Kakkar, 1984) • In these studies, low 
molecular weight heparins have exhibited effective anti-
thrombotic actions. When compared to unfractionated 
heparin, they require greater gravimetric concentrations 
to achieve similar anti thrombotic actions after intra-
venous administration. However in subcutaneous regimens, 
equal gravimetric dosages of unfractionated and low 
molecular weight heparin have ·produced similar anti-
• thrombotic actions. 
The antithrombotic activities of unfractionated and 
low molecular weight heparin correlate reasonably well 
with their in vitro anticoagulant actions. However, the 
significance of the correlation varies between different 
assay methods (anti Xa, anti IIa, APTT). For relating in 
vitro anticoagulant to in vivo antithrombotic actions, no 
one assay appears clearly superior. 
A study directly examining the effect of molecular 
weight on antithrombotic actions was reported by Bergqvist 
et al., (1985). In this study, various molecular weight 
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fractions (molecular weights ranging from 22,000 - 4,900 
daltons) and unfractionated heparin were compared for 
their ability to inhibit in vivo thrombosis in animal 
models. These studies utilized a high molecular weight 
fraction obtained by gel filtration as well as heparinase 
digested low molecular weight fractions. All except the 
lowest molecular weight fraction decreased the frequency 
of venous thrombosis and at equigravimetric dosages were 
not less effective that unfractionated heparin. 
In a dose response study, the unfractionated heparin 
was determined to be more efficacious than low molecular 
weight heparin. This observation was especially interest-
ing since the low molecular weight heparin was determined 
to have greater circulating anti Xa activity (Bergqvist et 
al., 1985). This observation was consistent with those of 
Carter et al., ( 1981) . ,. These observations suggest that 
the anti IIa activity of heparin is an important determ-
inant of antithrombotic actions. 
Recently, Walenga et al., (1986) reported anti-
thrombotic properties for a synthetic pentasaccharide. 
Although this agent displayed no thrombin inhibition, 
anti thrombotic actions were observed. When compared to 
unfractionated heparin an approximate 4 fold greater 
concentration was required for similar antithrombotic 
activity. This observation supports earlier observations 
that an anti II a component of heparin is important for 
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antithrombotic actions, but not necessary. These 
oDservations suggest that the relationship between 
molecular weight and antithrombotic actions is similar to 
the molecular weight dependent relationships of anti-
thrombin III affinity and thrombin inhibition. 
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CHAPTER II 
STATEMENT OF PURPOSE 
Molecular weight is an important factor in under-
standing the pharmacological actions of heparin. 
Heparin's antiprotease actions, pharmacokinetic behavior 
and antithrombotic effects have been shown to be dependent 
upon this parameter (Laurent et al., 1961 ; Harenberg et 
al., 1986 ; Bergqvist et al., 1983) • A greater under-
standing of the pharmacological actions of heparin as they 
relate to molecular weight may contribute to greater 
safety and efficacy of this agent. 
It was the purpose of this dissertation to inves-
tigate the molecular weight dependence of the pharmaco-
logical effects of heparin in terms of its anticoagulant, 
antithrombotic and pharmacodynamic behavior. 
In vitro anticoagulant studies wer.,e conducted for 
the purpose of identifying molecular weight dependent 
effects associated with specific coagulation pathways. 
· These studies utilized conventional clotting and amido-
lytic assays as well as novel protease generation tests. 
These tests were specifically designed to investigate 
possible actions of heparin not previously reported. Of 
particular importance were the protease generation systems 
using factor VII-thromboplastin and those based upon the 
release of fibrinopeptide-A. These assays were used to 
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investigate the molecular weight dependent effects of 
heparin on the extrinsic pathway of coagulation. 
The molecular weight fractions were studied for 
their antithrombotic effects in a rabbit thrombosis model. 
These studies were conducted for the-purpose of relating 
molecular weight to anti thrombotic activity. The frac-
tions were administered by both subcutaneous and intra-
venous routes of administration. Comparison of the 
antithrombotic efficacy in both routes provided infor-
mation about the effect of molecular weight on the 
absorption of active components after subcutaneous 
administration. 
The molecular weight fractions were also studied to 
determine the plasma concentration time course. These 
studies were carried out to investigate any molecular 
• 
weight dependence in heparin's apparent volume of 
distribution, biologic half-life or clearance after both 
subcutaneous and intravenous administration. Comparison 
of the area under the plasma concentration time curve 
after both routes of administration provided information 
about the effect of molecular weight on absolute 
absorption. 
The information obtained from this dissertation may 
provide a clearer pharmacological profile of the effects 
of heparin relative to molecular weight. This information 
may have practical value relative to therapeutic indi-
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cations, routes of administration and toxic effects. 
Several low molecular weight heparins are currently 
in pre-clinical and clinical trials. Knowledge about the 
molecular weight dependent effects of heparin may be 
especially important for predicting the pharmacological 
actions of these new agents. Furthermore, the test 
systems developed for this dissertation may be of value 
for potency determination, standardization and clinical 
monitoring of both heparin and its low molecular weight 
fractions. 
• 
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CHAPTER III 
MATERIALS AND METHODS 
A. Heparin and. its Fractions 
Unfractionated porcine sodium mucosa! heparin (lot # 
H 410) and CY 216 (lot # Pl57 XH) a low molecular weight 
heparin fraction, were obtained from Choay Institute 
(Paris, France). The CY 216 was prepared by ethanol 
extraction of porcine mucosa! heparin, followed by gel 
filtration on a Ultrogel ACA 44 column (Choay et al., 
1980) • The analytical profile of the porcine mucosa! 
heparin is seen in appendix v. 
B. Reagents 
1. Clotting Assays 
Thromboplastin-c reagent (lot #'s TPCD - 318, 348 
and 358) a rabbit brain thromboplastin ~ontaining .0116 M 
CaCl2, was obtained from American Dade (Miami, FL) and 
used in the prothrombin time assay (PT). A description of 
this assay is in appendix VI. APTT reagent (lot # 4W6-34) 
was obtained from General Diagnostics, (Morris Plains, NJ) 
and used in the activated partial thromboplastin assay. 
The APTT reagent was a rabbit brain cephalin with a 
micronized silica activator. The assay is described in 
appendix VII. Heptest heparin assay (lot #'s A 85, B-86-
2) were obtained from Haemachem (St. MO). A description 
of the assay is in appendix VII. 
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2 • protease Assays 
Human thrombin (Fibrindex brand lot # 3B340 50 
u/vial) was purchased from Ortho Diagnostics (Raritan, NJ) 
in powder form. The thrombin was reconstituted in dis-
tilled water, diluted with saline, standardized to 10 NIH 
u/ml using a plasma clotting assay and stored at -10° c 
until used. Bovine factor Xa (lot B44) was purchased from 
RQP Laboratories (South Bend, IN). The Xa was reconsti-
tuted in 1. O ml tr is buff er containing 1. O mg/ml bovine 
serum albumin, diluted 1:4 in saline and stored at -10° c 
until use. Human factors VII, X and Xa were purchased 
from Diagnostica Stago (Asniers, France). Human factor 
VII (lot # 67 100 ug/vial) was reconstituted with distil-
led water, diluted to 5 ug/ml with saline and stored at-
100 C until use. Human factor X (lot # H 11 F U/vial) was 
reconstituted in 0.5 ml of amidolytic assay buffer prior 
• to each use. Human factor Xa (lot # H 11 25 nKat/vial) 
was reconstituted with distilled water prior to each use. 
Human antithrombin III (lot # 85 07 01 86576 500 U/vial) 
obtained from Kabi Vitrum (Stockholm, Sweden), was re-
constituted in 1. o ml of distilled water, diluted to 5 
U/ml with saline and stored in aliquots at -10° c until 
use. The chromogenic substrates used in the amidolytic 
assays, spectrozyme TH (lot # 1051 /81) and spectrozyme 
Xa (lot # 1213 /85) were purchased from American 
Diagnostica (Greenwich, CT) . These substrates were 
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reconstituted with distilled water to the desired molarity 
prior to use. 
3. Plasma Preparation 
Normal human pooled plasma was prepared from at 
least 10 heal thy male and female volunteers under the 
guidelines established by the Institutional Review Board 
for the protection of human subjects (permit # SF ap-
pendix IX). Blood was collected by venipuncture using 
double syringe technique through a 21 gauge butterfly 
needle. The initial 2 - 3 ml's of blood were discarded 
and the subsequent blood was immediately added to 3. 8 % 
citrate (1 10) in plastic tubes. The tubes were then 
centrifuged for 20 minutes at 2,500 RPM to obtain platelet 
poor plasma. Additional human plasma was purchased from 
... 
the Loyola University Medical Center Blood Bank. This 
plasma was made by collecting blood from healthy donors 
into CPDAl anticoagulant. The blood was centrifuged and 
the resulting plasma was freshly frozen in 250 ml packs. 
Prior to use, the individual plasma packs were thawed in a 
water bath at 370 c and pooled. A minimum of at least 5 
individual plasma preparations were used to prepare a 
pool. Aliquots of all plasmas were stored at -700 C prior 
to use. 
Factor I deficient plasma (made deficient by plasma 
phoresis of normal donors) was obtained from George King 
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Biomedical (Overland Park, KS) This plasma was stored at 
-100 c until use. Plasma deficient in anti thrombin III 
was prepared by heparin affinity chromatography using a 
method described by Ofusu et al., (1981). Heparin-
sepharose CL 6B (lot # FE 15465) was obtained from 
Pharmacia (Piscataway, NJ). A column (Pharmacia K 15/90, 
total volume 156 ml) was packed with the heparin-
sepharose, and equilibrated with 0,06 M NaHP04 and 0.5 M 
NaCl pH 7.5. To obtain the antithrombin deficient plasma, 
200 ml of citrated normal human, platelet poor plasma was 
applied to the column. The plasma was eluted at a flow 
rate of about 2. 5 ml/ minute with equilibration buffer. 
The eluted plasma was dialyzed against 0.4% sodium citrate 
containing 0.15 M NaCl, aliquoted and frozen at -100 c 
prior to use. Anti thrombin III- levels were determined 
... 
using a synthetic substrate based automated method (aca 
automated chemistry analyzer E.I. Du Pont Co). Reference 
antithrombin III deficient plasma was provided dy Dr. F. 
Ofusu (McMaster Univ. Hamilton Ontario Canada). 
Platelet rich plasma was prepared in the following 
manner. Blood was drawn from individual donors into 3.8 % 
citrate ( 1: 10 ratio) and centrifuged at 225 x g for 20 
minutes to obtain plasma rich in platelets. The platelet 
count was then adjusted (using autologous platelets) to 
about 250,000 using a light microscope and a bright line 
hemocytometer. 
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Thrombogenic Reagents 4. 
Konyne brand of prothrombin complex concentrate 
(PCC) lot # NC 912, obtained from Cutter Laboratories 
(Berkley, CA) was reconstituted in 20 ml of sterile water 
to obtain a working solution of 25 U /ml. This solution 
was kept frozen at -10° C until use. Russell's viper 
venom (RVV) in cephalin lot # 20F 39581, obtained from 
sigma Chemical Co. (St. Louis, MO) was reconstituted with 
sterile water to 0.1 U/ml prior to each use. 
5. Anesthetics 
The anaesthetic agent utilized in both animal models 
was ketamine hydrochloride (Ketalar, Parke Davis Morris 
Plaines, NJ) • In the rabbit stasis thrombosis model, an 
additional anaesthetic xylazine "(Rompum Bayvet division, 
Miles Labs Shawnee, KS) was used. Both.anaesthetics have 
been shown to have no effect on the normal coagulation 
profile or heparinizability of either primates or rabbits 
(Fareed et al., 1985) • Pentobarbi tal sodium (Nembutal 
Abbott Chicago, IL) was used in rabbit euthanasia. 
6. Animals 
A mature primate colony (Macaca mulatta) consisting 
of 17 male and female animals (weight range 7-12 Kg) was 
housed in the AAA LAC approved animal research facility of 
Loyola University Medical Center. The health of all 
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primates was routinely evaluated by a licenced doctor of 
vetrinary medicine. Abnormal primates were excluded from 
experimentation. All primates were maintained on a 
standard diet of Purina monkey chow, had free access to 
water and kept on a regular 12 hour light /dark cycle 
during all experiments. 
New Zealand white rabbits (Oryctolagus cuniculus) 
weight range o. 5 - 2. o Kg, were obtained from Langshaw 
farms (Augusta, MI). These rabbits ranged in age from 9-
18 mos. Rabbits were also housed in the animal research 
facility and exposed to a regular 12 hour light / dark 
cycle. The rabbi ts were fed a standard diet of Wayne 
Rabbit Ration and allowed free exposure to water. 
For all animal studies, ethical guidelines 
established by the committee f·or animal welfare were 
.. 
strictly adhered to and all protocols were approved by the 
aforementioned committee. 
7. Analytical Instruments 
Most of the instruments used in this study were 
available through the departments of pharmacology and 
pathology at Loyola University Medical Center. These 
included a Biogamma gamma counter (Beckman Instruments 
Fullerton, CA) used in radioimmunoassays, a DU-7 spectre-
photometer (Beckman Instruments Fullerton, CA) used in 
chromogenic substrate assays and an Multistat centrifugal 
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analyzer (Instrumentation Labs Lexington, MA) used in the 
factor VII-thromboplastin assays. Several fibrometers, 
(BBL cockeysville, MD) used in clotting assays as well as 
two cone plate viscometers (Wells-Brookfield Stoughton, 
MA) were available in the hemostasis research laboratory. 
An personal computer XT (IBM Personal Computers Boca 
Raton, FL) and support software was utilized for statis-
tical and word processing applications. The software used 
in these applications was SYSTAT version 2.0 (Systat Inc. 
Evanston, IL) and WORDPERFECT 4 • 1 (SSI Oren, UT) 
respectively. 
A K 100/100 chromatography column and Pf-30 fraction 
collector (Pharmacia Laboratory Separation Division 
Piscataway, NJ) was used in the molecular weight frac-
tionation. A Waters (Milford, MA) HPLC-GPC chromatography 
system, equipped with a model 710 WISP sample processor, a 
model 490 Multiwavelength Detector, a model 510 HPLC pump, 
and a Digital 350 computer running Waters 840 software was 
utilized for molecular weight determinations. These 
instruments were made available at Choay Chemie (Roen, 
France). The columns used in the molecular weight 
determinations were LKB Ultropac tsk 2,000 and 3,000 
(Bromma, Sweden) . The porosity of these columns was 125 
and 250 angstroms respectively. 
c. Molecular Weight Fractionation 
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sodium porcine mucosa! heparin (lot # H 410) was 
fractionated into molecular weight subfractions utilizing 
a method similar to that of Johnson and Malloy (1976). 
The fractionation was performed at Choay Chemie (Roen, 
France) under the following conditions. A Pharmacia K 
100/100 column (dimensions 10 X 100 cm., total bed volume 
l L) was packed with Ultrogel ACA 44 agarose acrylamide 
matrix, size exclusion range 10,000-140,000 (Reactifs 
clichy, France). The column was connected to a mariott 
flask and a sample reservoir through a three way valve to 
facilitate sample application and maintain a consistent 
flow rate. Prior to the fractionation process, the column 
was equilibrated with O. 5 M NaCl and the flow rate was 
adjusted to 400 ml / hour. 
Five grams of the unfractionated heparin was 
dissolved in 70 ml's of distilled water and applied to the 
column through the sample reservoir. Heparin elution was 
monitored by manually recording absorbance of the eluent 
at 205 nM using a Beckman model 35 spectrophotometer. At 
the first absorbance peak, 15 fractions were collected 
with the aid of a Pharmacia Pf-30 fraction collector. The 
interval between fractions was 35 minutes. Since the 
absorbance peaks indicated low heparin concentrations in 
the initial and latter fractions, these fractions were 
pooled such that a total of nine fractions were obtained. 
The fractions were recovered using twice ethanol precip-
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itation. The ethanol precipitation was performed using 1 
volume of the fraction with 1.5 volume of 100 % ethanol 
while stirring. This mixture was centrifuged at 5,ooo rpm 
and the supernatant discarded. The precipitate was then 
homogenized and vacuum dried in glass filter funnels at 
The heparin content of the fractions was deter-
mined using a toluidine blue assay described in (NCCLS 5: 
(13) 373-376). The calibration curve for this assay is 
seen in appendix X. 
D. Molecular Weight Determination 
In order to determine the molecular weights of the 
gel filtered fractions, gel permeation chromatography was 
performed on a Waters liquid chromatography system. The 
system was equipped with a Digital 300 series mini-
• 
computer running Waters 840 software to facilitate data 
reduction. The Waters 840 system was specifically 
designed for applications in molecular weight determ-
inations of polymers. The system calculated not only mean 
molecular weight, but also values indicating the molecular 
weight distribution. These values were calculated from 
the chromatographic characteristics of standards with 
similar molecular composition on columns of specific 
porosity. Since the molecular weight range of heparin was 
large, two columns of different porosity were used. Thus 
prior to use, the columns were calibrated with anionic 
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polymers consisting of sulfated glucuronic acid, uronic 
acid and glucosamine. A description of these standards is 
given in appendix XI. Appendix XII and XIII show the 
calibration curves obtained by running the standards on 
the LKB tsk 2000 and 3000 columns respectively. Values 
for retention time (RT) and polymer dispersity (D) were 
determined, and used along with the molecular weights of 
' 
the standards to calculate a calibration curve. This 
curve was calculated by third polynomial regression and 
yielded polynomial coefficients (Do, Di, D2, D3) which 
characterized the average standard curve. The following 
equation was used: 
MW= Do+ D1 (RT) + D2 (RT)2 + D3 (RT)3 
The molecular weight of the samples were determined 
from their chromatographic characteristics under the 
following conditions: 
Columns: LKB tsk 2,000 and 3,000 
Mobile Phase: NaS04 0.5 M 
Detector: UV 205 nm 
Flow Rate: 1 ml/min. 
Sample: 20 ul of lOmg/ml 
Following chromatography, the total area under the 
elution curve for each sample was determined by integra-
tion. The computer divided the total area into about 50 
equal time slices. The retention time value of each slice 
was used in the previous equation to calculate the molec-
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ular weight of the individual slices. This provided 
approximately 50 (MW) and (RT) values for the following 
calculations where (Sx =the area of the x slice), (Mx = 
the molecular weight of the x slice) , (Mw = the weight 
average molecular weight), (Mn = the number average 
molecular weight) , (Mz = the z number molecular weight) 
and (D =the dispersity of the polymer). 
Mz = ---1.S.x--11xl2 D = Mw 
(Sx Mx) Mn 
Thus, Mw indicated the value for the mean molecular weight 
of the polymer. Mn and Mz were molecular weight values 
which characterized the high and low molecular weight 
areas of the elution curve. These values were of partic-
ular importance for evaluating the relative distribution 
• • of differing molecular weight components within a given 
fraction. For example, if Mw = Mn = Mz, then this indi-
cated that the polymer was monodisperse. Inequality in 
these values indicated a polydisperse mixture (Waters, 
1985) . 
Verification of the molecular weights determined by 
the HPLC-GPC method were achieved by measuring the 
viscosity of the fractions (Johnson and Malloy, 1976 and 
Laurent, 1961). For this purpose a Wells Brookfield cone 
plate viscometer was utilized. Prior to viscosity 
measurements, the instrument was calibrated with silicone 
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fluids of known viscosity (5 and 10 centipoise) standard-
ized by methods traceable to the U.S. National Bureau of 
standards. Measurements were made by adding l ml of the 
individual fractions (cone. 10 mg/ml) to the viscometer. 
The solution was allowed to equilibrate to 250 c at which 
time the viscosity measurements were recorded at shear 
rates of 90, 225 and 45osec-1. To obtain viscosity values 
in centipoise (mPa), the values read from the viscometer 
were multiplied by a constant based on the geometry of the 
cone and the shear rate. These values were . 0514 for 
shear rate 450, .102 for shear rate 225 and .257 for shear 
rate 90 (Wells 
mation). 
Brookfield Technical Product Infor-
E. In Vitro Anticoagulant studies 
... 
From the original nine, five fractions yielding the 
widest range of molecular weights were selected for the 
experimental studies. These fractions were supplemented 
to pooled normal human platelet poor plasma at concen-
trations ranging from o. 625 - 20 ug/ml and profiled in 
clotting assays routinely used for coagulation pro-
filing. These tests included: prothrombin time (PT), 
activated partial thromboplastin time (APTT) and Heptest. 
All assays were performed exactly as previously described. 
The test fractions were also supplemented to anti-
thrombin III deficient plasma (the antithrombin III 
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deficient plasma was prepared as previously described) at 
a concentration of 20 ug/ml and screened in an identical 
PT assay. 
Amidolytic antifactor Xa and IIa assays were per-
formed to assess the relative inhibition of these two 
enzymes by the various fractions. The test fractions were 
supplemented to pooled normal human platelet poor plasma 
and the assays were performed as follows. For the amido-
lytic anti Xa method: 375 ul of 0.05 M Tris and 0.175 M 
NaCl buffer pH 8.4 was equilibrated with 25 ul of plasma 
sample to 37° c. 50 ul of o. 5 nkat/ml human or bovine 
factor Xa was added and allowed to react for exactly 2 
minutes. After the 2 minute incubation, 50 ul of sub-
strate (spectrozyme-Xa 2.5 mM) was added and the change in 
absorbance was recorded at 405· nm over a one minute 
• period. To determine the effect of the individual 
fractions, the heparinized samples were compared to a 
saline control, and a value of relative % inhibition was 
calculated. 
The anti IIa method utilized the same buffer with a 
volume of 400 ul, to which 25 ul of plasma sample was 
added. The mixture was equilibrated as before and 25 ul 
of 10. o NIH unit thrombin was added and incubated for 
exactly for 1.0 minute. At the end of one minute, 50 ul 
of substrate (spectrozyme-TH 2. 5 mM) was added and the 
change in absorbance per unit time is recorded. Percent 
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inhibition was calculated in an identical manner as 
described for the anti Xa assay. 
Fibrinopeptide-A generation tests {FPAGT) were also 
used to examine the test fractions. This test was used 
essentially as previously described {Emanuele et al., 
1984, 1985) however, it was slightly modified to yield 
more reproducible results. The test was performed as 
follows. 0. 625 - 5.0 ug/ml concentrations of the test 
fractions were supplemented to pooled normal human 
platelet poor plasma. Thromboplastin c {Dade PT reagent) 
was standardized in a prothrombin time assay to achieve 
consistent and measurable amounts of {FPA) • The stan-
dardization was accomplished by diluting the thrombo-
plastin c in 0.025 M CaCl2 to obtain a PT value of about 
35 seconds for citrated human plasma. FPA generation was 
.. 
initiated by adding 100 ul of the standardized thrombo-
plastin ·to 400 ul of test plasma. A control FPA gener-
ation was also performed by adding 100 ul of saline to 400 
ul of test plasma. FPA generation proceeded for exactly 
2. O minutes, at which time 100 ul of inhibitor cocktail 
containing 10 mg/ml EDTA, 500 KIU/ml aprotinin, 1 ug/ml 
indomethecin { Indocin Merk Sharp & Dohme, Philadelphia, 
PA) and a thrombin inhibitor 5 antithrombin U/ml was 
added. The plasma was then treated with bentonite {2: 1 
bentonite to plasma) mixed well and centrifuged. The 
supernatant was then assayed for FPA using a Mallinckrodt 
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radioimmunoassay (RIA) kit (St. Louis, MO). This kit 
utilized competitive binding between Il25 labeled and 
unlabeled fibrinopeptide - A for a limited number of 
antibody binding sites. Quantitation of the generated FPA 
was achieved by comparing the assay results to a FPA 
standard curve. 
The FPAGT was performed identically in platelet 
rich, and antithrombin III deficient plasma. 
A whole blood system for the FPAGT was also util-
ized. The test was performed as follows: 12 X 75 non 
siliconized glass tubes were washed with saline, marked at 
a 2.0 ml level and supplemented with 100 ul of an appro-
priate concentration of heparin or heparin fraction. 
Blood was drawn from normal human volunteers using a 
double syringe technique. After discarding the first 2-
.. 
3 ml's, the whole blood was immediately added to the tubes 
and filled up to the 2. o ml mark. FPA generation was 
allowed to proceed for exactly 2.0 minutes. At the end of 
2.0 minutes, 200 ul of the inhibitor cocktail previously 
described was added to prevent further FPA generation. 
Plasma was obtained by centrifugation, treated with 
bentonite, re-centrifuged and assayed as before. 
The molecular weight dependent effects of heparin 
upon the extrinsic network were studied by developing an 
assay using thromboplastin and factor VII to activate 
factor x to xa. This amidolytic Xa generation assay was 
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performed on a centrifugal analyzer (Mulitstat III, IL 
Lexington KY) as follows: 25 ul of 80 ug/ml factor X, 25 
ul of 2. 5 ug/ml factor VII and 25 ul of the individual 
heparin fractions (25 ug/ml heparin diluted in 1.25 U/ml 
AT-III) were added to well # 1 of the centrifugal rotor. 
140 ul of 0.06 mM Tris and .1 mM CaCl2 buffer pH 8.1, 25 
ul of 2 • 5 mM spectrozyme Xa and human thromboplastin 
diluted 1:20 in 0.025 M CaCl2 were added to well # 2 of 
the rotor. After incubation to 37° c, the contents of the 
two wells were mixed by accelerating the rotor and the 
change in absorbance at 405 nM was recorded at 30 second 
intervals over a 5 minute time period, after a 5 second 
delay. 
This assay was slightly modified to allow for the 
use of a plasma matrix. In this modification, the plasma 
.. 
provided factors VII and X, thus additional buffer was 
added to achieve a similar volume. Dilute (1 2 in 
saline) f ibrinogen deficient plasma was used in these 
studies to avoid clotting. 
The results from assays run on the multistat kinetic 
analyzer were expressed in terms of uM of substrate 
cleaved per unit time. The multistat provides a recording 
of the absorbance change over time. Using the molar 
absorbance value for para-nitroanaline (9.2 X 103 L mo1-l 
cm), molar values were calculated per unit of time. Since 
the multistat has a .5 cm path length, absorbance values 
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were first divided by two. Values were calculated at 
three different time periods in the linear portion of the 
assay and averaged to obtain the rate of substrate 
cleavage in terms of uM/time. 
For all of the previously described in vitro assays, 
an appropriate dose response was determined by studying 
the test fractions in at least four concentrations. Since 
the pooled plasma was considered a reagent for the in 
vitro test systems, all fractions were assayed on five 
separate occasions to achieve statistical significance. 
F. In Vivo Studies 
l. Pharmacodynamic time course 
The pharmacodynamic time course of three test 
fractions (molecular weights 23,000; 13,300 and 5,100 
.. 
daltons) along with the unfractionated heparin and a 
commercial low molecular weight heparin (Fraxiparine 
were investigated in a primate model (Macaca mulatta) 
using both intravenous and subcutaneous routes of 
administration. The model was similar to that described 
by Fareed et al. , ( 1985) . Before initiating the study, 
all primates were profiled using clinical laboratory 
methods including SMAC, CBC and coagulation studies for 
the purpose of excluding abnormal animals. Before all 
blood sampling or drug injections, the animals were 
anaesthetized/immobilized by injection of 10 mg/kg 
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]Cetamine HCl . It has been shown that repeated 
administration of this anaesthetic does not significantly 
alter the normal coagulation or heparinization profile 
(Fareed et al., 1985) . At all times when test drug or 
anaesthesia was administered the safety and comfort of 
each primate was continually monitored. 
For subcutaneous administration, all fractions were 
compared at a dose of 1.0 mg/kg (stock solution cone. 10.0 
mg/ml). For intravenous administration, a dose of 250 
ug/kg was used (stock solution l. o mg/ml). Prior to 
injection of the test fraction, a baseline blood sample 
was drawn from the saphenous vein of the individual 
monkeys. For the intravenous route, the fractions were 
administered by a single bolus injection to the same vein. 
For the subcutaneous route, a single bolus was injected at 
.. 
a site in the lower abdomen. For both intravenous and 
subcutaneous routes, the test agents were injected through 
syringes incorporating sterile, pyrogen free 0.2 um 
Nalgene filters (Nalge Co. Rochester, NY). After 
injections and blood sampling, the animals were returned 
to their respective cages until the next sampling time. 
At the prescribed time intervals, the primates were 
anaesthetized and a blood sample was taken as before. For 
the subcutaneous route blood samples were taken at o, 2, 
4 I 6 f 8 10, 12 and 24 hours post injection. For the 
intravenous route blood samples were taken at o, 5, 10, 
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15 , 30, 60, 180, and 360 minutes post injection. At each 
sampling time 3.0 ml of blood was collected into silicon-
ized glass tubes containing 0.3 ml of 3.8 % sodium citrate 
and centrifuged to obtain plasma. Clotting times were 
performed on the fresh plasma samples in the intravenous 
study. The protease and fibrinopeptide - A assays were 
performed using the same plasma which had been stored at-
700 c for not more than two months. In the subcutaneous 
study, all assays were performed in plasma which had been 
stored at - 100 c. 
In the intravenous study, each fraction was tested 
in the same five animals. Since all animals received all 
test agents, a dosing schedule was utilized to account for 
effects possibly due to the order in which the agents were 
administered. The schedule was as follows: 
.. 
Animal Week 1 Week 2 Week 3 Week 4 Week 5 
1 I IV IX heparin CY 216 
2 IV I CY 216 IX heparin 
3 IX heparin IV CY 216 I 
4 heparin CY 216 I IV IX 
5 CY 216 IX heparin I IV 
During the study, the following protocol for blood 
sampling was strictly adhered to. 
9:15 A.M. injection of anaesthesia. 
9:30 A.M. o hour sample followed by test fraction 
injection. 
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9:35 A.M. 5 min. sample 
9:40 A.M. 10 min. sample 
9:45 A.M. 15 min. sample 
10:00 A.M. 30 min. sample 
10:45 A.M. animals were examined for determination if 
additional anaesthesia was required and injected if 
necessary. 
10:30 A.M. l hour sample 
12:15 P.M. additional anaesthesia administered 
12:30 P.M. 3 hour sample 
3:15 P.M. additional anaesthesia administered 
3:30 P.M. 6 hour sample 
For the subcutaneous study, the different molecular 
weight fractions were examined in 15 heal thy primates. 
These animals were randomly assigned to three groups of 5 
.. 
for the purpose of testing all 5 fractions on each exper-
imental day. Each fraction was tested in 5 different 
primates. The limited number of primates necessitated 
that individual monkeys be used more that once. At least 
10 washout days were allowed before a any animal was 
utilized for the second time. The following blood 
sampling time schedule was utilized. 
8:00 A.M. injection of anaesthesia 
8: 15 A.M. O hour blood sample followed by test fraction 
injection 
10:00 A.M. injection of anaesthesia 
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10:15 A.M. 2 hour blood sample 
12:00 P.M. anaesthesia 
12:15 P.M. 4 hour blood sample 
2:00 P.M. anaesthesia 
2:15 P.M. 6 hour blood sample 
4:00 P.M. anaesthesia 
4:15 P.M. 8 hour blood sample 
6:00 P.M. anaesthesia 
6:15 P.M. 10 hour blood sample 
8:00 P.M. anaesthesia 
8:15 P.M. 12 hour blood sample 
8:00 A.M anaesthesia 
8:15 A.M. 24 hour blood sample 
For both intravenous and subcutaneous studies, the 
pharmacodynamic time course was characterized in terms of 
... 
the biological half-life (t l/2) I apparent volume of 
distribution (Vd)i plasma clearance (Clp) and area under 
the plasma - drug time curve (AUC) • Individual parameters 
were calculated from heparin concentrations determined 
using each of the previously described in vitro assays 
(Heptest, FPAGT, Anti Xa, Anti IIa). A dilute thrombo-
plastin clotting time (PT) was also performed by using the 
standardized thromboplastin from the FPAGT in a PT assay. 
To convert the bio-assay parameter into relative heparin 
concentrations, calibration curves were used. To ensure 
the most accurate calibration, the curves were constructed 
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t est fraction supplementation of the individual zero from 
hour plasma samples. 
To determine Vd, the following formula was used. 
where 
Cp = maximal plasma concentration after distribution 
determined by back extrapolation of the beta slope to time 
zero and x = dose of drug given. t 1/2 was determined by 
observing the time required for the plasma concentration 
to decrease by 1/2 during the decay phase obtained from a 
semi-log plot of concentration / time. Clp was calculated 
using the following equation: Clp = Vd x Ke where, 
.693 
Ke = t1;2 
AUC was calculated using the trapezoidal rule. To 
determine the area between sampling times the following 
equation was used. 
t [AUCJt~-l = Cn-1 + Cn 
2 
The total area was calculated by summing the individual 
areas between consecutive time intervals. Absorption of 
the anticoagulant components after subcutaneous 
administration was determined relative to the intravenous 
route using the following formula. 
Absorption = AUC SC I dose 
AUC IV / dose 
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~~tithrombotic actions 2. ~· 
The anti thrombotic effects of the test fractions 
were studied in a modified stasis thrombosis model (Fareed 
et al., 1985) using both subcutaneous and intravenous 
routes of administration. In the subcutaneous route, all 
fractions were compared at 1.0 mg/kg. For the intravenous 
route all fractions were compared at 25, 50 and 100 ug/kg. 
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White New Zealand male rabbits were anaesthetized f-
with intramuscular injections of Xylazine (20 mg/kg) and 
ketamine (80 mg/kg). After induction of anaesthesia, the 
rabbits were weighed and prepared for surgery. Baseline 
blood samples were also taken at this time. The surgical 
procedure entailed the isolation of both right and left 
jugular vein segments. To minimize trauma and to ensure 
hemostasis, battery operated cauteries were used in the 
.. 
surgical procedures. After isolating the jugular vein 
segments, the test fractions were injected by intravenous 
route through a marginal ear vein and allowed to circulate 
for five minutes. For the subcutaneous route of admin-
istration, the surgical procedure was initiated 3.5 hours 
post subcutaneous injection in the lower abdomen. 
At the appropriate time, thrombogenic challenge of 
Konyne brand of PCC (25 U/kg) followed by RVV (0.01 U/kg) 
was administered through the marginal ear vein and allowed 
to circulate for exactly 2 o seconds. At this time, the 
isolated jugular vein segments were ligated and stasis 
produced. Blood samples, drawn by cardiac puncture for ex 
vivo analysis, were taken immediately prior to and after 
injection of the thrombogenic challenge. After exactly 10 
minutes of stasis time, the isolated segments were removed 
and examined for blood clots in a saline filled petri 
dish. Clot formation was visually graded using a + 
system. In this system, - represented blood only with no 
evidence of clotting, + indicated some small clots but 
mostly blood, ++ indicated mostly small but some medium 
clots, +++ indicated a large clot with some blood while 
++++ indicated a fully formed, casted clot with no blood. 
In order to analyze the data, the + grades were 
transformed into numerical values using the following 
scale. 
= 0 
+ = 1.25 
++ = 2.5 
+++ = 5.0 
++++ = 10.0 
After transformation, mean values were determined from the 
average of the left and right stasis scores. 
For statistical significance, all drugs were 
compared in 5 animals for each route of injection and 
concentration. 
G. Statistical analysis 
Various statistical tests were performed on the 
experimental data. For this purpose an IBM PC XT 
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utilizing SYSTAT and an Hewlett - Packard 32 E were used 
to facilitate data reduction and test statistic 
calculation. 
SY STAT is a commercial software program for 
statistical applications. It has the ability to perform 
most commonly used statistical tests, and was utilized in 
the calculation of means, standard deviations, correlation 
coefficients, t-tests, one way analysis of variance 
(AVOVA) and student-Newman-Keuls test statistics. All 
test statistics were calculated at a significance level of 
0.05. Critical values for t, F and H distributions were 
obtained from Zar, (1974). 
To establish relationships between molecular weight 
and effects in the various in vitro assays, regression 
analysis was used to calculate correlation coefficients . 
• To test for a difference in effect of the fractions 
in the various in vitro tests, one way ANOVA was utilized. 
If ANOVA revealed a significant difference, the Student-
Newman-Keuls test was used to more precisely determine 
which fractions differed. This procedure was selected in 
preference to both the Tukey and Duncans tests since it 
tends to be more powerful and more widely accepted (Zar, 
1984) • When using SYSTAT to perform the student-Newman-
Keuls test, only critical values for differences in 
ordered means were provided. These values were utilized 
by calculating the differences in ranked mean values for 
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the comparison groups and comparing this value at the 
appropriate gap order to determine significance. 
To test for a difference in the pharmacodynamic time 
course of the test fractions, ANOVA followed by student-
Newman-Keuls testing was again utilized. 
To test for difference between the anti thrombotic 
effects of the test fractions, the Kruskal Wallis 
nonparametric ANOVA was used. Multiple comparison testing 
of nonparametric ANOVA was done similar to the Newman-
Keuls test, however the ranked sums were used in the 
calculation of the test statistic. 
To represent the variation in mean values, standard 
deviation calculated using SYSTAT. Thus in all figures, 
error bars represent the standard deviation • 
• 
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CHAPTER IV 
RESULTS 
Fractionation of Heparin A· 
From the initial five grams of starting material, 
4 • 425 grams were recovered from the gel-filtration 
procedure in the following proportions. Fraction I 250 
mg, I I 7 2 5 mg, III 575 mg, IV 650 mg, V 626 mg, VI 
550 mg I VII 450 mg, VIII 500 mg and IX 100 mg. The 
elution profile of heparin lot # 410 is seen in figure 1. 
The elution pattern reflected the composition of molecular 
weight components in the unfractionated preparation. A 
normal distribution of these components was observed. 
To test whether the heparin content was similar for 
each of the gel-filtered fractions, a toluidine blue 
heparin assay was used. In this assay, the toluidine blue 
dye reacted with the sulfate groups on the heparin 
• 
molecules to produce a color change. This color change 
increased with increasing heparin content and was mea-
surable by absorbance at 606 nm. Appendix X shows the 
direct relationship between heparin content and absorbance 
at 606 nm. Figure 2 illustrates the results of the 
toluidine blue assay on the gel-filtered fractions. All 
fractions displayed similar absorbance characteristics 
suggesting similar glycosaminoglycan content. 
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Molecular Weight Determination B. 
The results of the HPLC-GPC chromatography of the 
fractions, the starting heparin and CY 216 using two 
columns of different porosity (LKB tsk 2000 and 3000) are 
represented in appendix XIV and XV respectively. A 
detailed description identifying various regions of the 
elution curves is shown in appendix XX. Due to the 
differences in porosity, slightly different molecular 
weights were obtained from the two columns. To achieve 
accurate values, the results from both columns were 
averaged used in the calculation of apparent mean and peak 
molecular weights. These values along with the approx-
imate molecular weight ranges are seen in table 1. 
Although significant overlap existed between the 
fractions, they were different when analyzied using HPLC 
in terms of mean molecular weight, peak• molecular weight 
and molecular weight distribution. 
Table 2 shows the results of the viscosity mea-
surements on the same heparin preparations. The viscosity 
of the individual fractions ranged from 0.76 mPa for the 
5,100 M.W. fraction to 1.28 mPa for the 23,000 M.W. frac-
tion. For all test heparins, the viscosity increased with 
increasing molecular weight. When the viscosity values 
were plotted as a function of molecular weight, a linear 
relationship was observed (figure 3). 
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c. In Vitro Screening (Clotting and Amidolytic 
A,?saysl. 
Five fractions with the broadest difference in 
molecular weight, the native heparin from which these 
fractions were obtained and CY 216 were supplemented to 
normal human pooled plasma. These agents were tested at 5 
concentrations for in vitro anticoagulant activity using 
assays described in the methods section. All assays were 
performed in duplicate on 5 separate days to achieve 
statistical validation. 
1. APTT Assay 
The results for the APTT, expressed in terms of 
clotting time in seconds, are given in table 3. For this 
and all other clotting assays, the prolongation of this 
parameter was directly related to the antlcoagulant action 
of the respective fraction. For all fractions a concen-
tration dependent response was observed within the o. 6-
10 ug/ml range. The lowest concentrations resulted in 
slight increases from the baseline clotting time of 27 
seconds. Higher concentrations, 
prolonged times for all fractions. 
concentrations, the 23, ooo . I 17,450 . I 
displayed greatly 
At the higher 
13 , 3 o o and 9 , o o o 
M.W. fractions, along with the native heparin, inhibited 
the assay beyond its linear range of 200 seconds. 
When compared for potency at a concentration of 2.5 
87 
ug/ml, large differences between the individual molecular 
weight fractions were observed.· The 13,300 M.W. fraction 
was the most potent with a clotting time of 82 seconds. 
At the same concentration, the 5,100 M.W. fraction 
displayed the least potent actions, with a time of 3 6 
seconds. The apparent potency rank order of the different 
heparins in this assay was 13,300 M.W. > Native Heparin > 
17,·450 M.W. > 9,000 M.W. > 23,000 M.W. > CY 216 > 5,100 
M.W.. ANOVA revealed that these potency differences were 
significant (p < • 0001) • Newman-Keuls (.05) comparison 
suggested significant differences between the following: 
13,300 'I' heparin 'I' 17,450 'I' 9,000 = 23,000 = CY 216 = 
5,100. 
Testing the 5 gel-filtered fractions for correlation 
between potency and M.W. indicated a poor relationship (r 
• 
= .187). Although a good correlation existed from 5,100 
through 13, 300, beyond this point, further increases in 
molecular weight did not result in greater potency. 
2. PT Assay 
The results of the PT assay are shown in table 4. 
Since this assay was not sensitive to the actions of 
heparin below 1.25 ug/ml, relatively higher concentrations 
were used. Between 1.25 20 ug/ml, concentration 
dependent effects were observed for all fractions. These 
concentration dependent effects varied in potency response 
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between the different molecular weight fractions. At 20 
ug/ml, the 23,000 M.W. fraction prolonged the clotting 
time to 55 seconds while a identical concentration of the 
s,100 M.W. only elevated the time to 15 seconds. When 
ranked in terms of apparent potency at the 2 o ug/ml 
concentration, the 23,000 M.W. > 17,450 M.W. > 13,300 M.W. 
> Native Heparin > 9,ooo M.w. > CY 216 > 5,100 M.W •• 
ANOVA suggested that these potency differences were 
significant (p < • 0001) • The overall conclusion 
determined by Newman-Keuls at • 05 suggested significant 
differences between the following: 23,000 r 17,450 r 
13,300 r heparin r 9,000 = CY 216 r 5,100. 
Regression analysis demonstrated a strong relation-
ship between clotting time in the PT assay and molecular 
weight (r = .97). From 5,100 through 23,000 M.W., potency 
directly increased with increasing M. W ... It was inter-
esting to note that the potency of both the native heparin 
and CY 216 both correlated well to their respective 
molecular weights. 
An identical PT assay was run in plasma deficient in 
antithrombin III (antithrombin III levels were determined 
to be 6.2 % of normal using a synthetic substrate based 
functional assay [aca method] (table 5). In this plasma, 
20 ug/ml concentrations of all test agents produced a 
slight prolongation from the baseline clotting time. No 
difference in potency was observed between any of the test 
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fractions (p = .83). 
3 • Heptest Assay 
The results for the heptest assay are presented in 
table 6. The baseline value of the assay in normal human 
pooled plasma was 16 seconds. Supplementation of the test 
fractions at concentrations between o. 6 and 10 ug/ml to 
the same plasma resulted in concentration dependent 
increases in clotting time. Increasing concentration 
resulted in increased clotting time for all fractions. 
These concentration dependent actions were different in 
terms of potency response between the various test agents. 
When compared at a concentration of 2. 5 ug/ml, the ap-
parent rank order of the test heparins was as follows: 
Native heparin> 13,300 > 9,000 > 23,000 > 17,450 >CY 216 
> 5,100. •• ANOVA indicated significant differences between 
these potency responsesn(p = .OOO). The overall conclu-
sion determined by Newman-Keuls analysis at .05 suggested 
the following differences in potency were significant: 
Heparin 'I 13, 300 'I 9, 000 = 23, ooo 'I 17, 450 'I CY 216 'I 
5,100. 
The correlation observed between potency and molec-
ular weight in this assay was poor (r = • 08) . Potency 
increased with increasing molecular weight from 5, 100 to 
13,300. Higher M.W.'s (17,450 and 23,000) did not demon-
strate greater potency but rather were less potent when 
90 
compared to the 13,300 M.W. fraction. 
4 • Anti Xa Assay 
The results of the amidolytic anti Xa assay are 
shown in table 7. The results of this assay are expres-
sed in terms of % inhibition and were calculated as pre-
viously described in methods. These values represent the 
inhibition of factor Xa by the different heparin prepar-
ations. For all test fractions, this inhibition increased 
with increasing concentration, however large differences 
in potency were observed. At 10 ug/ml, the most potent 
fractions resulted in inhibition ranging from 87 - 88 %. 
The least potent fraction displayed 69 % inhibition at an 
identical concentration. When ranked in order of apparent 
potency determined at a concentration of 2.5 ug/ml, 13,300 
• > Heparin > 2 3 , O o o > 17 , 4 5 O > 9 , o O o > CY 216 > 5 , loo • 
ANOVA suggested that the apparent potency differences were 
significant (p = .031). Newman-Keuls multiple comparison 
test (.05) suggested actual differences between the 
following fractions: 13,300 = heparin =23,000 = 17,450 r 
9,000 r 5,100 = CY 216. 
Potency correlated well with M.W. from 5,100 through 
13,300. However, above 13, 300 M. W. all fractions dis-
played similar potency, thus the overall correlation 
between potency and M.W. was poor (r = .67). 
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5 • Anti IIa Assay 
The results for the anti II a amidolytic assay are 
seen in table a. These results are expressed in terms of 
% inhibition and reflect the actions of the fractions on 
factor IIa. As with all previous assays, concentration 
dependent effects were observed for all test agents 
between o. 626 and 10 ug/ml concentrations. Between the 
individual fractions, large differences in potency were 
observed. At 10 ug/ml, the most potent fractions resulted 
in inhibition ranging from 90 93 % • Less potent 
fractions produced about 60 % inhibition at identical 
concentrations. The apparent potency rank order observed 
at a concentration of 2.5 ug/ml was 23,000 > 13,300 > 
17,450 > Heparin > 9,000 > 5,100 > CY 216. AN OVA 
suggested the potency differences were significant (p = 
.000). Newman-Keuls (. 05) demonstrated significant 
differences between the following fractions: 23,000 = 
17,450 = 13,300 =heparin~ 9,000 ~ 5,100 ~CY 216. 
The correlation between potency and M. w. was r = 
.60. These results were similar to those achieved in the 
anti Xa assay. Potency increased with increasing 
molecular weight from 5, 100 through 13, 3 oo. Molecular 
weights above 13, 300 showed no additional increases in 
potency. 
It is interesting that in most conventional clotting 
and amidolytic assays, similar patterns of molecular 
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weight dependent potency were observed. The noteworthy 
exception was the PT assay. This assay was also the only 
method which utilized an extrinsic activation system. 
For the purpose of further examining the molecular 
weight dependent effects of heparin on extrinsic acti-
vation, a assay based upon the release of fibrinopeptide-A 
was utilized. The assay was used as described in methods. 
6. FPA Generation Assays 
The test agents were examined in four FPA generation 
matrices (normal platelet poor plasma, antithrombin III 
deficient plasma, normal platelet rich plasma and whole 
blood) • For all plasma systems, thromboplastin was used 
as an activator (extrinsic activation). The whole blood 
system was activated by contact with glass (intrinsic 
activation) • The results of all FPA generation assays 
were expressed in terms ng/ml of FPA generated over a two 
minute period. This value was inversely related to the 
potency of the test fractions in the assay. 
a. FPA Generation In Normal Human Plasma 
The results of the test fractions in normal platelet 
poor plasma are shown in table 9. Between the ranges of 
0.6 5 ug/ml, concentration dependent effects were 
observed for all test fractions. Differences in potency 
between the fractions were observed and appeared to be 
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related to molecular weight. The 23, ooo M. W. fraction 
displayed the most potent inhibition of FPA. At 5 ug/ml 
42 ng/ml were generated. In contrast, the 5, 100 M. W. 
fraction displayed the least inhibition. At an identical 
concentration, 763 ng/ml of FPA were generated over the 
two minute time period. When the test fractions were 
compared for their ability to inhibit FPA generation at a 
concentration of 2. 5 ug/ml, the following potency rank 
order was observed 23, 000 > Heparin > 17, 450 > 13, 300 > 
9 1 000 > CY 216 > 5,100. Significant differences were in 
potency were determined by ANOVA (p =.000). Newman-Keuls 
analysis (.05) suggested differences between the fol-
lowing: 23,000 = 17,450 =native heparin r 13,300 r 9,000 
! 5,100 = Cy 216. 
b. FPA Generation In Antithrombin III Deficient Plasma 
Plasma from the same source used in the previous in 
vitro assays was made deficient in antithrombin III using 
the heparin affinity chromatography technique described in 
methods. Antithrombin III levels were determined to be 
6. 2 % of normal using a functional method (ACA). The 
plasma was supplemented at 10 ug/ml with the test 
fractions and assayed in the same thromboplastin activated 
FPA generation assay. The results illustrating the ef-
f ects of the molecular weight fractions and a saline 
control, in this plasma are presented in table 10. 
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In the plasma deficient in antithrombin III, 
addition of the test fractions did not result in the 
inhibition of FPA generation. In the saline control, 
thromboplastin activation resulted in the generation of 
1216 ng/ml FPA over the 2 minute assay period. When the 
test fractions were supplemented to the antithrombin III 
deficient plasma, the generated FPA was similar to control 
values (ANOVA value p = .73). 
c. FPA Generation In Platelet Rich Plasma 
The effects of the test fractions on FPA generation 
were compared in platelet poor and platelet rich normal 
human plasma at a concentration of 2.5 ug/ml. The results 
are seen in figure 4 . All fractions inhibited the gen-
eration of thromboplastin activated FPA generation in both 
the platelet rich and platelet poor plasmas. Using paired 
t-tests, no difference was observed between the effects of 
any of the test fractions in the platelet rich or platelet 
poor plasma. The individual probabilities were as fol-
lows: 23,000 p = .104; 17,450 p = .072; 13,300 p = .60; 
9,000 p = .60; 5,100 p = .83; heparin p = .51; CY 216 p = 
.so. 
Although no significant differences were detectable 
between the two plasmas, slightly more FPA was consis-
tently generated in the platelet rich plasma. 
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d. FPA Generation In Whole Blood 
Five fractions were screened in the whole blood FPA 
generation assay exactly following the procedure described 
in methods. The results are illustrated in table 11. All 
test fractions displayed concentration dependent inhi-
bition of FPA generation. These concentration dependent 
effects were different in terms of potency response 
between the test agents. At 10 ug/ml the most potent test 
fractions produced complete inhibition of FPA generation. 
In contrast in the presence of the least potent fraction 
( 5, 100 M. W.) , 12. 6 ng/ml FPA was generated over the 2 
minute assay period. The apparent potency rank order was 
as follows: 13,300 > 23,000 > Heparin > CY 216 > 5,100. 
Using Newman-Keuls analysis (.05), significant differences 
were observed between the following: 13,300 = 23,300 = 
Heparin~ Cy 216 = 5,100 was achieved. • 
It was interesting to note that unlike the 
thromboplastin activated assays, the potency of the 
fractions did not appear to be related to molecular 
weight. 
7. VII - Thromboplastin Assay 
The enhanced potency of high molecular weight 
fractions observed in thromboplastin activated assays 
suggested high molecular weight heparin may inhibit the 
actions of thromboplastin. To investigate this relation-
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ship, a assay using thromboplastin and factor VII to 
activate factor X to Xa was developed. The assay endpoint 
was determined by monitoring the release of pNA from a Xa 
specific substrate. In this assay factor VII and 
thromboplastin were both necessary to activate factor x. 
The activation of factor X was directly related to factor 
VII and thromboplastin concentrations (fig. 5). 
Figure 6 shows the effect of the test fractions on 
this assay system. Although compared at an identical 
concentration of 1.25 ug/ml, large differences in the 
potency of the individual fractions were observed. The 
potency appeared to be related to the molecular weight of 
the individual fractions. The 23, ooo M. W. fraction was 
the most potent inhibitor of the assay. In the presence 
of this fraction, p-NA was generated at a rate of • 55 
uM/min. In contrast, the 5,100 M.W. fraction produced the 
least inhibition. In its presence, p-NA was generated at 
a rate of 2. 75 uM/min. The potency of the remaining 
fractions followed the following rank order: 23,000 > 
17,450 > 13,300 > Heparin > 9,000 > CY 216 > 5,100. 
Significant differences in potency, as determined by 
Newman-Keuls analysis (.05) were detected between the 
following fractions: 23,000 i 17,450 i 13,300 i Heparin i 
9,000 = CY 216 i 5,100. 
As with other assays using thromboplastin 
activation, a high correlation between potency and 
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molecular weight was observed (r = .97). 
To distinguish whether the pattern of molecular 
weight dependent inhibition was due actions of the test 
fractions inhibiting factor Xa, the original assay was 
\ 
modified. Factor's VII and X were eliminated and replaced 
by a concentration of factor Xa which generated an amount 
of p-NA equivalent to the antithrombin III control in the 
original assay. The effect of the test fractions on this 
system are shown in figure 7. In the presence of the test 
fractions higher rates of p-NA release were observed 
compared to the original assay. All fractions inhibited 
the Xa, however no direct molecular weight dependent 
inhibition was observed as before. The 23,000 ; 17,450 ; 
13,300 . I 9,000 and native heparin preparations all 
resulted in similar rates of p-NA release between 5 - 6 
uM/min. In contrast to the results witn the presence of 
factor VII, Newman-Keuls multiple comparison (. 05) sug-
gested that 23,000 = 17,450 = 13,300 =Heparin i 9,000 i 
CY 216 = 5,100. 
To further investigate the mechanism of the molec-
ular weight dependent potency differences between the 
fractions, two systems isolating the various fractions 
with either factor VII-thromboplastin or factor X were 
used. The centrifugal rotors were designed with two wells 
which allowed initial isolation with subsequent mixing of 
all reagents after acceleration. This design allowed the 
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test fractions to incubate either in the well containing 
the factor VII - thromboplastin or with the factor X. 
Figure s shows the result of the test fractions in this 
experiment. Paired t-tests revealed significant dif-
f erences between the actions of the test fractions in the 
two incubation systems for only the 23,000 ; 17,450 M.W. 
fractions and unfractionated heparin (p = .ooo, .ooo and 
.001 respectively). For these three fractions, incubation 
with factor VII thromboplastin resulted in greater 
inhibition than incubation with factor X. The 13, 300 ; 
9,100 ; 5,100 M.W. fractions and CY 216 showed no dif-
ference between the two incubation systems (probabil-
ities .084, .935, .101 and .95 respectively). 
The % differences between the two incubation systems 
were calculated to provide a better indication of the 
• 
molecular weight differences between the two incubation 
systems. These values were 64 %, 48 %, and 23 % for the 
23, ooo, 17, 450 and unfractionated heparin respectively. 
These results demonstrated that in this assay the 23,000 
M.W. fraction produced the most inhibition followed by the 
17,450 M.W. fraction and unfractionated heparin 
respectively. 
a. VII - Thromboplastin in Plasma 
The original VII - Thromboplastin assay was modified 
to examine the actions of the test fractions in a plasma 
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matrix. Fibrinogen deficient plasma was used to prevent 
clot formation and was the source factors VII and x. This 
assay was performed exactly as described in methods using 
both xa and thrombin specific substrates. Figure 9 shows 
the effects of the molecular weight fractions at a 
concentration of 5 ug/ml in the plasma system with a Xa 
substrate. In this system the potency response of the 
fractions resembled that of the pure Xa system. The 
23,000 ; 17,450 ; 13,300 and native heparin all exhibited 
similar potency. Significant differences, determined by 
Newman-Keuls analysis (.05) were observed between the 
following 13,300 = 17,450 =Heparin= 23,000 f 9,000 =CY 
216 f 5,100. This observation was in strong contrast to 
other thromboplastin activated assays, where potency 
consistently increased with increasing molecular weight. 
Figure 10 shows the results of the same assay using 
a 2. 5 ug/ml concentration of the test fractions. A 
similar pattern of molecular weight dependent effects was 
observed. At this concentration, the 13,300 M.W. fraction 
appeared to be the most potent inhibitor of the assay. 
This observation was even more evident at 1.25 ug/ml 
(figure 11) . The apparent potency rank order for both 
concentrations was 13,300 > 17,450 > Heparin > 23,000 > 
9 I 0 0 0 > Cy 216 > 5 I 10 0 . Newman-Keuls (. 05) suggested 
significant differences between the following: 13, 300 f 
17,450 =Heparin= 23,000 f 9,000 =CY 216 f 5,100. 
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The effects of the test fractions at a concentration 
of 5 ug/ml, in the plasma system using thrombin substrate 
are shown in figure 12. The pattern of molecular weight 
related potency in this system was similar to that 
observed with the Xa substrate. The apparent potency 
order of the fractions was as follows: 13,300 > 17,450 > 
23,000 > Heparin > 9,000 > CY 216 > 5,100. Significant 
differences were detected using Newman-Keuls (.05) between 
all fractions except CY 216 = 5,100 M.W. 
At a test fraction concentration of 2. 5 ug/ml, a 
similar pattern of molecular weight dependent effects were 
observed. Consistent with the lower concentrations of the 
test fractions, less inhibition of the assay was seen 
(figure 13). 
At a concentration of 1. 25 ug/ml, additional 
concentration dependent decreases in the actions of all 
test fractions were observed (figure 14). At this 
concentration, the 13,300 M.W. fraction appeared to be the 
most potent inhibitor of the assay, however it was not 
significantly different from the 23, ooo and 17, 450 M. w. 
fractions. 
D. In Vivo·Results CPharmacodynamic Concentration I Time 
Course) 
The intravenous and subcutaneous pharmacodynamic 
concentration / time course of CY 216, unfractionated 
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heparin the 23,000 ; 13,300 and 5,100 M.W. fractions were 
studied in the primate Macaca mulatta as described in 
methods. Plasma concentrations of the test fractions were 
determined using 5 assays (Heptest , dilute PT, anti Xa, 
anti IIa and FPAGT). These assays were performed exactly 
as previously described. Gravimetric concentrations were 
extrapolated from calibration curves made by supplementing 
the test agents to autologous plasmas. The resulting 
concentrations were plotted as a semi-log function of time 
and used to estimate the time course parameters. The 
formulas used in these calculations are described in 
methods. 
1. Intravenous Administration 
Figure 15 shows the semi-log concentration / time 
• plot for the 23, 000 M. W. fraction calculated from data 
obtained using the Heptest assay. After injection, plasma 
concentrations declined at a constant rate throughout all 
sampling times. The apparent distribution volume was .049 
L/Kg suggesting that this fraction remained within the 
plasma. The half-life was calculated at 29 ± 2.2 minutes. 
The semi-log concentration / time plot for the 
13, 300 M. W. fraction calculated from data obtained using 
the Heptest assay is seen in figure 16. After injection, 
an initial rapid decrease in plasma concentration was 
observed through the 5, 10 and 15 minute sampling times. 
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Afterward, a slower rate of decrease persisted until the 
drug could no longer be detected. These differences in 
elimination rates demonstrated that for this agent both 
alpha and beta phases of distribution and elimination 
occurred. The half-life during the alpha phase was 25 ± 3 
minutes compared to the 34.5 ± 4.5 minutes during the beta 
phase. The observation of a biphasic elimination curve 
suggested distribution of this fraction within two 
compartments. 
Figure 17 shows the concentration / time plot for 
the 5, 100 M. W. fraction calculated from plasma concen-
trations determined using the Heptest assay. A bi-phasic 
elimination pattern was again observed. The half-life 
calculated from the alpha slope was 25 ± 2 minutes 
compared to 51 ± 6.5 minutes during the beta phase. The 
• kinetic behavior of this fraction suggested distribution 
to two compartments. 
Figure 18 shows the concentration / time plot for CY 
216 calculated from heptest assay data. The concentration 
I time course of this agent was similar to the 5,100 M.W. 
fraction. The alpha phase persisted throughout the 5,10 
and 15 minute sampling times. The half-life during this 
phase was 22.5 ± 4 minutes. The beta phase half-life was 
58 ± 4. 8 minutes. A slightly larger distribution volume 
(.006 L/Kg) was calculated for this agent compared to the 
other test fractions. 
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The concentration / time course of the unfraction-
ated heparin calculated using the Heptest assay is shown 
in figure 19. After injection, the plasma concentrations 
rapidly decreased over the first 10 minutes. Between 10 
and 15 minutes, plasma concentrations decreased at a 
qreatly reduced rate compared to the initial 10 minutes. 
Beyond this point, elimination increased to a rate similar 
to that initially observed. These different rates 
sugqested distribion to more that two compartments. The 
half-life values for the elimination phases were 25 ± 3.5 
and 31 ± 2. 2 minutes for the alpha and beta phases 
respectively. 
a. Pharmacodynamic Concentration / Time Course of the Test 
Fractions Using Different Assays 
i. Heptest 
A summary table for the intravenous plasma concen-
tration / time course of the test fractions calculated 
using the heptest assay is seen in table 12. Comparison 
of the half-life values demonstrated an inverse relation-
ship between this parameter and molecular weight. Half-
life increased with decreasing molecular weight from 29 
minutes for the 23,000 M.W. fraction, to 58 minutes for CY 
216 (M.W. 4,500). This response was consistent for all 
test fractions, however significant differences were only 
observed between the highest and lowest molecular weighs. 
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The overall conclusion based upon ANOVA and Newman-Keuls 
(.05 ) multiple comparison for similarity in half-life was: 
23 , ooo = 13, 300 = Heparin '! CY 216 = 5, 100. Clearance 
values were consistent with the half-life results. 
The apparent distribution volume of all test 
fractions approximated the plasma volume (.05 -.06). With 
the exception of CY 216, no difference was observed in 
this parameter among the test agents (p = • 01) It is 
interesting to note that the lowest molecular weight 
fraction (CY 216) had the greatest apparent volume of 
distribution. 
Comparison of the molecular weight fractions for 
their response in terms of area under the plasma concen-
tration / time curve (AUC) were similar to the half-life 
results. AUC increased with increasing molecular weight . 
• This observation was consistent for all test fractions, 
however only the lowest M.W. fractions were significantly 
different. Comparison using Newman-Keuls (.05) suggested 
an overall conclusion of CY 216 = s,100 'f: 13,300 = heparin 
= 23,000. 
ii. Anti Xa Assay 
The results of the intravenous concentration / time 
course for the anti Xa activity of the test fractions is 
shown in table 13. The curves from which these values 
were calculated are given in appendix XVIa. No signif-
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icant difference between the time course observed using 
the Heptest or anti Xa method was calculated {for Vd p = 
• for T 1/2 p = .26 ; for Cl p = .35 and for AUC p = 
.03 I 
• 67) • 
iii. Anti IIa Assay 
The results of the time course for the anti II a 
activity of the fractions is seen in table 14. The curves 
from which these values were calculated are shown in 
appendix XVIb. No increase in half-life was observed with 
decreasing M. W. All test fractions displayed a similar 
plasma half-life which ranged from 30 - 32 minutes. These 
slight differences were not significantly different {p = 
• 28) • In addition, no molecular weight dependent effects 
were observed for clearance or apparent distribution 
volume. A molecular weight related effect was observed 
• for AUC. CY216 and the 5, 100 M. W. fraction displayed 
significantly greater values {4.0 & 4.73 respectively) 
compared to the higher molecular weight fractions (3.31, 
3.53 and 3.5 for 23,000 ; 17,450 and heparin respectively. 
iv. Dilute Thromboplastin Assay 
The time course values of the test fractions 
calculated from the dilute thromboplastin assay are 
illustrated in table 15. The concentration / time plots 
from which these values were calculated are shown in 
appendix XVIc. Molecular weight dependent effects were 
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observed for all parameters. Half-life, apparent Vd and 
AUC all increased with decreasing molecular weight. 
Accordingly, plasma clearance decreased in a similar 
manner. 
The concentration / time course of the test 
fractions calculated using this assay, showed a similar 
pattern of molecular weight dependence to those calculated 
from other assays. These values were less compared to 
those calculated using the heptest and anti Xa assays. 
The values ranged from 26 minutes for the 23, ooo M. W. 
fraction, to 39 minutes for CY 216. 
v. FPAGT 
Table 16 shows the summary of the intravenous 
concentration / time course for the test agents calculated 
• from the FPAGT. The concentration / time plots from which 
these values were calculated are shown in appendix XVId. 
As with previous assays, significant differences in the 
kinetic parameters of the molecular weight fractions were 
observed. Half-life and AUC increased as the molecular 
weight of the test fraction decreased. 
inversely related to half-life. 
Clearance was 
When the time course as determined in this assay 
was compared to those calculated by other methods, 
significant differences were observed. Half-life values 
were longer for all fractions compared to those calculated 
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from other methods. These values ranged from 30 minutes 
for the 23,000 M.W. fraction, to 61 minutes for CY 216. 
Accordingly, AUC values for all fractions increased 
relative to their increased halflives. 
Subcutaneous Administration 2. 
Figure 20 shows the semi-log concentration / time 
plot for the 23,000 M.W. fraction after subcutaneous 
injection. The concentrations used in this plot were 
determined using the Heptest assay. Poor absorption from 
the subcutaneous injection site was observed for this 
agent. After injection, plasma concentrations rose to a 
average peak of • 06 ug/ml at 4 hours. From this point, 
plasma levels slowly declined until 12 hours when no drug 
was detectable. 
The area under the plasma concentration time curve 
• {AUC) was similarly low (. 47 ug hr/ml). A half-life of 
205 minutes was observed. 
The semi-log concentration / time plot for the 
13,300 M.W. fraction after subcutaneous injection is seen 
in figure 21. The plasma concentrations used in this plot 
were determined using the Heptest assay. A peak plasma 
level of about .25 ug/ml was observed at 4 hours. From 
this point, plasma levels slowly declined at varying 
rates. At 12 hours, a slight amount of drug was detect-
able in the circulation. No drug was detectable at 24 
hours. The half-life and AUC values observed for this 
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fraction were 144 minutes and 1.54 ug hr/ml respectively. 
When compared to the 23, 000 and 13, 300 M. W. frac-
tions, the 5,100 M.W. fraction displayed much greater 
absorption from the subcutaneous injection site (figure 
22 ). A peak plasma concentration (determined using the 
Heptest assay) of about 4.0 ug/ml was observed at 4 hours 
post injection. Plasma concentrations declined to a level 
of 1.5 ug/ml after 12 hours. No drug was detectable at 24 
hours. 
The greater absorption of this fraction was also 
reflected in the AUC, which was more that 15 X greater 
than either the 13,300 or 23,000 M.W. fractions (23.7 ug 
hr/ml). The half-life for this fraction was 108 minutes. 
The semi-log concentration / time plot for CY 216 
after subcutaneous administration determined from Heptest 
assay data, is seen in figure 23. • • The pharmacodynamic 
time course of this fraction was similar to that of the 
5,100 M.W. fraction. A peak absorption of about 3.7 ug/ml 
was observed at 4 hours. The AUC and half-life were 22 ug 
hr/ml and 144 minutes respectively. 
Figure 24 shows the subcutaneous pharmacodynamic 
concentration / time course of the unfractionated heparin. 
The data points were plotted using plasma concentrations 
determined from the Heptest assay. A peak plasma concen-
tration of 1.5 ug/ml was observed at 4 hours post adminis-
tration. From this peak, plasma levels steadily declined 
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to minimally detectable levels at 12 hours. No drug was 
detectable at 24 hours. The half-life of this agent was 
the shortest of all the test fractions (94 minutes). The 
AUC was 6.8 ug hr/ml. 
a. Pharmacodynamic Time Course of the Molecular Weight 
Fractions After Subcutaneous Administration, Determined in 
oif f erent Assays 
i. Heptest 
A comparison of the subcutaneous concentration / 
time course for the molecular weight fractions calculated 
from the heptest assay are seen in table 17. A direct 
relationship was observed between the molecular weight of 
the fractions and relative absorption. Absorption and AUC 
• 
increased with decreasing molecular weight. Comparison of 
the absorption of the test fractions using ANOVA followed 
by Newman-Keuls analysis suggested significant differences 
between some of the test agents. The overall conclusion 
ranked in order of increasing absorption was: 23, 000 'I 
13,300 'I Heparin 'I CY 216 'I 5,100. 
ii. Anti Xa 
The summary table for the subcutaneous pharmaco-
dynamic concentration / time course of the test fractions 
calculated from the anti Xa assay are seen in table 18. 
These values were determined from the semi-log concentra-
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tion / time plots shown in appendix XVIIa. As with the 
results calculated using the Heptest assay, relative 
absorption and AUC increased with decreasing molecular 
weight. The absorption of all fractions as calculated 
from this method was slightly greater when compared to 
that calculated from Heptest. The relative absorption of 
CY 216 and the 5,100 M.W. fraction approached 100 % (96 
and 94 % respectively). The 23, ooo M. W. fraction dis-
played the least absorption at 10 %. 
iii. Anti IIa 
Table 19 shows the subcutaneous pharmacodynamic 
concentration / time course for the test fractions 
calculated from the anti IIa assay. The plots from which 
these values were determined are shown in appendix XVIIb • 
.. 
As with previous assays, relative absorption increased 
with decreasing molecular weight. As determined by ANOVA 
and Newman-Keuls, the differences in absorption between 
the fractions was significant. The overall conclusion, 
ranked by decreasing absorption was: 5,100 'I Cy 216 'I 
Heparin 'I 13,300 = 23,000. These values were lower than 
those observed using the heptest and anti Xa assays. 
Values ranged from a low of 6 % , to a high of 60 % for 
23,000 and 5,100 M.W. fractions respectively. 
iv. Dilute Thromboplastin 
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The results of the subcutaneous plasma concentration 
I time course for the test fractions calculated from the 
dilute thromboplastin assay are seen in table 20. These 
values were determined from concentration / time curves 
shown in appendix XVIIc. When compared to the relative 
absorption values calculated from other assays, these 
results were much lower. In contrast to the 96 % absorp-
tion observed with CY 216 using the anti Xa assay (table 
17), the absorption of CY 216 calculated from this assay 
was 38 %. As with other assays, the relative absorption 
increased with decreasing molecular weight. 
v. FPAGT 
The concentration / time course values for subcu-
taneous administration of the test fractions calculated 
from the FPAGT are seen in table 21. ... The plots from which 
these values were determined are shown in appendix XVIId. 
The absorption increased with decreasing molecular weight. 
The 23,000 M.W. fraction displayed 28 % absorption 
compared to 100 % for CY 216. Significant differences 
were determined using Newman-Keuls analysis between all 
fractions except CY 216 and the 5,100 M.W. fraction. 
Half-life also appeared to be different between the 
test fractions. Half-life increased with decreasing 
molecular weight however, a significant difference was 
only observed for CY 216. The overall conclusion for 
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equivalence in half-life based on Newman-Keuls analysis in 
order of decreasing values was: CY 216 ;':- 5,100 M.W. = 
131 300 M.W. = heparin = 23,000 M.W. 
E. In Vivo Results (Antithrombotic Actions) 
The test fractions were compared for their anti-
thrombotic actions in a rabbit stasis thrombosis model. 
The model used stasis, combined with prothrombin complex 
concentrate and Russell's viper venom as a thrombogenic 
challenge. The antithrombotic effects of the test agents 
were compared using both intravenous and subcutaneous 
routes of administration. 
1. Intravenous (25 ug/kg) 
The results obtained after intravenous adminis-
.. 
tration of the test fractions at 25 ug/kg, compared to a 
saline control are seen in figure 25. The control rabbits 
averaged stasis clot scores of 6.5. Scores between 2 and 
3 were observed for all agents except for the 5,100 M.W. 
fraction which resulted in a score of 5. 5. When tested 
using the Kruskal Wallis nonparametric ANOVA and appropri-
ate multiple comparison test, significant differences were 
detected between all test agents and control, except for 
the 5,100 M.W. fraction. Between the 23,000 and 13,300 
M.W. fractions, CY 216 and unfractionated heparin, no 
difference in the anti thrombotic effects were observed. 
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The overall conclusion determined by multiple comparison 
analysis (. 05) ranked in order of decreasing anti throm-
botic potency was: 13,300 M.W. = 23,000 M.W. = Heparin = 
CY 216 r 5,100 M.W. = control. 
The circulating pharmacodynamic effects of the 
molecular weight fractions in the test rabbits are shown 
in table 22. These effects were measured in the clotting 
and amidolytic assays described in methods. The baseline 
values were determined prior to drug administration. Pre-
challenge values indicate the circulating drug actions 
immediately prior to administration of the thrombogenic 
challenge. 
Comparison of the pre-challenge and baseline values 
demonstrated minimal anticoagulant actions for all 
fractions in all assays. These observations were consis-
.. 
tent with the low dose at which the fractions were 
administered. As with the in vitro studies, the potency 
of the individual fractions was dependent upon the assay 
method. However, due to the low plasma concentrations, 
significant differences between the effects of the 
fractions in different assays were not observed. 
To determine whether the circulating pharmacodynamic 
actions were related to the anti thrombotic effects, cor-
relations coefficients were calculated. Poor correlation 
between the activity in the heptest assay and anti-
thrombotic actions was observed ( r = - • 4 7) . Activated 
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partial thromboplastin time (PTT), anti Xa and IIa 
amidolytic assays demonstrated better correlations (r = 
.65, .68 and .60 respectively). 
2. Intravenous (50 ug/kg) 
Figure 26 shows the antithrombotic effects after 
intravenous administration of the test agents at a 
concentration of 50 ug/kg. All fractions displayed stasis 
scores which were significantly different from the control 
score of 6. 5 . These values ranged from O. 25 for the 
unfractionated heparin, to 2. 5 for the 5, 100 M. W. frac-
tion. Comparison for similarity between the test agents, 
suggested significant differences in their antithrombotic 
actions. The overall conclusion based upon multiple 
comparison analysis, ranked in order of potency was: 
• Heparin r 13,300 = 23,000 = CY 216 r 5,100 r control. 
The circulating pharmacodynamic actions of the test 
fractions in this experiment are shown in table 23. All 
fractions produced inhibition of the various assays 
relative to baseline values. Compared to the 2 5 ug/kg 
dose, the circulating pharmacodynamic actions of the test 
fractions were only minimally increased. 
Correlations were calculated as before to determine 
relationships between the circulating pharmacodynamics and 
the observed anti thrombotic actions. Poor correlations, 
(r = .50 - .24) were observed in all assays. 
I ntravenous (100 ug/kg) 3. 
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The anti thrombotic actions of the test fractions 
after intravenous administration at 100 ug/kg are il-
iustrated in figure 27. All fractions displayed anti-
thrombotic actions which were significantly different from 
control. At this concentration, the unfractionated 
heparin resulted in complete inhibition of thrombosis. 
The other test agents resulted in stasis clot scores 
ranging from 0.25 for the 13,300 M.W. fraction to 2.75 for 
the 5,100 M.W. fraction. The variation in the stasis 
scores produced by the various agents were significantly 
different. The overall conclusion for similarity in 
antithrombotic actions, ranked in order of potency, 
determined using multiple comparison analysis was: Heparin 
= 13 I 3 0 0 M. w. = 2 3 I 0 0 0 M. w. = CY 216 ;:. 5 I 10 0 M. w. ;:. 
• 
control. 
The circulating pharmacodynamics of the test 
fractions for this experiment are shown in table 24. 
Anticoagulant actions were observed for all agents at the 
time of thrombogenic challenge. These anticoagulant 
actions were elevated·, consistent with the higher dose at 
which the agents were compared. As with the lower 
dosages, the degree of anticoagulant potency differed 
between the individual fractions and assay methods. The 
correlation of these activities to antithrombotic actions 
was also higher than observed for the lower dosages. The 
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correlation values for heptest, anti Xa and anti IIa were 
r = .89, .87 and .82 respectively. 
4. subcutaneous (1 mg/kg) 
The anti thrombotic effects of the test fractions 
after subcutaneous administration at a concentration of 
i.o mg/kg are illustrated in figure 28. Significant anti-
thrombotic actions were observed for all agents with the 
exception of the highest molecular weight fraction (23,000 
M. W.) • This fraction resulted in a stasis score of 6.0 
compared to a control value of 6.5. CY 216 displayed the 
greatest potency (stasis score 1.25). When compared for 
similarity using non parametric ANOVA and multiple 
comparison testing, significant differences in antithrom-
botic potency were calculated between the test agents . 
The overall conclusion ranked in • order of decreasing 
potency was: CY 216 = 13,300 M.W. = 5,100 M.W. = unfrac-
tionated heparin ~ 23,000 M.W. = control. 
The circulating pharmacodynamic activities of the 
individual fractions observed after subcutaneous admin-
istration are shown in table 25. A good correlation 
between the circulating anticoagulant and antithrombotic 
actions was observed in all assays. Correlation values 
for heptest, anti Xa, anti IIa, and PTT were r = .76, .81, 
.63 and .78 respectively. 
CHAPTER V 
DISCUSSION 
Molecular Weight Fractionation and Determination A· 
To study the effect of molecular weight on the 
anticoagulant, antithrombotic and pharmacokinetic actions 
of heparin, fractions differing in molecular weight were 
used. These fractions were obtained from one source of 
native porcine mucosal heparin using a gel - filtration 
technique. This technique has previously been used for 
studying the molecular weight dependent effects of heparin 
(Bergqvist et al., 1985 ; Losito et al., 1981 ; Thunberg 
et al., 1979). In these studies, gel filtration was shown 
to be useful since it relied almost exclusively on size 
for separation. For this reason, differences between the 
pharmacological properties of gel-filtered fractions are 
primarily due to characteristics related to or associated 
with molecular size. 
The elution profiles of the gel-filtered fractions 
used in the current studies, illustrated that each 
fraction was composed of a bell-shaped distribution of 
molecular weight components. For each fraction, the 
average of these components determined the mean molecular 
weight. For most fractions, the molecular size range of 
the individual components was narrow, however the lower 
molecular weight fractions contained a broader molecular 
weight distribution range. The difference in molecular 
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weight range was due to the size exclusion properties of 
the Ul trogel, which lost resolution at lower molecular 
weights. The broader molecular weight distribution range 
of the low molecular weight fractions also reflected the 
composition of the unfractionated heparin, which contained 
a greater percentage of low molecular weight components. 
The molecular weights of all experimental agents 
were determined using HPLC - gel permeation chromatog-
raphy. This was an accurate method for determining 
molecular weight since well defined calibration standards 
of similar molecular composition were used (Harenberg and 
De Vries, 1983 ; Rodriquez, 1976). 
HPLC - gel permeation chromatography also demon-
strated the frequency distribution and range of molecular 
weight components within each fraction • This allowed 
• 
evaluation of the results relative to both mean molecular 
weight and molecular weight distribution. Character-
ization relative to both these parameters was important 
since an almost unlimited number of molecular weight 
distributions could result in an identical mean molecular 
weight. 
B. Comparison of the Pharmacological Actions of the 
Molecular Weight Fractions 
For all experimental studies, gravimetric expres-
sions (ug/ml or ug/Kg) were primarily used to indicate 
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test fraction concentrations. These expressions were 
selected primarily for reasons of accuracy and reproduc-
ability. Alternatively, concentrations could have been 
expressed in molar or unit amounts. No clear advantage 
existed for using any of these methods. To express the 
concentrations of the test agents in terms of units, 
standardization against a reference heparin preparation 
such as the International Standard would have been 
required. While this preparation was suitable for 
standardizing unfractionated heparins, it appeared 
unsuitable for fractionated heparins. In an international 
collaborative study, fractionated heparins did not 
parallel the International Standard Heparin in any of four 
assay systems used (Barrowcliffe et al., 1985). Since no 
suitable standard for cross-referencing the test agents 
• 
was available, unit expressions were not used. 
Molar expressions of concentration were used when 
they contributed to the explanation of molecular weight 
dependent differences between the test fractions. These 
expressions were not used more frequently since they could 
not be precisely determined but only approximated from the 
average molecular weight. 
1. In Vitro Analysis 
a. Clotting and Amidolytic Assays 
Profiling the effects of the test agents, in 
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different clotting and amidolytic assays, revealed 
distinct differences in their molecular weight related 
anticoagulant potency in all assays. Interestingly, the 
pattern of these molecular weight dependent effects was 
different between assays of the intrinsic and extrinsic 
coagulation network. 
In the APTT, Heptest, anti Xa and anti IIa assays, 
the 13,300 M~W. fraction consistently displayed the most 
potent anticoagulant and antiprotease actions. Similar, 
but slightly less potent effects were observed from the 
17,450 and 23,000 molecular weight fractions respectively. 
The 9,000 and 5,100 M.W. fractions displayed the least 
anticoagulant and anti protease actions. The potency of 
these two fractions decreased in direct proportion to 
their molecular weights. The anticoagulant potency of 
both CY 216 and the unfractionated hepa~in was consistent 
with other fractions of similar molecular weight. 
The differences in potency between the various 
molecular weight fractions in the aforementioned assays 
were best explained through differences in affinity to 
antithrombin III, neutralization by anti-heparin proteins 
and molar ratios. 
Heparin's affinity to antithrombin III has been 
shown to be related to its molecular weight. High 
affinity binding of heparin to this protein is dependent 
upon a specific tetrasaccharide sequence within the 
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heparin. The affinity of heparin to antithrombin III 
increases with the relative abundance of this sequence 
(Rosenberg et al., 1978). The probability of this 
sequence occurring, increases with molecular weight 
(Laurent et al., 1978) . For these reasons, heparin of 
higher molecular weight generally displays greater 
affinity to antithrombin III compared to its low molecular 
weight counterparts. 
The decreases in the anticoagulant potency observed 
between the 13,300 . I 9, ooo and 5, 100 molecular weight 
fractions were most likely due to molecular weight related 
decreases in antithrombin III affinity. These potency 
differences were even more dramatic when compared in terms 
of molar ratios. Since the fractions were compared at 
equal gravimetric concentrations, the 5,100 M.W. fraction 
had almost a three-fold higher molar rati6c relative to the 
13, 300 M. w. fraction. If the test fractions had been 
compared at equal molar concentrations, much greater 
potency differences would have been observed between the 
high and low molecular weight fractions. At equal 
gravimetric concentrations, the low molecular weight 
fractions had more molecules available to bind to anti-
thrombin III, however less anticoagulant actions were 
observed due to the decreased affinity of these components 
to this important heparin cofactor. 
There was no possibility that the decreased anti-
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coagulant actions of the lower molecular weight fractions 
were due to saturation of antithrombin III. This protein 
was always present in at least 5 - 10 X molar excess for 
all concentrations at which the test agents were compared 
(table 30). 
The potency differences between the 23,000 ; 17,450 
and 13, 300 M. W. fractions most likely were not due to 
differences in antithrombin III affinity. Between these 
three fractions, potency decreased with increasing molec-
ular weight. The molar ratio between the respective 
fractions and anti thrombin III also decreased with in-
creasing molecular weight. This observation suggested 
that the potency differences between these three fractions 
may have been due to relative molarity differences. Since 
heparin interacts with antithrombin in a 1 : 1 stoichio-
metric manner (Jordan et al., 1979), the greater molarity 
of the 13,300 M.W. fraction resulted in more molecules 
free to interact with antithrombin III. 
It has been reported that in plasma, high molecular 
weight heparin is more readily neutralized by anti-heparin 
factors compared to lower molecular weight fractions 
(Andersson et al., 1979 ; Hubbard and Jennings, 1985) . 
This differential neutralization along with the less 
favorable molar ratio of the high molecular weight 
heparin, most likely resulted in the decreased potency 
observed between the high molecular weight fractions. 
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As previously mentioned, the potency rank order of 
the molecular weight fractions was similar in the Heptest, 
APTT, anti Xa and anti IIa assays. These results were not 
surprising since these assays primarily reflect heparin's 
actions upon either factor Xa, thrombin or both. 
When the test fractions were screened in the 
prothrombin time assay (PT), the relationship between 
potency and molecular weight was different from that 
observed in the previous assays. The 23,000 M.W. fraction 
displayed the greatest anticoagulant effects. The anti-
coagulant actions of all other fractions decreased in 
direct proportion to molecular weight. The potency 
differences between the individual fractions were signif i-
cant and were even greater when molar ratios were consi-
dered. The different pattern of molecular weight depen-
. . . dent potency suggested that heparin was possibly acting 
through a different mechanism in the PT assay. 
The prothrombin time differed from the other 
coagulation assays used to compare the fractions in that 
it reflected the extrinsic pathway of coagulation. The 
distinguishing factors of this pathway were factor VII and 
tissue thromboplastin. (Nemerson, 1983). Since these 
factors were not reflected by assays such as the APTT and 
heptest, it was possible that the different pattern of 
molecular weight dependence was due to effects by the test 
fractions on these factors. 
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It is important to mention that due to the insensi-
tivity of the prothrombin time assay to the actions of 
heparin, two-fold higher concentrations of the test agents 
(5-20 ug/ml) were used in comparison to the other screen-
ing assays. 
At high heparin concentrations (> 20 ug/ml), heparin 
cofactor II has been suggested to contribute to the 
overall anticoagulant actions of heparin (Ofosu et al., 
1985). A molecular weight dependent activation of this 
factor has also been reported (Choay et al., 1986 ; 
Yamagishi et al., 1986). For these reasons, it was 
interesting to investigate whether heparin cofactor II 
played a role in the molecular weight dependent effects 
displayed by the fractions in the prothrombin time assay. 
This was accomplished by supplementing the various molec-
ular weight fractions to antithrombin II1 deficient plasma 
and performing identical prothrombin time assays. 
The antithrombin III deficient plasma 
using heparin affinity chromatography. 
was prepared 
This method 
resulted in plasma with functional antithrombin III levels 
which were 6 % of normal. Heparin cofactor II levels in 
plasma prepared using this method have been reported to be 
unchanged (personal communication). 
If the molecular weight dependent effects of the 
test agents in the PT assay were mediated exclusively 
through antithrombin III, they should have been diminished 
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or eliminated in plasma deficient in this protein. 
However, if the effects were due to heparin cofactor II 
activity, they should have remained in the antithrombin 
III deficient plasma. As shown in table 5, removal of 
antithrombin _III resulted in the loss of the molecular 
weight dependent potency observed in the PT assay in 
normal plasma. These results suggested that in this 
assay, the increased potency of the high molecular weight 
fractions were mediated by antithrombin III. 
b. Fibrinopeptide-A Generation Tests 
The f ibrinopeptide - A generation test was developed 
for the purpose of studying the collective actions of 
heparin on the proteases of the coagulation network. The 
assay is based upon quantitation of a 16 amino acid 
• peptide known as fibrinopeptide - A (FPA) , after acti-
vat ion of citrated blood or plasma. This peptide is 
released from fibrinogen by the action of thrombin, and 
has been shown to be a specific indicator of thrombin' s 
coagulant actions (Emanuele et al., 1986). Any event, 
either intrinsic or extrinsic, which results in thrombin 
generation will result in FPA release. FPA release is the 
final endpoint of coagulation prior to fibrin monomer 
polymerization. For this reason FPA release can be used 
to assess the collective anticoagulant activity of any 
agent which acts prior to this step. Since the assay uses 
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an immunoquantitation technique to measure the generated 
FPA, it has great sensitivity to any anticoagulant action. 
In addition to its sensitivity, this assay can be per-
formed in a variety of matrices, provided thrombin and 
fibrinogen are present. This feature allowed comparison 
of the molecular weight fractions in platelet rich and 
platelet poor plasma as well as whole human blood. The 
efficacy of these tests in different matrices has previ-
ously been discussed (Emanuele et al., 1985). 
In order to further profile the effects of the 
different molecular weight fractions, four variations of 
the FPA generation assay were used. The results of these 
assays were dependent upon the method of activation and 
matrix used. 
When the test agents were studied in normal human 
• plasma using the thromboplastin activated system, the 
results were similar to those obtained in the PT assay. 
The 23,000 M.W. fraction displayed the greatest potency in 
terms of inhibiting FPA generation. The potency of the 
other fractions decreased in direct proportion to their 
molecular weights. The similar pattern of molecular 
weight dependence observed in the PT and FPA generation 
assays was not surprising since both methods utilized 
thromboplastin activation. Both systems were reflecting 
the action of heparin along the extrinsic pathway. The 
similarity between the two systems implied that . similar 
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JDechanisms were responsible for the pattern of molecular 
weight dependent potency. These observations further 
reinforced the notion that high molecular weight heparin 
was inhibiting either factor VII or thromboplastin. The 
results from this assay were particularly interesting 
since they occurred at lower heparin concentrations (2.5 & 
5 ug/ml) compared to the PT assay. 
The thromboplastin activated FPA generation assay 
was also performed in antithrombin III (AT III) deficient 
plasma. The effects of the test agents in this assay were 
consistent with those observed in the PT assay performed 
in AT III deficient plasma. All agents failed to produce 
any inhibition of FPA generation al though high heparin 
concentrations were used (10 ug/ml). No significant 
differences in the effects between any of the test agents 
• 
were observed. This observation further reinforced the 
previous hypothesis, that the molecular weight dependent 
anticoagulant effects, displayed by the test fractions in 
thromboplastin activated plasma, were mediated through 
antithrombin III. Furthermore, at these concentrations, 
it was unlikely that Heparin cofactor II contributed to 
these molecular weight dependent effects. 
several reports have suggested that interactions 
between platelets and heparin may be important in terms of 
an overall hemostatic effect (Salzman et al., 1980). Ad-
ditional reports have demonstrated that these interactions 
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are dependent upon heparin's molecular weight (Salzman et 
al., 1982 Brace and Fareed, 1986) • Platelets also 
contain a small peptide (platelet factor 4) within their 
alpha granules which has been shown to neutralize the 
anticoagulant actions of heparin (Dawes et al., 1982). 
To study whether the presence of platelets affected 
the molecular weight dependent responses of the test 
agents, they were studied in platelet rich and platelet 
poor plasma using the thromboplastin activated FPA 
generation assay. No significant difference was observed 
in the actions of any test fractions between the two 
plasmas (figure 4) • These results suggested that the 
presence of platelets did not affect the molecular weight 
dependent actions of these agents. 
It was interesting to note that in all cases, the 
amount of FPA generated was slightly• higher in the 
platelet rich plasma. Since these slight differences were 
present between the controls of both plasmas, they were 
not attributed to neutralization of the test agents by 
platelet factor 4. 
Phospholipoproteins (platelet factor 3) from the 
platelet membrane are known to accelerate two critical 
steps of blood coagulation (factor Xa activation and 
prothrombin conversion) (Ofosu et al., 1981) . It was 
likely that the platelet rich plasma contained a greater 
concentration of these factors compared to the platelet 
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poor plasma. Thus, the greater FPA generation in the 
platelet rich plasma was probably due to accelerated 
factor X and prothrombin conversion due to phospholipo-
proteins contributed by the platelets. 
The molecular weight fractions were also tested in a 
whole blood FPA generation assay. This test differed from 
the previous FPA assays in both the generation matrix and 
method of activation. The assay utilized contact between 
the glass surf ace of a test tube and the whole blood for 
activation. This procedure was intended to mimic in-
trinsic or contact activation of whole blood. 
The molecular weight dependent effects of the test 
fractions were different in this assay compared to the 
thromboplastin activated system. Although not signif-
icantly different from the 23,000 M.W. fraction, the 
13, 300 M. W. fraction appeared to be• the most potent 
inhibitor of FPA generation. The unfractionated heparin 
also displayed strong inhibitory actions. The two low 
molecular weight fractions were significantly less 
effective in inhibiting FPA generation compared to the 
higher molecular weight agents. These observations were 
consistent with results obtained in previous assays of the 
intrinsic pathway. It was likely that in this assay, the 
different potencies of the test fractions resulted from 
similar differences in the molar ratios and susceptibility 
to neutralization previously discussed for the other 
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assays utilizing intrinsic activation. 
c. VII-Thromboplastin Assay 
The different pattern of potency observed for the 
molecular weight fractions between assays of the intrinsic 
and extrinsic pathway, suggested possible inhibition of 
factor VII by heparin. Previous investigators have 
suggested this may occur (Dahl et al., 1982 ; Godal et 
al.,1974 ; Osterud et al., 1976). However, these reports 
were controversial and other investigations concluded that 
factor VII was not inhibited by heparin 
Rosenberg, 1977). 
(Jesty, 1978 ; 
In order to more accurately investigate the inter-
actions between factor VII and heparin, the test fractions 
were screened in an amidolytic VII-thromboplastin assay. 
This assay was performed on a Mult!stat centrifugal 
analyzer. The advantages of using this instrument in 
coagulation testing have been previously reviewed (Hills 
et al., 1983). In the assay, factor VII-thromboplastin 
was used to activate factor X to Xa. The assay endpoint 
was then determined by measuring the absorbance change due 
to Xa chromophore release. A direct relationship between 
this endpoint and factor VII concentration was established 
(figure 5). Since thrombin was not a necessary component 
of the assay, any effects by heparin could only be due to 
factor VII, thromboplastin or factor Xa. 
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When the test agents were screened in this assay, 
similar molecular weight dependent effects as seen in the 
PT and thromboplastin activated FPA generation assays were 
observed. The highest molecular weight fraction (23,000) 
displayed the greatest inhibition of the assay. The 
potency of the other fractions decreased in direct 
relation to their molecular weight. These observations 
were consistent with the hypothesis that high molecular 
weight fractions of heparin were inhibiting either factor 
VII or thromboplastin. The VII-thromboplastin assay 
relied on the actions of factor Xa for endpoint determ-
ination. The inhibition of this factor by heparin has 
been shown to be dependent upon molecular weight (Lane et 
al.,1978 . I Andersson et al. , 1978 . I Thunberg et al . , 
1979) • To study the possibility that the pattern of 
molecular weight dependence in this assay was due to 
effects on factor Xa, an identical assay substituting Xa 
for factors VII and X was used. Thromboplastin was also 
present in this system. Under these conditions, the 
23,000 . I l 7 , 4 5 o and 13 , 3 O o M. W • fractions all displayed 
similar effects and no difference in potency was observed. 
These results suggested that the increased potency of 
23, 000 and 17, 450 M. W. fractions observed in the VII-
thromboplastin assay were not due to the inhibition of 
factor Xa. 
To demonstrate that the increased potency of the 
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high molecular weight fractions were due to actions 
occurring prior to the activation of factor X, the test 
fractions were studied in two systems of the VII-thrombo-
plastin assay. The test fractions were incubated either 
with VII-thromboplastin or factor X. These two incubation 
systems differed only in the incubation step and otherwise 
were identical in the volumes and concentrations of all 
reactants. The X Xa activation catalyzed by VII-
thromboplastin occurred in the presence of identical 
heparin-antithrombin III concentrations. Under these 
conditions, any difference between the two systems could 
only be due to inhibition by heparin-antithrombin III on 
VII-thromboplastin. 
When the test agents were screened in this assay, 
only the 23,000 and 17,450 M.W. fractions, along with the 
• 
unfractionated heparin, produced significant differences 
between the two incubation systems. These results sug-
gested that only these fractions were inhibiting factor 
VII-thromboplastin. The potency of these three agents 
decreased with decreasing molecular weight implying that 
inhibition of VII-thromboplastin was inf 1 uenced by 
molecular weight. These results further suggested that 
the increase potency of the high molecular weight frac-
tions observed in all assays reflecting the extrinsic 
pathway were due to a molecular weight dependent inhibi-
tion of either factor VII or thromboplastin. 
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It was interesting that the unfractionated heparin 
[(12,575 M.W) demonstrated inhibition of factor VII-
t[hromboplastin while the 13, 300 M. W. fraction did not. 
This appeared contradictory since other observations 
indicated that the inhibition of VII-thromboplastin was 
influenced by molecular weight. The apparent discrepancy 
was explained by the molecular weight distribution range 
of the two fractions. The unfractionated heparin was 
composed of a range of molecular weight components from 
l,500 - 44,000 while the 13,300 M.W. fraction contained 
components ranging from 7, 000 - 22, 000 (Table 1) . The 
different molecular weight distributions of both agents 
resulted in similar mean molecular weights. The presence 
of high molecular weight components in the unfractionated 
heparin and their absence in the 13,300 M.W. fraction most 
• • likely contributed to the inhibition observed with the 
unfractionated heparin. 
The VII-thromboplastin assay was modified to study 
the effects of the test agents in a plasma matrix. As 
before the assay was performed using a centrifugal ana-
lyzer, however factors VII, X and anti thrombin III were 
replaced by fibrinogen deficient plasma. The fibrinogen 
deficient plasma was used to prevent the formation of a 
clot. Either a Xa or thrombin specific substrate was 
added for the purpose of monitoring p-NA release as an 
endpoint. Both assays used dilute (1:20) thromboplastin 
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to activate the plasma. For this reason it was thought 
that the actions of the test agents would be similar to 
those observed in other assays using extrinsic activation. 
However, the actions of these agents in this system were 
very different. In the assay using the Xa substrate, the 
13,300 M.W. fraction displayed the most potent anti-
protease actions. Above and below this molecular weight, 
the potency of the test agents decreased with increasing 
or decreasing molecular weight respectively. With the 
thrombin substrate, similar but · slightly less potent 
effects were observed for all fractions. These results 
did not resemble those obtained in other assays of the 
extrinsic pathway, but rather were similar to results 
obtained with intrinsic and anti Xa and IIa assays. The 
similarity suggested that these assays were reflecting the 
• 
actions of the test fractions on the enzyme directly 
cleaving the substrate (Xa and thrombin) and not on the 
initial activation process. 
It was difficult to explain the failure of the test 
heparins in the plasma VII-thromboplastin system to re-
flect any inhibition of the initial activation process as 
observed with other extrinsic activated assays. A 
possible explanation was attributed to differences between 
the assay systems. The plasma VII-thromboplastin assay 
differed from the other extrinsic assays in two important 
properties. Unlike the pure VII-thromboplastin assay, 
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this assay was performed in plasma. Thus, in addition to 
factors VII and X, all other coagulation proteases and 
inhibitors were present. Also, compared to a conventional 
prothrombin time assay, the incubation and assay time 
period were much longer. It is known that extrinsic 
activation is a fast system compared to the longer 
activation time period involved in the intrinsic network 
(Thompson and Harker, 1983). It was possible that the 
longer time interval and the additional factors provided 
by the plasma VII-thromboplastin assay, resulted in the 
activation of intrinsic coagulation factors. Thus, the 
plasma VII-thromboplastin assay actually did not reflect 
the actions of the test fractions on extrinsic but rather 
intrinsic proteases. 
• i. Possible Significance of Factor VII or Thromboplastin 
Inhibition by Heparin 
The observation that factor VII or thromboplastin 
may be inhibited by high molecular weight heparin may have 
relevance to the hemorrhagic side effects of this agent. 
Reports have suggested that low molecular weight may have 
less bleeding tendencies compared to higher molecular 
weight heparin (Salzman, 1986). 
Factor VII has been shown to be a key factor in the 
regulation of hemostasis (Nemerson, 1983). The results 
presented in this dissertation have demonstrated the 
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inhibition of factor VII or thromboplastin only by high 
molecular weight heparin. If factor VII or its activation 
by thromboplastin are important to hemostasis, then their 
inhibition by high molecular weight heparin would compro-
mise a key hemostatic mechanism and contribute to hepa-
rin's hemorrhagic effects. Conversely, low molecular 
weight heparin may have less hemorrhagic tendencies due to 
its lack of inhibition on factor VII or thromboplastin. 
2. In Vivo Actions (Pharmacodynamic Concentration / Time 
course) 
a. Intravenous Administration 
The pharmacodynamic concentration / time course of 
the test agents was studied in the primate Macaca mulatta. 
The validity of studying the plasma concentration / time 
. . . 
course of heparin in this species has been demonstrated 
for both fractionated and native heparins (Fareed et al., 
1985) • Kinetic values were calculated from plasma 
concentrations determined at different time intervals. 
The clotting and protease assays used in the in vitro 
profiling were used in these determinations. Individual 
calibration curves for each test agent and primate were 
used to transform the individual assay parameters into 
gravimetric amounts. This technique was a accurate method 
for quantitation of the circulating heparin levels since 
individual variations were nullified by the separate 
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calibration curves. 
The results of the concentration / time course 
studies indicated that heparins of different molecular 
weight displayed significantly different kinetic behavior. 
Differences between the test agents were observed in their 
absorption, half-life and distribution characteristics. 
Upon introduction into the circulation, all test 
agents, with the exception of the 23,000 M.W. fraction, 
displayed bi-phasic rates of elimination (figures 16-
19). The 23,000 M.W. fraction displayed a constant 
elimination rate (figure 15). The bi-phasic elimination 
consisted of an initial rapid decrease in plasma activity, 
followed by a reduced elimination rate. These two phases 
were due to an initial equilibration within the vascular 
compartment and subsequent distribution to a second tissue 
compartment. . ' . ' Differences in the rates of elimination were 
observed between the test fractions showing bi-phasic 
elimination. The higher molecular weight fractions were 
removed from the circulation at a greater rate compared to 
those of lower molecular weight. These observations were 
consistent with the molecular weight dependent differences 
in apparent volume of distribution and half-life. 
All test agents were compared at equal gravimetric 
dosages. Since these agents differed in molecular weight, 
the circulating molar concentrations were of these agents 
were not equal . To test whether the different molar 
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concentrations resulted in different plasma concentration 
I time profiles, these values were calculated using both 
molar and gravimetric concentrations. The profiles were 
similar whether calculated from either value. (table 26). 
To explain the differences between the concentration 
I time profiles of the molecular weight fractions it is 
important to review the mechanisms involved in the 
elimination ·of heparin. It has been suggested that 
heparin is removed from the circulation through a combi-
nation of saturable and non-saturable mechanisms. Only a 
combination of these mechanisms can account for the non-
linear, dose dependent elimination of heparin from the 
circulation (de Swart et al., 1982). 
The non-saturable mechanism is thought to be due to 
the renal elimination of heparin (Estes, 1980 ; Cocchetto 
and Bjornsson, 1984). • • The saturable mechanisms are more 
complex and involve neutralization of heparin molecules 
through a variety of processes. It is known that desulfa-
tion of heparin by various desulfating enzymes results in 
the loss of heparin's anticoagulant activity. Heparin 
desulfamidases have been isolated from lymphoid tissue. 
For this reason, the reticuloendothelial system has been 
associated with the saturable processes of heparin 
elimination (Estes, 1980). Inactivation of heparin by 
desulfation is thought to be saturable since increasing 
doses of heparin, result in greater amounts of intact (non 
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desulfated) drug in the urine (de swart et al., 1982). 
Heparin has been shown to bind to endothelial cells 
both in vitro and in vivo (Mahadoo et al., 1977 ; Barzu et 
al., 1984). The affinity of this binding has been shown 
to increase with increasing molecular weight (Choay et 
al., 1986 ; Boneu et al., 1985). The binding of heparin 
to endothelial cells effectively neutralizes its anti-
coagulant activity (van Rijn et al., 1987). For these 
reasons endothelial cell binding has been implicated in 
the saturable mechanism involved in the elimination of 
heparin (van Rijn et al., 1987). 
The similarity between heparin's molecular weight 
dependent plasma concentration time profile and endothe-
lial cell binding characteristics suggested that these 
phenomena were related. The binding of heparin to 
endothelial cells may explain the short nalf-life of the 
high molecular weight and relatively longer half-life of 
the lower molecular weight fractions. The high molecular 
weight heparin may have been effectively neutralized by 
high affinity binding to endothelial cells. This process 
would be less effective for low molecular weight fractions 
due to their reduced affinity for these cells. In 
addition, the binding of low molecular weight components 
to endothelial cells may have acted as a tissue reservoir. 
The relative low affinity of the molecules to their 
endothelial binding sites may have allowed for the slow 
release of these components into the circulation. 
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This 
mechanism was consistent with the two compartment distri-
bution and elimination behavior displayed by the lower 
molecular weight test fractions. 
since the loss of heparin's anticoagulant activity, 
due to endothelial cell binding, was a saturable process, 
the relative molar differ enc es between the high and low 
molecular weight fractions may also have contributed to 
the differences in the kinetic behavior. 
b. Comparison of the Intravenous Concentration / Time 
Profile in Different Assays 
The intravenous plasma concentration / time course 
of the test fractions were calculated using five different 
ex vivo assays. Consistent with reports of other inves-
tigators (Cocchetto and Bjornsson, 1984r, the concentra-
tion / time profile of all test fractions were assay 
dependent. Plasma concentrations determined from identi-
cal plasma samples yielded different heparin concentra-
tions when different assays were used. These results were 
not surprising since the various assays were sensitive to 
different pharmacodynamic actions. 
The sensitivities of the individual assays to the 
different molecular weight fractions were reflected in the 
concentration / time profiles. Those assays sensitive 
primarily to high molecular weight fractions (the anti IIa 
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and dilute PT assays) indicated short half-lives and small 
distribution volumes. Assays with greater sensitivity to 
loW molecular weight fractions (anti Xa, heptest and 
FPAGT) suggested longer half-lives and greater distribu-
tion volumes. Thus, the assay dependent concentration / 
time profiles directly reflected the molecular weight 
dependent time course. 
The different assay methods were useful to study the 
kinetics of the biological response of the individual 
fractions. The various assays reflected specific anti-
coagulant and antiprotease actions. For this reason, the 
time course calculated from different assays reflected the 
kinetics of specific pharmacodynamic actions. Thus, the 
time course observed using the anti IIa assay represented 
the kinetics of heparin components inhibiting this factor. 
Similarly, the anti Xa assay represente~ the kinetics of 
anti Xa components. Based on this reasoning, the differ-
ent kinetic profiles of identical fractions calculated 
from different assays, were due to differences in the 
kinetics of the assay specific pharmacodynamic action. 
The results demonstrated that those components 
expressing anti factor Xa actions displayed the longest 
halflives. These actions were reflected in the anti Xa 
assay and Heptest. The long halflives calculated from the 
FPAGT were also due to anti Xa actions. The association 
between low molecular weight and anti Xa activity, sug-
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gested that the prolonged half-life of the anti Xa actions 
were a molecular weight related effect. Thus the mech-
anisms contributing to the increased half-life of low 
molecular weight heparin, were also responsible for the 
prolonged anti Xa actions. 
The half-life of those components inhibiting 
thrombin, as indicated by the anti IIa assay, were signif-
icantly shorter than those exhibiting anti Xa effects. 
The short half-lives and distribution volumes observed in 
the dilute PT assay, suggested that components inhibiting 
extrinsic activation also have a short half-life. The 
associations of these actions with high molecular weight 
heparin, suggested that the short half-lives of these 
components were also molecular weight related. 
c. Subcutaneous Administration 
The subcutaneous concentration / time course study 
was carried out primarily for the purpose of comparing the 
effect of molecular weight on the absorption of heparin. 
This was accomplished by comparing the AUC of the indivi-
dual fractions after intravenous and subcutaneous adminis-
tration. After intravenous injection, 100 % absorption 
was observed for the test fractions. This was demonstra-
ted by the recovery of plasma levels predicted from 
injection of a prescribed mg/kg dose. Differences in 
plasma concentrations of identical fractions after 
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subcutaneous injection were attributed to differences in 
the rate and extent of absorption from the subcutaneous 
site. This conclusion was only valid if the rate constant 
of elimination after both routes of administration was 
similar. Heparin has been shown to display both dose 
dependent elimination and reduced absorption after 
subcutaneous administration. For these reasons, a larger 
dosage of the test fractions was used in the subcutaneous 
route for the purpose of achieving similar plasma concen-
trations after both routes of administration. The dose 
adjusted AUC values were then used to calculate relative 
absorption. 
It should be mentioned that since the absorption was 
calculated from anticoagulant data, only components of the 
test fractions expressing these actions were reflected. 
. . .. Thus, the exact gravimetric concentrations may or may not 
have been directly reflected. Also, the net absorption 
may have been different if a different endpoint (anti-
thrombotic) was used. 
Profound differences were observed in the absorption 
of the test fractions after subcutaneous injection. These 
differences were attributed to molecular weight dependent 
effects. Comparison of the AUC values for the test 
fractions demonstrated that absorption increased with de-
creasing molecular weight. Poor absorption was observed 
with the 23,000 M.W. fraction indicating that very little 
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h 's agent actually reached the circulation after of t 1 
subcutaneous injection (figure 20). Slightly better 
absorption was observed with the 13,300 M.W. fraction 
(attributed to its lower molecular weight) (figure 21). 
CY 216 and the 5,100 M.W. fraction displayed much better 
absorption characteristics. At these low molecular 
weights almost all of the drug reached the circulation 
from the subcutaneous injection sites. 
Since the absorption of the test agents was compared 
at equal gravimetric concentrations, the circulating molar 
concentrations were different. However, no difference was 
observed, whether the absorption was calculated from 
gravimetric or molar concentrations (table 27). 
It was interesting that although the unfractionated 
heparin and the 13,300 M.W. fraction had similar mean 
molecular weights, significantly • better absorption was 
displayed by the unfractionated heparin. This apparent 
contradiction to the molecular weight dependent dif f eren-
ces in absorption observed with other fractions, probably 
was due to differences in the respective molecular weight 
distributions. The unfractionated heparin was composed of 
molecular weight components ranging from 44, 000 - 1, 500 
M.W., while the 13,300 M.W. fraction contained components 
ranging from 22,000 - 7,000 (table 1). The presence of a 
greater percentage of low molecular weight components in 
the unfractionated heparin contributed in its greater 
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absorption. 
The differences in absorption between the test 
fractions suggested a molecular weight dependent threshold 
for the absorption of heparin from subcutaneous sites. 
This threshold was determined to be about 10, ooo M. W. 
based on comparisons between the relative absorption of 
the test fractions and their molecular weight distribu-
tions. A high correlation (r = .99) between the percent-
age of molecular weight components below 10,000 and 
relative absorption was observed (table 28). This data 
suggested that primarily those components of the test 
fractions with molecular weights less than 10, 000 were 
absorbed from the subcutaneous site into the circulation. 
It is important to mention that this absorption 
threshold may not have been exclusively determined by 
molecular size exclusion. • • It is well known that charge 
plays an important role in the absorption characteristics 
of most therapeutic agents. Since heparin is a highly 
charged molecule, it is reasonable to assume that the 
charge characteristics of the test fractions also may have 
influenced their absorption. 
The observation of a molecular weight dependent 
threshold for the absorption of heparin may be important 
relative to its therapeutic use. If the absorption of 
subcutaneously administered heparin is limited by 
molecular weight, then administration by this route may 
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restrict some of its molecular weight dependent actions. 
The data presented in this study suggests that only 
components of molecular weight of about 10,000 or less are 
absorbed after subcutaneous injection. Thus, actions of 
heparin exclusively associated with molecular weights 
above 10, 000 should not be displayed after subcutaneous 
administration. 
Furthermore, this observation suggests that sub-
cutaneous administration of native heparin may be inef-
ficient and uneconomical since a significant portion of 
the drug never reaches the circulation. Heparins whose 
molecular weight range does not exceed 10,000 may be 
better suited for this route of administration. 
d. Comparison of the Pharmacodynamic Concentration / Time 
Course After Subcutaneous Injection Using.Different Assays 
As with the intravenous study, the pharmacodynamic 
·concentration / time course of the test fractions after 
subcutaneous injection was assay dependent and consistent 
with the sensitivities of the assay methods to molecular 
weight. Assays reflecting low molecular weight components 
demonstrated greater absorption, compared to those 
reflecting the actions of higher molecular weight compo-
nents. 
The different assay methods also reflected the 
differences in absorption relative to pharmacodynamic 
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response (tables 16 - 20). The highest absorption was 
associated with components inhibiting factor Xa. This was 
due to the potent anti Xa actions of low molecular weight 
components. The high absorption observed in the Heptest 
and the FPAGT also were attributed to anti Xa effects. 
Consistent with the association between efficient 
anti thrombin inhibition and higher molecular weight 
heparin, poor absorption was observed for all test 
fractions using the anti IIa assay. This observation 
suggested that after subcutaneous administration, compo-
nents of the fractions with high antithrombin actions were 
not efficiently absorbed into the circulation. Similar 
results were observed with the dilute thromboplastin 
clotting time. The low overall absorption observed in 
this assay was due to poor absorption of high molecular 
weight components which were • necessary to efficiently 
inhibit this assay. These results suggested that compo-
nents necessary for the inhibition of extrinsic proteases 
are not effectively absorbed after subcutaneous adminis-
tration. 
3. In Vivo Antithrombotic Actions 
a. Intravenous Administration 
The antithrombotic effects of the molecular weight 
fractions were studied in a rabbit stasis model. This 
model utilized a complex of human factors II, VII, IX, X 
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and Russell's viper venom (a factor X activator) along 
with stasis to produce a localized clot. This thrombo-
genie procedure, produced high factor Xa levels which 
subsequently generated thrombin to produce a clot. Since 
the method relied on both factor Xa and thrombin for 
thrombus formation, inhibitory actions of the test 
fractions directed toward either of these factors should 
have resulted in antithrombotic actions. 
It is important to mention that the results obtained 
using this model were relative to the thrombogenic 
challenge. The use of a different challenge may have 
resulted in a different anti thrombotic profile for the 
test agents. As previously stated, this model primarily 
relied upon the actions of factor Xa to initiate thrombus 
production. Thus, this model may have resulted in a more 
• favorable antithrombotic profile for the lower molecular 
weight fractions by virtue of their high anti factor Xa 
actions. A less favorable antithrombotic profile may have 
resulted for these fractions if thromboplastin or thrombin 
had been used as the thrombogenic challenge. 
Using the PCC/RVV challenge, control animals 
consistently produced a similar degree of thrombus for-
mation. Administration of a low dose (25 ug/Kg) of the 
test agents resulted significant antithrombotic actions 
for all but the 5, 100 M. W. fraction. The experimental 
design included quantitation of the thrombus size. This 
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design made it possible to compare the antithrombotic 
potencies of the individual test fractions. At the 25 
ug/kg dose, differences in anti thrombotic potency were 
observed. These differences were reflected the in vitro 
anticoagulant potency profiles observed in the APTT, 
Heptest, anti Xa and anti II a assays. As previously 
discussed, these assays primarily reflected the effects of 
the fractions on factors Xa and thrombin. The similarity 
between the anticoagulant and antithrombotic potency 
profiles suggested that the antithrombotic effects 
observed in the rabbit model were primarily due to the 
inhibition of these two proteases. 
When a higher dosage of the test agents was used in 
the rabbit model, greater antithrombotic effects were 
observed. These results demonstrated that as with the in 
vitro anticoagulant effects, the anti t:tirombotic effects 
were dose dependent. At these higher dosages, the anti-
thrombotic effects correlated relatively well with the in 
vitro anticoagulant and circulating pharmacodynamic ef-
f ects for most of the molecular weight fractions. How-
ever, a poor correlation was observed with the unfrac-
tionated heparin. After intravenous administration of 
both the 50 and 100 ug/kg doses, the unfractionated 
heparin was the most effective antithrombotic agent. Only 
this agent resulted in the complete inhibition of throm-
bosis in all experimental animals. The anti thrombotic 
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potency of this agent was not reflected by its in vitro 
anticoagulant or circulating pharmacodynamic actions since 
these activities were greater for both the 23, 000 and 
13,300 M.W. fractions. 
The poor correlation between the anticoagulant and 
antithrombotic potency of fractionated heparins has been 
reported by other investigators {Merton et al., 1984 ; 
Barrowcliffe et al., 1984). These investigators have 
shown that heparin fractions with relatively higher 
anticoagulant actions, have been shown to be less ef-
fective antithrombotic agents compared to unfractionated 
heparin when administered at equivalent units. The 
enhanced antithrombotic effects of native heparin were 
attributed to the actions of low antithrombin III affinity 
components. 
In this study, the d . . t,.. isassocia ion between the 
anticoagulant and anti thrombotic actions of the unfrac-
tionated heparin further suggested a role for the low 
antithrombin III affinity components in the antithrombotic 
effects of this agent. Speculation about the mechanisms 
by which the low antithrombin affinity components contrib-
ute to antithrombotic effects may involve pro-fibrinolytic 
actions, the inhibition of platelets or other cellular 
components and interactions resulting in a less thrombo-
genie endothelial surface (Barrowcliffe et al., 1984). 
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p. subcutaneous Administration 
After subcutaneous administration, apparent molec-
ular weight dependent differences were observed in 
anti thrombotic potencies of the test agents. With the 
exception of the 23,000 M.W. fraction, all test agents 
produced significant antithrombotic effects. Between the 
agents displaying antithrombotic effects, no statistically 
significant differences in potency were calculated. How-
ever, the lower molecular weight fractions did appear to 
be the more effective antithrombotic agents. The enhanced 
antithrombotic actions of these fractions was probably due 
to better absorption from the subcutaneous injection 
sites. 
For most fractions, the antithrombotic effects 
increased in direct proportion to the circulating pharm-
acodynamic actions (table 29). These elfects correlated 
well with the absorption of the respective agents observed 
in the primate model (table 29). Only the 13,300 M.W. 
fraction displayed a poor correlation between these 
actions. This agent resulted in good antithrombotic 
effects while displaying only minimal circulating pharma-
codynamic actions. These results suggested that after 
subcutaneous administration of this fraction, components 
expressing anti thrombotic but not anticoagulant effects 
were absorbed into the circulation. The differential 
absorption between the anticoagulant and anti thrombotic 
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actions may have been due to the charge characteristics of 
the heparin. It has been shown that highly anionic 
heparin displays high anticoagulant actions (Sache et al., 
1981) • A highly charged heparin would also be less 
efficiently absorbed from a subcutaneous injection site. 
After subcutaneous injection of the 13,300 M.W. fraction, 
the highly charged high anticoagulant components did not 
appear to have been absorbed into the circulation. This 
may have been due to size and charge characteristics. 
Those components responsible for the antithrombotic 
actions may have been less charged since they displayed 
only minimal anticoagulant actions. The lower charge of 
these components may have allowed for absorption and the 
subsequent production of anti thrombotic effects not 
mediated through anticoagulant actions. 
Since the antithrombotic actions ot the 13,300 M.W. 
fraction appeared to be independent of its anticoagulant 
actions, it was difficult to account for these effects. 
Similar observations by other investigators have been 
accounted for by increased fibrinolytic actions, effects 
on platelets or endothelium and by effects contributing to 
a reduction in blood viscosity (Merton et al. , 
Ruggerio et al., 1983). 
1984 . I 
It was interesting that only the 13,300 M.W. 
fraction showed a disassociation between the anticoagulant 
and anti thrombotic effects after subcutaneous injection. 
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one possible interpretation of this observation is that 
the low anticoagulant, high antithrombotic components of 
heparin are primarily of this molecular weight. Ad-
ditional experimentation would be required to verify this 
hypothesis. 
c. Integration of the Molecular Weight Dependent Anticoag-
ulant, Antithrombotic and Concentration / Time Profile of 
Heparin 
The results obtained from the anticoagulant, 
concentration / time course and anti thrombotic studies 
using the different test agents, suggested that these 
pharmacological functions were influenced by molecular 
weight. Since the therapeutic effect of heparin is 
determined by these actions, integration of the molecular 
weight dependent anticoagulant, .. . anti thrombotic and 
pharmacodynamic properties should result in a comprehen-
sive understanding of the molecular weight dependent 
effects of this agent. 
The in vitro anticoagulant studies demonstrated that 
more potent anticoagulant actions were associated with the 
higher molecular weight heparins. The enhanced potency of 
these agents was primarily due to greater molecular weight 
dependent anti factor IIa actions. The inhibition of 
factor VII or thromboplastin by these agents, may also 
have contributed to their enhanced potency. These results 
155 
predicted that higher molecular weight heparins should be 
more effective antithrombotic agents compared to those of 
lower molecular weight. This prediction was based upon 
the assumption that heparin's antithrombotic effects were 
due primarily to its anticoagulant actions. 
The antithrombotic studies verified that, for most 
agents, the in vitro anticoagulant potency was predictive 
of antithrombotic actions, however this only applied to 
the intravenous route of administration. In this route, 
all but the unfractionated heparin demonstrated good 
correlation between the in vitro anticoagulant and in vivo 
antithrombotic actions. After subcutaneous administration 
the in vitro anticoagulant activity was not predictive of 
antithrombotic effects. Molecular weight dependent dif-
ferences in absorption resulted in the production of 
• greater antithrombotic effects by fractions which had 
displayed the least in vitro anticoagulant actions. This 
observation demonstrated that route of administration, due 
to its influence on drug absorption, was an important 
characteristic for determining the antithrombotic effects 
of the different molecular weight heparins. 
Significant differences in half-life were also 
observed between the molecular weight fractions. The 
lower molecular weight fractions, possessing the least 
anticoagulant actions, displayed the longest half-lives. 
The amount by which the half-life increased in the lower 
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molecular weight fractions, was dependent upon the method 
of assay. 
It is interesting to speculate on whether the 
increased anticoagulant half-life of lower molecular 
weight heparins results in a similar prolongation of their 
antithrombotic effects. Intuitively, the prolonged 
presence of these agents in the circulation should 
contribute to a sustained antithrombotic response. 
However, half-life values of identical fractions were 
different when calculated in different assays. As 
previously discussed, these different values were inter-
preted to represent different half-lives for the assay 
specific pharmacodynamic response of the individual 
agents. 
Different pharmacodynamic responses have been 
. . . . 
associated with different ant1thrombot1c potencies. It is 
generally believed that the pharmacodynamic actions of 
heparin associated with its antithrombotic effects are the 
inhibition of factors Xa and IIa. Previous investigators 
have speculated on the relative importance of these two 
factors to the anti thrombotic actions of this drug. A 
strong argument has been made for the necessity of anti 
factor IIa actions for efficient antithrombotic actions 
(Buchanan et al., 1985 ; Carter et al., 1982). However, 
Walenga et al (1986) have recently shown antithrombotic 
actions using a synthetic heparin like pentasaccharide 
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possessing only anti factor Xa actions. No clear answer 
is readily apparent for determining the contribution of 
the anti Xa or II a actions of heparin to its anti throm-
botic actions. However, it seems likely that any con-
tribution to a prolonged anti thrombotic effect due to a 
molecular weight related increase in half-life, is 
relative to its pharmacodynamic action. 
This dissertation has suggested that the increased 
half-life of the lower molecular weight heparins is 
primarily associated with anti factor Xa actions. When 
measured in terms of anti factor IIa actions, no similar 
increase in half-life was observed. Thus, if anti factor 
IIa effects are required for efficient antithrombotic 
actions, the greater half-lives of lower molecular weight 
heparins may not result in a concomitant prolongation in 
anti thrombotic actions. . . . However if the anti factor Xa 
actions are sufficient for effective antithrombotic 
actions, then the longer half-life should contribute to 
prolonged antithrombotic effects. 
Due to the molecular weight dependent differences in 
the half-life of heparins anti Xa and IIa actions, it may 
be possible to identify heparins therapeutic actions as a 
function of its pharmacokinetic time coarse. Initially 
when both anti Xa and IIa effects are present, heparin may 
have therapeutic actions relative to inhibiting an ongoing 
thrombotic process. At a later time point, when primarily 
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only anti Xa actions are present, the actions of heparin 
may be better described as prophylactic relative to a 
similar thrombotic process. If this argument is true, 
then low molecular weight heparins by virtue of their high 
anti Xa / IIa ratio and long half-lives, may be more 
appropriately indicated as prophylactic agents. Clearly 
such a distinction could only be determined through large 
scale clinical trials. 
CHAPTER VI 
SUMMARY AND CONCLUSIONS 
By studying the in vitro anticoagulant, in vivo 
antithrombotic and concentration / time profile of 
different molecular weight fractions of heparin, several 
molecular weight dependent actions were observed. 
1. The in vitro potency of the test fractions 
increased with increasing molecular weight from 5,100 
through 13,300 molecular weight in assays reflecting the 
intrinsic pathway. Beyond 13,300 no further increases in 
potency were observed. The potency differences between 
the fractions were attributed to the molecular weight 
dependent inhibition of factor Xa and thrombin. 
2. It was interesting to note that all low molecular 
weight heparins used in this study (including CY 216) 
displayed similar anti Xa to IIa ratios. Although anti Xa 
activity was slightly higher in the lower molecular weight 
fractions, the ratio was not significantly greater than 
1. O as reported by other investigators. This low ratio 
was probably due to the relatively wide molecular weight 
distributions of these fractions. 
3. In assays of the extrinsic pathway, potency 
increased in direct relation to molecular weight for all 
agents tested (M.W. 's 5,100 23,000). The enhanced 
potenqy of the high molecular weight fractions was due to 
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either the inhibition of factor VII or thromboplastin. 
The direct inhibition of this enzyme or cofactor was 
observed only by fractions containing high molecular 
weight components. 
4. It was not possible to distinguish the point of 
inhibition by the high molecular weight fractions between 
factor VII or thromboplastin. The observation that the 
inhibition was dependent upon antithrombin III implicated 
factor VII, since the inhibition of this serine protease 
was consistent with the mechanism of action for antithrom-
bin III. 
5. The inhibition of factor VII and thromboplastin 
by high molecular weight heparin may be of importance 
relative to the side effects of this agent. Reports have 
suggested greater hemorrhagic tendencies for high compared 
to low molecular weight heparin. Factor VII has been 
shown to be a key hemostatic enzyme (Nemerson, 1983). The 
results of this thesis suggest that this key enzyme is 
inhibited only by high molecular weight heparin. This 
observation, along with the association between high 
molecular weight heparin and increased hemorrhagic 
tendencies, suggests a possible association between these 
two events. Further studies investigating factor VII or 
thromboplastin inhibition with the bleeding tendencies of 
different molecular weight fractions would be required to 
test this theory. 
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6. Molecular weight proved to be an important 
determinant of the pharmacodynamic time course of heparin. 
The highest molecular weight fraction exhibited distri-
bution and elimination characteristics consistent with a 
one compartment model. Fractions of lower molecular 
weight clearly fit a two compartment model. These 
molecular weight related differences in distribution and 
elimination may have been due to different molecular 
weight dependent interactions with endothelial cells. 
7. Significant differences were observed in the 
half-life of the different molecular weight fractions. 
Half-life increased with decreasing molecular weight. The 
half-life of the lowest molecular weight fractions was 
almost 100 percent greater than the highest molecular 
weight fraction. 
• a. The half-life values of the individual fractions 
were assay dependent. Assays with greater sensitivity to 
low molecular weight components demonstrated longer half-
lives. Similarly, assays reflecting higher molecular 
weight components resulted in shorter half-life values. 
These results also demonstrated the differences in the 
kinetics of the pharmacodynamic actions of the different 
molecular weight fractions. 
9. Absorption studies suggested that molecular 
weight was an important determinant of this character-
istic. Absorption increased with decreasing molecular 
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weight. The high absorption of low molecular weight 
heparins suggests that subcutaneous administration may be 
an efficient route by which to administer these agents. 
10. The high correlation between absorption and 
percent content of molecular weight components under 
10,000 M.W. suggested that only components of about 10,000 
molecular weight or less reached the circulation after 
subcutaneous administration. It is important to mention 
that this molecular weight dependent absorption threshold 
was relative only to the anticoagulant actions of the 
fractions and may have been different for other pharmaco-
dynamic effects. 
11. After intravenous injection, the antithrombotic 
potency of most agents was directly related to the in 
vitro anticoagulant potency. Only the unfractionated 
• heparin displayed a dissociation between its anticoagulant 
and anti thrombotic effects. For this agent, the anti-
thrombotic effects were greater than the anticoagulant 
effects suggested. After subcutaneous administration, the 
antithrombotic effects of most agents were similarly 
related to absorption. However, the 13,300 M.W. fraction 
exhibited strong antithrombotic effects with poor absorp-
tion. These two observations suggested that not all 
antithrombotic effects of heparin are reflected by 
anticoagulant actions. 
12. For all molecular weight dependent actions of 
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heparin, the effect was influenced not only by mean 
molecular weight but also by the percent distribution of 
molecular weight components. 
CHAPTER VI I 
TABLES 
Table 1 
HPLC-GPC Molecular Weight (MW) Determinations for 
Fractions Obtained by Gel Filtration 
Fraction MW Mw Distribution Ran2e Peak MW 
-
I 23,000 44,000 - 12,500 22,000 
II 17,450 30,000 - 11,000 16,780 
III 15,000 24,000 - B,000 14,4i0 
IV 13,300 22,000 - 7,000 13,000 
v 11,750 21,000 - 5,500 11,200 
VI 10,400 20,000 - 4,300 9,500 
VII 9,000 20,000 - 2,600 7,600 
VIII 7,400 18,000 - 2,400 5,600 
IX 5,100 15,000 - 1,500 3,800 
heparin 12,575 44,000 - 1,500 13,550 
CY 216 5,400 14,000 - 1,000 
• 
4,400 
Table l. The molecular weight characteristics of the 
fractions obtained from the gel - filtration procedure 
were determined by HPLC - GPC. The molecular weight 
values.were calculated by comparing column retention times 
to those obtained from standards of known molecular 
Weight. The values in the table represent the averages 
calculated from two columns of different porosity. 
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Table 2 
Viscosity of the Test Fractions 
Heparin preparation 
unfractionated 
CY 216 
23,000 
17,450 
15,000 
13,300 
11,750 
10,400 
9,000 
7,400 
5,100 
Viscosity (mPa's) 
1.02 
0.95 
1. 28 
1.18 
1.10 
1.05 
0.98 
0.97 
0.94 
0.92 
0.76 
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Table 2. The viscosity of the gel - filtered fractions 
was measured using a Wells-Brookfield viscometer. The 
viscometer was calibrated with oils of known viscosity and 
10 mg/ml solutions of the test fractions were measured at 
2s0 c at three shear rates. Values in centipoise were 
obtained by multiplying the readings from the viscometer 
by a constant based upon the geometry of the cone plate. 
The values in the table represent averages of two deter-
minations at the three rates. 
Table 3. 
Table 3 
Effect of Molecular Yeight on APTT 
Molecular Yeight 
23,000 
17,450 
13,300 
9,000 
5,100 
Native Heparin 
CY 216 
Control 
N - 5 
Concentration 
ug/ml 
10 
5 
2.5 
1. 25 
.625 
10 
5 
2.5 
1. 25 
.625 
10 
5 
2. 5 
1. 25 
.625 
10 
5 
2. 5 
1. 25 
.625 
10 
5 
2.5 
1. 25 
.625 
10 
5 
2. 5 
1. 25 
.625 
10 
5 
2.5 
1. 25 
.625 
Clotting Time 
seconds 
> 200 
163 :!: 9 
55 :!: 4. 3 
36 :!: 2. 4 
3l :!: .9 
> 200 
183 :!: 12.4 
61 :!: 5. 7 
38 :!: 2 
31 :!: • 7 
> 200 
> 200 
82 :!: 4 
47 :!: 2.7 
34 :!: 1. 1 
> 200 
121 :!: i.i 
5 7 :!: 3. 4 
38 :!: 2.l 
32 :!: l 
64 :!: 
44 :!: 
36 :!: 
30 :!: 
29 :!: 
> 200 
> 200 
2.5 
1.4 
1. 6 
.4 
l. 2 
78 :!: 7. 6 
52 :!: 2. 3 
,.16 :!: 3 
85 :!: 4. 8 
67 :!: 3. 3 
55 :!: 2.6 
36 :!: 3 
30 :!: l. 3 
27 :!: • 4 
The molecular weight fractions were supplemented 
to pooled normal human platelet poor plasma at concen-
trations ranging from 0.625 through 10.0 ug/ml. The APTT 
assay was performed on five separate occasions exactly as 
described in appendix VII. The results represent the mean 
and the standard deviation of the five determinations. 
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Table 4 
Effect of Molecular W'eight on PT 
Molecular Weight Concentration <u1u:m1) Clotting Time 
23,000 20 55 ± 2.7 
10 23 ± 1. 3 
5 16 ± 1. 4 
2.5 14 ± . 8 
1. 25 13 ± . 3 
17,450 20 47 ± 3. 6 
10 21 ± 1. 7 
5 16 ± . 9 
2. 5 14 ± 1 
1. 25 13 ± . 3 
13,300 20 36 ± 1. 5 
10 22 ± 1. 3 
5 17 ± . 8 
2.5 14 ± . 6 
1. 2 5 13 ± .4 
9,000 20 21 ± .7 
10 18 ± . 7 
5 15 ± . 6 
2. 5 14 ± . 7 
1. 25 13 ± . 6 
5,100 20 15 ± . 9 
10 14 ± .6 
s 13 ± .6 
2. s 13 ± .4 
1. 25 13 ± . 7 
Native heparin 20 23 ± 3. 3 
10 20 ± 1. 9 
5 17 ± 1. 4 
2.5 14 ± . 8 
1. 25 • 13 ± . 9 
CY 216 20 18 ± 1. 4 
10 16 ± . 8 
5 15 ± . 7 
2. 5 14 ± . 9 
1. 25 13 ± .4 
Control 13 ± .5 
N 
-
5 
Table 4. The molecular weight fractions were supplemented 
to pooled normal human platelet poor plasma at concen-
trations ranging from o. 625 through 10. O ug/ml. The PT 
assay was performed on five separate occasions exactly as 
described in appendix VI. The results represent the mean 
and the standard deviation of the five determinations. 
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Table 5 
The Effect of Molecular Weight Fractions of Heparin on PT 
in Antithrombin III Deficient Plasma 
Fraction Clotting Time (seconds) . 
23,000 M.W. 16.3 + . 3 
17,450 M.W. 16.4 + .5 
13,300 M.W. 16.4 + .4 
9.000 M.W. 16.0 + . 7 
5,100 M.W. 15.9 + . 8 
CY 216 16.1 + .4 
unfractionated heparin 16.2 + .2 
control 13.8 + .3 
• 
Table 5. Antithrombin III deficient plasma was prepared 
as described in methods. The antithrombin content of this 
plasma was determined to be 6 . 2 % of normal. The test 
fractions were supplemented to the anththrombin deficient 
plasma at a concentration of 20 ug/ml and the PT assay was 
performed exactly as described in appendix VI. 
Table 6 
Effect of Molecular Yeight on Heptest 
Molecular lJeight 
23,000 
17,450 
13. 300 
9,000 
5,100 
Native Heparin 
CY 216 
Control 
N - 5 
Concentration (ug/ml) 
10 
5 
2. 5 
1. 25 
.625 
10 
5 
2. 5 
1. 25 
.625 
10 
5 
2.5 
1. 25 
• 6 25 
10 
5 
2. 5 
1. 25 
.625 
10 
5 
2.5 
1. 25 
.625 
10 
5 
2. 5 
1. 25 
.625 
10 
5 
2. 5 
1. 25 
.625 
Clotting Time 
290 ± 16 
145 ± 3.2 
70 ± 3 
43 ± 8.2 
35 ± 2.4 
256 ± 12 
135 ± 6.5 
64 ± 5 
52 ± 3.4 
38 ± 1.9 
346 ± 14.7 
170 ± 9.6 
82 ± 2.8 
62 ± .5 
41 ± 3.9 
235 ± 18.6 
120 ± 8 
72 ± 9.4 
54 ± 5.4 
38 ± 1.3 
128 ± 11.7 
69 ± 17.6 
56 ± 2.2 
42 ± 2.5 
29 ± 2.7 
353 ± 9.4 
160 ± 12.3 
84 :!: 4.6 
50 ± 3.4 
'9±1.7 
120 :!: 5.6 
86 :!: 6.6 
64 ± 4.3 
48 ± 4.5 
31 :!: 2 
16 ± .9 
Table 6. The molecular weight fractions were supplemented 
to pooled normal human platelet poor plasma at concen-
trations ranging from o. 625 through 10. o ug/ml. The 
heptest assay was performed on five separate occasions 
exactly as described in appendix VIII. The results 
represent the mean and the standard deviation of the five 
determinations. 
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Table 7 
Effect of Molecular Yeight on Xa amidolytic activity 
Molecular Yeight Concentration (ug/ml) 
' 
inhibition 
23,000 10 87 ± 2. 2 
5 87 ± 1. 7 
2.5 76 ± 1. 3 
1. 25 51 ± 2. 2 
.625 28 ± . 7 
17,450 10 89 ± 1. 7 
5 86 ± 1. 4 
2. 5 75 ± . 7 
1. 25 51 ± 2.9 
.625 26 ± 1. s 
13,300 10 88 ± 2. 7 
5 88 ± 1. 3 
2. s 77 ± 1.1 
1. 25 53 ± 2.2 
.625 29 ± 1. l 
9,000 10 88 ± 2. 3 
5 72 :!: l 
2.S 48 ± 1. 9 
l. 25 38 ± . 6 
.625 13 ± 1 
5,100 10 69 ± 1. 3 
s 45 ± .9 
~ ~ ~. ~ ;:4 ± 1. 3 
1. 25 13 ± 1.1 
.625 8 ± • 6 
Native Heparin 10 87 ± 2.0 
s 86 ± 1. 4 
2. s 77 ± 1. 2 
1. 25 so ± 2.2 
.625 2J ± 1. 7 
CY 216 10 80 ± 3. 2 
s 59 ± 1. 6 
2. s 37 ± 1. 4 
1. 25 21 ± 1. 3 
.625 13 ± 1. 3 
Control 6 ± 1. 2 
N 
-
5 
Table 7. The molecular weight fractions were supplemented 
to pooled normal human platelet poor plasma at concen-
trations ranging from 0.625 through 10.0 ug/ml. The anti 
factor Xa assay was performed on five separate occasions 
exactly as described in methods. The results represent 
the mean and the standard deviation of the five 
determinations. 
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Table e 
Effect of Molecular Yeight on Anti II a Activity 
Molecular Weight Concentration (u~/ml) 
' 
Inhibition 
23,000 10 91 :: 2. 2 
5 86 :: 3.5 
2.5 82 ± 3.l 
l. 25 62 :: :.. 7 
.625 40 ! 4.3 
17,450 10 90 ± 1. 3 
5 89 ± 2.7 
2. 5 79 
= 
3.4 
1. 25 68 ± 4. 7 
.625 44 ! 2. 6 
13,300 10 93 ± 2.4 
5 88 ± 1. 7 
2. 5 79 ::: 1. 6 
1. 25 74 :: 3.l 
.625 41 ::: 4.6 
9,000 10 88 ± 1. 8 
5 77 :!: :. . 2 
2. 5 59 ::: 2.1 
1. 25 42 ± 2. 9 
. 6 25 15 :: . 7 
5,100 10 68 :!:. 2.1 
!i.4 :: ~. 9 
2. 5 24 ± l. 7 
l. 25 13 ± 3.5 
.625 2 ± l. 7 
Native Heparin 10 87 ± 2.1 
5 84 :!:. 3.1 
2. 5 76 :: l. 6 
l. 25 64 ± 2.4 
.625 6 36 :!:. 4.2 
CY 216 10 58 ± 3.1 
5 34 ::: 3.2 
2. 5 14 :!:. 4.6 
l. 25 9 ± 3.1 
.625 3 ± 2. 7 
Control 3 ± 1.4 
N 
-
5 
Table 8. The molecular weight fractions were supplemented 
to pooled normal human platelet poor plasma at concen-
trations ranging from 0.625 through 10.0 ug/ml. The anti 
factor IIa assay was performed on five separate occasions 
exactly as described in methods. The results represent 
the mean and the standard deviation of the five 
determinations. 
Table 9 
Effect of Molecular Weight on Thromboplastin Activated FPA 
Generation 
Molecular Weight 
23,000 
17,450 
13,300 
9,000 
5,100 
Native Heparin 
CY 216 
Control 
N - 5 
Concentration (ug/ml) 
5 
2. 5 
l. 25 
.625 
5 
2. 5 
l. 25 
.625 
5 
2. 5 
1. 25 
.625 
5 
2. 5 
l. 25 
.625 
5 
2. 5 
1. 25 
.625 
5 
2. 5 
1. 25 
.625 
5 
2. 5 
1. 25 
.625 
FPA (ng/ml) 
42 ± 22 
64 ± 19 
425 ± 60 
713 ± so 
63 ± 30 
87 ± 21 
528 ± 76 
836 ± 110 
75 ± 30 
146 ± 29 
509 ± 115 
823 ± 82 
221 ± 89 
332 ± 44 
686 ± 76 
947 :!: 147 
763 ± 116 
915 ± 60 
1,023 ± 143 
1,357 ± 276 
81 ± 15 
66 ± 18 
475 ± 62 
762 ± 123 
756 ± 110 
820 ± 134 
997 ± 138 
1,059 ± 106 
l~ 27 5 ± 186 
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Table 9. The molecular weight fractions were supplemented 
to pooled normal human platelet poor plasma at concen-
trations ranging from O. 625 through 5. O ug/ml. The 
fibrinopeptide - A generation assay was performed on five 
separate occasions exactly as described in methods. The 
results represent the mean and the standard deviation of 
the five determinations. 
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Table 10 
Comparison of Molecular Weight Fractions of Heparin on FPA 
Generation in At III Deficient Plasma 
Heparin concentration: 10 ug/ml 
HEPARIN 
Control 
23,000 M.W. 
17,450 M.W. 
13,300 M.TJ. 
9,000 M.W. 
·s,100 M.W. 
Native Heparin 
CY 216 
N - 5 
FPA GENERATED (ng/ml) 
AT III DEFICIENT 
1216 ± 167 
1254 ± 181 
1183 + 139 
1180 ± 124 
1100 ± 162 
1138 ± 121 
1118 ± 109 
1156 + 182 
• 
Table 10. Antithrombin III deficient plasma was prepared 
as described in methods. The antithrombin content of this 
plasma was detennined to be 6. 2 % of normal. The test 
fractions were supplemented to the anththrombin deficient 
plasma at a concentration of 10 ug/ml and the fibrino-
peptide-A generation assay was performed exactly as 
described in methods. 
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Table 11 
The Effect of Molecular Weight Fractions of Heparin on FPA 
Generation in Whole Human Blood 
Heparin Fraction 
23,000 M.W. 
13,300 M.W. 
5,100 M.W. 
Native Heparin 
CY 216 
control 
N - 4 
Concentration 
(ug/ml) 
10 
5 
2.5 
10 
5 
2.5 
10 
5 
2.5 
10 
5 
2.5 
10 
5 
2.5 
FPA Generated 
(ng/nl) 
0.66 ± .3 
3.5 ± 2.7 
18.3 ± 9.0 
0.5 ± .5 
0.37 ± .5 
6.0 ± 3.6 
12.6 ± 3 
14.2 ± 4.4 
42.6 ± 6.4 
0.0 ± 0 
6.0 ± 3.0 
12.0 ± 6.8 
4.3 ± 1.1 
12.5 ± 3.3 
24.0 ± 3.4 
so ± 10.0 
• 
Table 11. Three concentrations of the individaul test 
fractions were added to freshly drawn human whole blood. 
The whole blood fibrinopeptide - A generation assay was 
performed on these samples exactly as described in 
methods. The results represent the mean and standard 
deviation from assays performed in the whole blood of four 
individuals. 
Table 12 
Time Course Values Obtained Using Heptest 
FRACTION 
23,000 M.W. 
KINETIC PARAMETER 
Vd (L/Kg) 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUC (ug hr/ml) 
VALUE 
.OS ± .OOOS 
29 ± 2.2 
1.18 ± .l 
3.99 ± .2 
-----------------------------------------------
Vd (L/Kg) .OS ± .003 
t 1/2 {min. ) 34.S ± 4.S 
13,300 M.W. 
Clp (ml/min/Kg) 1.12 ± .11 
AUC (ug hr/ml) 4.36 ± .53 
---------------------------------------------------
Vd ( L/Kg) .oss ± .004 
t 1/2 (min.) S0.8 ± 6.5 
S,100 M.W. 
Clp (ml/min/Kg) .76 ± .09 
AUC (ug hr/ml) 6.38 ± .61 
-------------------------~---------------------------------
CY 216 4,SOO M.W. 
Native Heparin 
Vd (L/Kg) 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUC (ug hr /ml) 
Vd (L/Kg} 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUC (ug hr/ml) 
.061 ± .008 
S8 ± 4.8 
.72 ± .06 
• 
6.2S ± .57 
.OS ± .0001 
31 ± 2.2 
1.14 ± .08 
4.26 ± .3 
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Table 12. The intravenous Plasma time course Of the 
individual test fractions was calculated exactly as 
described in methods. The data in this table represents 
the time course parameters calculated from data 
obtained with the heptest assay. All values indicate the 
mean and standard deviation obtained from administration 
of the individual fractions to five primates. 
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Table 13 
Time Course of plasma Anti Xa Activity 
FRACTION KINETIC PARAMETER VALUE 
Vd (L/Kg) .oso ± .cos 
t 1/2 (min.) 29 ± 2.~ 
23.000 M.W. 
Clp (ml/min/Kg) 1.18 ± .03 
AUC (ug hr/ml) 4.10 ± .07 
--------------------------------------------------------------
13' 300 M. \J. 
5,100 M.W. 
CY 216 4,SOO M. t,;. 
Vd (L/Kg) 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUC (ug hr/ml) 
Vd (L/Kg) 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUC (ug hr/ml) 
Vd (L/Kg) 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUC (ug hr/ml) 
.OS4 ± .005 
34.4 ± 4.3 
l. lS ± .08 
4.36 ± .35 
.OS ± .004 
50.6 ± 7.7 
.77±.58 
6.08 ± .35 
.064 ± .005 
SS ± 4.0 
.77 ± .13 
s. 9 ± .57 
-----------------------------~---~~-----------------------
Vd (L/Kg) .OS ± .004 
t 1/2 (min.) 31 ± 2.0 
Native Heparin 
Clp (ml/min/Kg) 1. 06 ± .06 
AUC (ug hr/ml) 4.36 ± .43 
Table 13. The intravenous plasma time course of the 
individual test fractions was calculated exactly as 
desc~ibed in methods. The data in this table represents 
the time course parameters calculated from data 
obtained with the anti factor Xa assay. All values 
indicate the mean and standard deviation obtained from 
administration of the individual fractions to five 
prima1:es. 
Table 14 
Time Course of Plasma Anti Ila Activity 
FRACTION PHARMACOXINETIC PARAMETER 
23,000 !i.IJ. 
13,300 M.W. 
S,100 M.W. 
CY 216 4,500 M.W. 
Vd (L/Kg) 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUC (ug hr/ml) 
Vd (L/Kg) 
t 1/2 (min.) 
c1,, (ml/min/Kg) 
AUG (ug hr/ml) 
Vd (L/Kg) 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUG (ug hr/ml) 
Vd (L/Kg) 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUC (ug hr/ml) 
VALUE 
.OS ± .009 
30 ± l.S 
1.4 ± .03 
3.31 ± .2 
.06 ± .006 
32 ± 1. 3 
1. 46 ± .05 
3.53 ± .04 
.OS ± .004 
32 ± 1. 9 
1. 08 ± .08 
4.73 ± .14 
.OS ± .005 
32 ± 1. 4 
1.1 ± .07 
4.0 ± . 5 
.,A. _____________ 
Vd (L/Kg) .06 ± .01 
t 1/2 (min.) 32 ± 1. 5 
Native Heparin 
Clp (ml/min/Kg) 1. 4 ± .22 
AUC (ug hr/ml) 3.S ± .52 
Table 14. The intravenous plasma time course of the 
individual test fractions was calculated exactly as 
described in methods. The data in this table represents 
the time course parameters calculated from data 
obtained with the anti factor II a assay. All values 
indicate the mean and standard deviation obtained from 
administration of the individual fractions to five 
primates. 
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Table 15 
Time Course Values Obtained From PT Assay 
FRACTION 
23,000 M.W. 
13,300 M. i;. 
5,100 M.Y. 
CY 216 4,500 M.Y. 
Native Heparin 
KINETIC PARAMETER 
Vd (L/Kg) 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUC (ug hr/ml ) 
Vd (L/Kg) 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUC (ug hr/ml) 
Vd (L/Kg) 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUC (ug hr/ml) 
Vd (L/Kg) 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUC (ug hr/ml) 
Vd (L/Kg) 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUC (ug hr/ml) 
VALUE 
.1 ± .01 
26.2 ± 2.0 
2.68 ± .39 
2.4 ± .3 
.11 ± .004 
35 ± 3.4 
2.14 ± .15 
2.42 ± .16 
.09 ± .005 
36 ± 2.1 
1.8 ± .19 
2. 6 :: . 2 
.06 ± .007 
39 ± 7.2 
1. 2 ± .14 
3.80 ± .58 
-------
.07 ± .01 
29 ± 5.4 
1.76 ± .16 
2.78 ± .34 
Table 15. The intravenous plasma time course of the 
individual test fractions was calculated exactly as 
described in methods. The data in this table represents 
the time course parameters calculated from data 
obtained using a dilute PT assay. All values indicate the 
mean and standard deviation obtained from administration 
of the individual fractions to five primates. 
Table 16 
Time Course of Plasma FPA Inhibiting Actions 
FRACTION 
23,000 M.IJ. 
13,300 M.IJ. 
5,100 M.IJ. 
CY 216 4,500 M. IJ. 
KINETIC PARAMETER 
Vd (L/Kg) 
t 1/2 (min. ) 
Clp (ml/min/Kg) 
AUC (ug hr/ml) 
Vd (L/Kg) 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUC (ug hr/ml) 
Vd (L/Kg) 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUC (ug hr/ml) 
Vd (L/Kg) 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUC (ug hr/ml) 
VALUE 
.07 ± .008 
30 ± 2.7 
2.05 ± . 5 
2.56 ± 1. 1 
.10 ± .1 
45.6 ± 5 
1.9 ± .3 
3.13 ± .1 
.07 ± .01 
52 ± 7 
l. 0 ± .23 
5.1 ± .49 
.09 ± .01 
61 ± 6.8 
1. 21 ± .1 
3.9 ± .14 
-----------------------------------------------
Native Heparin 
Vd (L/Kg) 
t 1/2 (min.) 
Clp (ml/min/Kg) 
AUC (ug hr/ml) 
.08 ± .02 
37 ± 1.9 
1.6 ± .2 
3.57 ± .3 
Table 16. The intravenous plasma time course of the 
individual test fractions was calculated exactly as 
described in methods. The data in this table represents 
the time course parameters calculated from data 
obtained using a the fibrinopeptide - A generation assay. 
All values indicate the mean and standard deviation 
obtained from administration of the individual fractions 
to five primates. 
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Table 17 
Subcutaneous Time Course Obtained Using Heptest Assay 
FRACTION KINETIC PARAM!TE~ VALUE 
t 1/2 (min.) 205 ± 40 
23,000 M.IJ. AUC (ug hr/ml) .47 ± .38 
Absorption 3 % 
-----------------~-----------------------------------------
13,300 M.IJ. 
t 1/2 (min.) 
AUC (ug hr/ml) 
Absorption 
144 ± 32 
1.54 ± .2 
9 % 
------------------------------------------------------------
5,100 M.\J. 
t 1/2 (min.) 
AUC (ug hr/ml) 
Absorption 
108 ± 20 
23.7 ± .9 
93 % 
-------------------------------------------------------
CY 216 4,500 M.~. 
t 1/2 (min.) 
AUC (ug hr/ml) 
Absorption 
144 ± 26 
21.9 ± 2.2 
88 % 
-----------------------------------------------
Native Heparin 
t 1/2 (min.) 
AUC (ug hr/ml) 
Absorption 
• 
94 ± 32 
6.8 ± 1.4 
40 % 
Table 17, T~e !)lasma time course of the test fractions were 
calculated after subcutaneous injection at a concentration 
of 1. O mg/kg. The blood sampling protocal and time 
course calculations were performed exactly as previously 
described. These results were calculated from data 
obtained using the heptest assay. All values represent 
the mean and standard deviation of calculations from five 
individual primates. 
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Table 18 
Subcutaneous Time Course of Plasma Anti Xa Activity 
FRACTION 
23,000 M.IJ. 
13,300 M.W. 
5,100 M.\;. 
CY 216 4,500 M.IJ. 
Nat:ive Heparin 
KINETIC PARAMETER 
t 1/2 (min.) 
AUC (ug hr/ml) 
Absorption 
t 1/2 (min.) 
AUC (ug hr/ml) 
Absorption 
t 1/2 (min.) 
AUC (ug hr/ml) 
Absorption 
t 1/2 (min.) 
AUC (ug hr/ml) 
Absorption 
t 1/2 (min.) 
AUC (ug hr/ml) 
Absorption 
VALUE 
106 ± 12 
1.5 ± .4 
10 ' 
163 ± 19 
2.9 ± .4 
14 ' 
200 ± 18 
21.4±1.7 
94 ' 
201 ± 17 
22 ± 2 
96 ' 
154 ± 17.5 
•5.7±1.3 
32 ' 
Table 18. The plasma time cours1~ of the test fractions was 
calculated after subcutaneous injection at a concentration 
of 1. O mg/kg. The blood sampling protocal and time 
course calculations were performed exactly as previously 
described. These results were calculated from data 
obtained using the anti factor Xa assay. All values 
represent the mean and standard deviation of calculations 
from five individual primates. 
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Table 19 
Subcutaneous Time Course of Plasma Anti Ila Activity 
FRACTION 
23,000 M.lJ. 
KINETIC PARAMETER 
t 1/2 (min.) 
AUC (ug hr/ml) 
Absorption 
-------------------------
t 1/2 (min.) 
13,300 M.lJ. AUC (ug hr/ml) 
Absorption 
t 1/2 (min.) 
5,100 M.lJ. AUC (ug hr/ml~ 
Absorption 
VALUE 
104 ± 16 
0.9 ± . 3 
6 
' 
147 ± 2 8. 3 
1. 4 ± .63 
10 
' 
139 ± 22 
12. 2 = 2.:. 
60 ' 
-------------------------------------------------
t 1/2 (min.) 167 ± 15 
CY 216 4,500 M.lJ. AUC (ug hr/ml) 7.5 ± 1 
Absorption 47 ' 
t 1/2 (min.) 119 ± 19 
• 
Native Heparin AUC (ug hr/ml) 3.5 ± .7 
Absorption 24 ' 
Table 19. The plasma time course of the test fractions was 
calculated after subcutaneous injection at a concentration 
of 1. o mg/kg. The blood sampling protocal and time 
course calculations were performed exactly as previously 
described. These results were calculated from data 
obtained using the anti factor IIa assay. All values 
represent the mean and standard deviation of calculations 
from five individual primates. 
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Table 20 
Subcutaneous Time Course Determined Using A PT Assay 
F1lACTION ~INETIC PAIAMET?i VALCE 
23,000 lt.~. 
13,300 M.IJ. 
5,100 IL~. 
t 1/2 (11in.) 
AUC (ug hr/ml) 
Absorption 
t l/2 (min.) 
AUC (ug hr/ml) 
Absorption 
t 1/2 (min.) 
AUC (ug hr/ml) 
Absorption 
--------------- ----
t 1/2 (min.) 
CY 216 4,500 M.~. AUC (ug hr/ml) 
Absorption 
t l/2 (min.) 
Nati•.re Heparin AUC (ug hr/ml) 
Absorption 
~.A. 
?LA. 
0 
l6i : z:-
l. 2 : . 4 
13 ' 
----------
121 : 17 
3.3 : .6 
30 ' 
135 ± 14 
5.8 ± l.l 
38 ' 
-------
117 ± 14 
3.7:: .5 
36 ' 
Table 20. The plasma time course of the test frac"tions were 
calculated after subcutaneous injec"tion at a concentration 
Of l. 0 mg/kg. The blood sampling protocal and time 
course calculations were per!cr.:ied exac~ly as previously 
described. These results were calculated fro~ data 
obtained using a dilute PT assay. All values represent 
the mean and standard deviation of calculations from five 
individual primates. 
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Table 21 
Subcutaneous Time Course Determined Using the FPAGT 
FRAC':'ION 
23,COO ff.Ii. 
XIN!TIC PARAM!T!R 
c 1/2 (min.) 
AUC (ug hr/ml) 
Absorption 
89 : 41 
2. 8 : . .5 
28 ' 
·--------------- --~---------------------------
c 1/2 (min.) 131 ! 2C 
13.~00 !Lil. AUC (ug hr/ml) S.7 ! c 
Absorption 44 ' 
--------------------·----------------------
s.:..co ~.~. 
CY 216 4,500 ff.Ii. 
Native Heparin 
c l/2 (min.) 
ACC (ug !':.r/ml) 
Absorption 
c l/2 (min.) 
AUC (ug hr/ml) 
Absorption 
c 1/2 (min.) 
AUC (ug hr/ml) 
Absorption 
.. 
l!B :: 19.: 
• a , 
. ...... : : .. :.. 
95 ' 
195 = ;: 
19.9 = ::.; 
100 ' 
120 :: 24 
8.2: l.4 
66 ' 
Table 21. The plasma time course of the test fractions was 
calculated after subcutaneous injection at a concent~ation 
Of l. 0 mg/kg. The blood sampling protocal and time 
course calc~lations were performed exactly as previously 
desc:-ibed. These results were calculated fro~ data 
obtained using the fibrinopeptide - A generation assay. 
All values represent the mean and standard deviation of 
calculations from five individual primates. 
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Table 22 
Circulating Pharmacod"118mi.c Effects of the Molecular Weight 
Fractions in the Rabbit Stasis Thrombosis Hodel 
Dose: 25 ug/Kg 
Route: Intravenous 
Clottins Time in Seconds 
Test Fraction PTl' IT Hep test 
23,000 M.W. 
Baseline 78 .± 6 37 .± 7 27 .± 4 I 
Pre-challenge 85 .± 9 39 .± 9 31 .± 3 I 
13,300 M.W. 
Baseline 83 .± 7 33 .± 4 32 .± 6 I 
Pre-challenge 88 .± 8 44 .± 6 40 .± 6 I 
5,100 M.W. 
Baseline 84 .± 7 34 .± 6 31 .± 5 I 
Pre-challenge 82 .± 9 35 .± 6 39 .± 7 I 
CY 216 
Baseline 80 .± 9 32 .± 5 29 .± 3 I 
Pre-challenge 83 .± 8 37 .± 6 39 .± 6 I 
Unfractionated Heparin 
Baseline 
Pre-challenge 
82 .± 14 35 .± 6 30 .± 6 I 
92 .± 17 38 .± 5 35 .± 6 I 
I 
I Percent Inhibition 
Anti Ia 
5 .± 3 
14 .± 6 
4 .± 1 
13 .± 4 
3 .± 2 
8 .± 3 
4 .± 2 
15 .± 6 
4 .± 3 
12 .± 5 
Anti !Ia 
4 .± 2 
16 .± 10 
3 .± 1 
13 .± 5 
5 .± 3 
10 .± 7 
4 .± 2 
8±3 
3 .± 1 
13 .± 7 
Table 22. The circulating pharmacodynamic actions of the 
test fractions were measured during the stasis thrombosis 
experiments using the PTT, PT, heptest, anti Xa and anti 
IIa assays. The baseline values represent the coagulation 
profile prior to drug administration. The pre-challenge 
levels represent the circulating pharmacodynamic actions 
immediately prior to administration of the thrombogenic 
challenge. All results represent the mean and standard 
deviation obtained from five experimental animals. 
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Table 23 
Circulating Pbarmacod!:!!a.mic Effects of the Molecular Weight 
Fractions in the Rabbit Stasis Thrombosis Hodel 
Dose: 50 ug/Kg 
Route: Intravenous 
Clotting Time in Seconds I Percent Inhibition 
Test Fraction PTI TI Hep test I Anti Xa Anti IIa 
23,000 H.W. 
Baseline 84 ± 11 36 ± 3 29 ± 4 I 5±3 4±3 
Pre-challenge 105 ± 15 109 ± 40 42 ± 6 I 23 ± 6 32 ± 6 
13,300 H.l•i. 
Baseline 84 ± 7 33 ± 3 28 ± 7 I 5±2 5 ± 3 
Pre-challenge 100 ± 16 55 ± 12 37 ± 4 I 23 ± 6 29 ± 14 
5,100 M.W. 
Baseline 87 ± 14 33 ± 3 33 ± 3 I 6 .±. 3 4 ± 2 
Pre-challenge 93 ± 12 37 ± 6 38 ± 3 I 12 ± 6 7 ± 3 
CY 216 
Baseline 83 ± 9 32 ± 4 31 ± 4 I 5±3 5 ± 1 
Pre-challenge 96 ± 13 39 ± 7 40 ±. 7 I 17 ± 7 10 ± 5 
Unfractionated Heparin 
• Baseline 86 ± 8 30 ± 2 30 .±. 2 I 6±3 4 ± 3 
Pre-challenge 90 ± 16 70 ± 15 37 ± 4 I 23 ±. 6 29 ± 12 
Table 23. The circulating pharmacodynamic actions of the 
test fractions were measured during the stasis thrombosis 
experiments using the PTT, PT, heptest, anti Xa and anti 
IIa assays. The baseline values represent the coagulation 
profile prior to drug administration. The pre-challenge 
levels represent the circulating pharmacodynamic actions 
immediately prior to administration of the thrombogenic 
challenge. All results represent the mean and standard 
deviation obtained from five experimental animals. 
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Table 24 
Circulating Pharmacodynamic Effects of the Molecular Weight 
Fractions in the Rabbit Stasis Thrombosis Hodel 
Dose: 100 ugiKg 
Route: Intravenous 
Clotting Time in Seconds I Percent Inhibition 
Test Fraction PIT TT Heptest I Anti Ia Anti IIa 
23,000 M.W. 
Baseline 86 ± 10 38 ± 2 30 ± 5 I 5 ± 2 4±3 
Pre-challenge > 150 > 150 63 ± 14 I 40 ± 11 47 ± 14 
13,300 M.W. 
Baseline 82 ± 8 34 ± 5 27 ± 3 I 4 ± 3 5 ± 2 
Pre-challenge > 150 > 150 63 .:t 9 I 50 .:t 9 47 .:t 7 
5,100 M.W. 
Baseline 83 ± 7 35 ± 5 33 ± 6 I 6±2 4 ± 2 
Pre-challenge 85 ± 5 47 ± 7 48 ± 17 I 20 .:t 9 19 ± 12 
CT 216 
Baseline 82 ± 9 33 ± 3 31 ± 3 I 6±3 3±2 
Pre-challenge 86 ± 3 50 ± 9 53 ± 7 I 27 ± 12 22 ± 7 
Unfractionated Heparin 
• 
Baseline 84 ± 9 36 ± 4 28 ± 5 I 7±4 4 ± l 
Pre-challenge 123 ± 30 >150 57 ± 12 I 43 ± 13 47 ± 17 
Table 24. The circulating phannacodynamic actions of the 
test fractions were measured during the stasis thrombosis 
experiments using the PTT, PT, heptest, anti Xa and anti 
IIa assays. The baseline values represent the coagulation 
profile prior to drug administration. The pre-challenge 
levels represent the circulating phannacodynamic actions 
immediately prior to administration of the thrombogenic 
challenge. All results represent the mean and standard 
deviation obtained from five experimental animals. 
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Table 25 
Circulating Pharmacodrn.amic Effects of the Molecular Weight 
Fractions in the Rabbit Stasis Thrombosis Hodel 
Dose: lmg/Kg 
Route: Subcutaneous 
Clotting Time in Seconds I Percent 
Test Fraction PTT IT Hep test I Anti Xa 
---
23,000 M.W. 
Baseline 79 .± 9 32 .± 2 27 .± 2 I 3 .± 2 
Pre-challenge 84 .± 11 36 ·.± 3 23 .± 3 I 3 .± 2 
13,300 M.w. 
Baseline 80 .± 7 34 .± 2 30 .± 2 I 3 .± 2 
Pre-challenge 90 .± 9 42 ± 6 33 .± 5 I 12 ± 6 
5,100 M.W. 
Baseline 84 ± 10 32 .± 3 29 ± 6 I 4±3 
Pre-challenge 94 ± 12 44 ±. 16 55 ±. 13 I 17 ±. 8 
CY 216 
Baseline 81 .± 9 31 .± 4 27 .± 3 I 4 .± 2 
Pre-challenge 96 .± 10 47 .± 7 62 .± 9 I 23 ±. 9 
Unfractionated Heparin 
Baseline 79 .± 10 35 .± 3 24 .± 5 I 3 .± 2 
Pre-challenge 88 ± 12 37 .± 5 33 .± 8 I 19 .± 5 
Inhibition 
Anti IIa 
3 .± 6 
2 .± 4 
4 ± 4 
10 + 8 
5 .± 3 
23 ±. 8 
4 .± 2 
19 .::. 12 
2 .± 2 
4 ± 5 
Table 25. The circulating pharmacodynarnic actions of the 
test fractions were measured during the stasis thrombosis 
experiments using the PTT, PT, heptest, anti Xa and anti 
IIa assays. The baseline values represent the coagulation 
profile prior to drug administration. The pre-challenge 
levels represent the circulating pharmacodynarnic actions 
immediately prior to administration of the thrombogenic 
challenge. All results represent the mean and standard 
deviation obtained from five experimental animals. 
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Table 26 
Comcarison of Half-life Calculated from 
M~lar and Gravimetric Concentrations 
Fraction Time EOSt concentration concentration 
Injection ~ (ug/ml) 
5 .207 4.78 
10 .18 4.2 
23,000 15 .16 3.7 
30 .10 2.5 
60 .05 1.15 
180 .001 .02 
t 1/2 .. 27 a:in. t 1/2 . 29 min. 
5 .35 4.72 
10 .30 4.0 
13,300 15 .26 3.5 
30 .18 2.4 
60 .09 l. 3 
180 . 01 .13 
t l/Z := 33 :nin. t 1/2 34 min. 
5 .93 4.77 
10 .81 4.14 
5,100 15 .70 3.61 
30 .59 3.05 
60 .42 2.14 
180 .078 .40 
t 1/2 - 52 min. t 1/2 = so min. 
5-- .89 4.81 
10 .79 4.29 
CY 216 15 .70 3.8 
30 .54 2.9 
60 .35 l. 9 
180 .09 
,..47 
t 1/2 • 60 min. t 1 2 .. 58 min. 
5 .375 4.72 
10 .329 4.14 
Heparin 15 .304 3.82 
30 .227 2.85 
60 .10 l. 27 
180 .002 .02 
t 1/2 
-
30 min. t 1/2 .. 31 min. 
Table 26. The gravimetric concentrations from the primate 
kinetic study were converted to molar amounts using the mean molec-
ular weights in table 1. Semi - log concentration I time plots 
were generated for both values from which half-1.ife values were 
calculated. These values were similar for both molar and grav-
imetric concentrations. 
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Table 27 
Comparison of Relative Absorption Calculated From 
Molar and Gravimetric Concentrations 
Molar Gravimetric 
Test Fraction Absorotion Absorption 
23,000 2.89 % 3 % 
13,300 8.85 % 9 % 
5' 100 92 % 93 % 
CY 216 86 % 88 % 
Heparin 41 % 40 % 
Table 27. Absortion was calculated using the AUC 
data obtained from the heptest assay exactly as described 
in methods. The ug hr/ml concentrations were transformed 
to uM values using the mean molecular weights of the 
individual fractions (table 1). 
Table 28 
Relationship Between Absorption 
Fraction 
Native Heparin 
23,000 M.W. 
13,300 M.W. 
5,100 M.W. 
CY 216 
Distribution 
% of components 
less than 10,000 
38 
1 - 2 
7 
96 
97 
correlation between absorption 
molecular weight components less 
weight (r = .99) 
191 
and Molecular Weight 
approximate 
Absortpion 
40 % 
6 % 
11 % 
• 93 
91 
and the % content of 
than 10,000 molecular 
Table 29 
Relationship Between Absorption , Pharmacodynamic 
Effects and Antithrombotic Actions After Subcutaneous 
Administration 
Fraction Antithrombotic 
Actions 
23,000 7.7 
13,300 62.0 
5,100 47.0 
CY 216 81.0 
Heparin 27.0 
Absorption 
(Primate) (%) 
3.0 
9.0 
93.0 
88.0 
40.0 
correlation 
absorption 
between antithrombotic 
r = • 55 
Pharmacodynamic 
Effects 
3.7 
9.9 
48.0 
57.0 
28.0 
actions and 
correlation between antithrombotic actions and circulating 
anticoagulant actions r = .63 
• 
Table 29. The antithrombotic actions represent the percent 
reduction in thrombus formation in the rabbit model 
compared to control. The absorption was calculated 
from the primate heptest data exactly as previously 
described. The pharmacodynamic effects indicate the 
circulating drug actions in the rabbit model prior to 
injection of the thrombogenic challenge. These values 
represent the percent difference from baseline values. 
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Table 30 
Molar Concentration of Antithrombin III in Normal Human 
Plasma and the Test Fractions at a gravimetric 
concentration of 5 ug/ml 
Test Fraction Concentration (uM) 
23,000 M.W. .217 
17,450 M.W. .286 
13,300 M.W. .375 
9,000 M.W. .555 
5,100 M.W. .98 
CY 216 .92 
Heparin .397 
Antithrombin III 4.53 
.. 
Table 30. The molar concentrations of the test fractions 
were based on the molecular weights determined by HPLC-
GPC (table 1) • The molar concentration of anti thrombin 
III was based upon a molecular weight of 64, 000 and a 
normal plasma concentration of 29 mg/dL. The molar ratio 
between the test fractions and antithrombin III was even 
greater than the calculations indicate since only about 
one third of a given heparin preparation possesses af-
finity to antithrombin III. 
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Figure 1. Five grams of porcine sodium heparin were 
fractionated on an Ul tro-gel ACA-44 column. Fourteen 
fractions were collected at 35 minute intervals and the 
absorbance at 205 nm was recorded to deter:iine heparin 
content. Initial and latter fractions were pooled i~ order 
to ac~ieve a sufficient quantity for experiment3l work. The 
elution profile demonstr3 ted a normally distributed 
·population of molecular weight components wit~in the native 
hep3rin. 
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Figure 2 
Comparison of the Glycosaminoglycan Content of 
the Various Test Heparins Using a 
Toluidine Blue Assay 
Abs 606 
0.50 Heoarin cone. 100 u;/•1 
s. untrect1on•tld Heoartn 
2. 23.000 •ol1cu11~ .. 1ght 
0.40 3. S7.~0 1t0lecu11r w11;nt 
4. S!.300 11Gl1cu1ar w11;ht 
s. 1.000 aolecular w11;ht 
0.30 I. 15.. 100 •olecular wet;ht 
0.20 
0.10 
1 2 3 4 5 6 
N = 5 
Figure 2. The glycosaminoglycan content of the gel-filtered 
fractions was measured using a toluidine blue assay. The 
dye reacted with the sulfate groups of the heparin molecules 
to produce a color change which was measured in a 
spectrophotometer. The absorbance at 606 nm was directly 
proportional to the heparin content of the individual 
frations. All fractions displayed similar heparin content. 
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Figure 3 
Relationship Between Viscosity and the Molecular Weight 
of the Test Heparins Determined by HPLC - GPC 
viscosity (mPa 's) 
2.00 
1.50 
1.00 
• 
0 . 50 _______ __,__ _ __.._ _ ___. _ __. 
Figure 3. 
0.50 1.00 1.50 2.002.50 
molecular weight x 10-4 
Viscosity measurements were cade on 10 mg/:nl 
solut!ons of the gel-filtered fractions using a cone-plate 
viscocieter. The figure shows the relationship bet·.•een the 
resulting viscosity and the molecular weight deter:Jined by 
HPLC-GPC. A linear relationship was observed bet·.;een 
Viscosity and molecular weight. 
196 
Figure 4 197 
Effect of Molecular Weight on Thromboplastin Activated 
FPA Generation in Platelet Poor and Platelet Rich Plasma 
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Figure 4. The molecular weight fractions were compared in 
the thromboplastin activated FPA generation assay in both 
platelet rich and platelet poor plasmas. Both plasmas were 
prepared from the saoe donor (N = 5) and supplemented with 
the individual test fractions at 2.5 ug/ml.. FPA generation 
was perforced exactly as described in methods. The effects 
of all fractions were si:nilar in both platelet rich and 
platelet poor plasmas. 
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Figure 5 Effect of Factor VII Concentration 
on VII-Thromboolastin Activation 
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Figure S. The factor VII-thromboplastin assay was performed 
as described in methods using five different concentrations 
of factor VII. The concentration of all other reactants was 
kept constant. The rate of p-NA release was directly 
related to the concentration of factor VII. 
Figure 6 
Effect of the Test Fractions on Factor VII - Thromboplastin 
Activated Factor Ia in an Amidolytic Assay 
J-H& 1'111811 fl,iM/a&nl 
' • 23. 000 ..... 
,.ooj 
I • t7. 4!0 M.W. 
a.~o ..-
3 • tJ. 300 ..... 
4. 1.000 ..... 
1.00 ..... s • s. 100 .... 
I I • C:Y 211 
I 1 • ,,.o ... ," 
1.:0 .... 
i.00 i-
0.::11-
N • ! 
I I 3 4 S I 7 
Figure 6. !be test fractions were compared for their effect 
in the factor VII-Thromboplastin assay. !be assay used 
factor VII-1bromboplastin to activate factor I to Ia. !be 
assay endpoint was measured by recording the kinetics of p-
NA release from a Ia specific substrate using a kinetic 
analyzer (IL Multistat). The effects of the H.~. fractions 
were studied using 25 ug/ml solutions of the i~divual test 
fractions diluted 1 :2 in 1.25 U/ml antithrocbin III and 
comparing the resulting p-NA release. 
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Figure 7 
Effect of the Test Fractions on Factor Ia as Studied 
in an Am.idolytic Assay 
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Figure 7. The factor VII-Thromboplastin assay was modified 
to study the effects of the M.W. fractions on factor Ia in 
this assay. The assay was perfonied by replaci~g factor's 
VII and X with an equivalent a::ount of Xa. Thrc~boplastin 
re~ai~ed in the reaction mixture. 25 ug/ml conce~trations 
of the test fractions were diluted 1: 2 in 1. 25 U/ml 
antithrocibin III and compared for their effect on p-NA 
release fro~ a Xa specific substrate. With the exception of 
the two low molecular weight fractions, no difference in 
potency was observed. 
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Figure 8 201 
Differential Effect of the Test Fractions When Incubated With 
Factor VII - Tiiromboplastin or Factor I in the 
VII - 'ln.romboplastin Activated Amidolytic Assay 
J.00 r- C::::::~•o•~l" w/Vtt-TP c;:::::;~•o•~1n w/factor X 
Figure 8. The factor VII-Thromboplastin assay was modified 
to distinguish the effects of the M.W. fractions on factor 
VII. 25 ug/ml concentrations of the test fractions were 
diluted 1 :2 in 1.25 U/ml antithrombin III and incubated 
either vith factor VII-thromboplastin or factor X. 
Differences in p-NA release were compared from the two 
incubation systems (N • 5). Significant differences between 
the two systems were only observed for the 23,000 and 17,450 
H.W. fractions. 
Figure 9 
Effect of the Test Fractions on a Tb.romboplastin Activated 
Amidolytic Assay in Plasma 
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Figure 9. The test fractions were compared for their 
effects in the plasma VII-Thromboplastin assay. In this 
assay, factor's VII, I and antithrombin III were provided by 
the plasma. The assay used dilute thromboplastin (1:20) to 
activate dilute (1:2), factor II deficient plasma 
supplemented with 5 ug/ml of each test fraction. p-NA 
release from a Xa specific substrate was compared to 
determine the effects of the test fractions. The 23,000 ; 
17, 450 and 13, 300 M. W. fractions displayed the most 
inhibition in this assay. 
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Figure 10 
Effect of the Test Fractions on a Thromboplastin Activated 
Aai.dolytic Assay in Plasma 
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Figure 10. The test fractions were compared for their 
effects in the plasma VII-Thromboplastin assay. In this 
assay, factor's VII, I and antithrombin III were provided by 
the plasma. The assay used dilute thromboplastin (1:20) to 
activate dilute (1:2), factor II deficient plasma 
supplemented with 2.5 ug/ml of each test fraction. p-NA 
release from a Xa specific substrate was compared to 
determine the effects of the test fractions. In contrast to 
the results observed at 5 ug/ml concentrations, the 13,300 
M.W. fraction displayed the greatest potency. 
203 
Figure 11 204 
Effect of the Test Fractions on a Th.romboplastin Activated 
Amidolytic Assay in Plasma 
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Figure 11. The test fractions were compared for their 
effects in the plasma VII-ThroJiboplastin assay. In this 
assay, factor's VII, X and antithrombin III were provided by 
the plas~a. The assay used dilute thromboplastin (1:20) to 
activate dilute (1:2), factor II deficient plasma 
supplemented with 1.25 ug/ol of each test fraction. p-NA 
release from a Xa specific substrate was compared to 
determine the effects of the test fractions. Less 
inhibition was observed compared to the 2.5 and 5 ug/ml 
concentrations. 
Figure 12 
Effect of the Test Fractions on a Thromboplastin Activated 
Am.idolytic Assay in Plasma 
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Figure 12. The test fractions were compared for their 
effects in the plasma VII-Thromboplastin assay. In this 
assay, factor's VII, X and antithrombin III were provided by 
the plasma. The assay used dilute thromboplastin (1:20) to 
activate dilute (1 :2), factor II deficient plasma 
supplemented with 5 ug/ml of each test fraction. p-NA 
release from a thrombin specific substrate was compared to 
determine the effects of the test fractions. Similar with 
the results observed with the Xa substrate, the 13,300 M.W. 
fraction displayed the greatest potency. 
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Figure 13 206 
Effect of the Test Fractions on a Thromboplastin Activated 
Amidolytic Assay in Plasma 
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Figure 13. The test fractions were compared for their 
effects in the plasma VII-Thromboplastin assay. In this 
assay, factor's VII, X and antithrombin III were provided by 
the plasma. The assay used dilute thromboplastin (1:20) to 
activate dilute (1:2), factor II deficient plasma 
supple:iented with 2.5 ug/ml of each test frac~:.on. p-NA 
release from a thrombin specific substrate was compared to 
deter::iine the effects of the test fractions. 
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Figure 14. The test fractions vere compared for their 
effects in the plasma VII-Thro::'!lboplastfo assay. In this 
assay, factor's VII, I and antithrombio III vere provided by 
the plasma. The assay used dilute throcboplastin (1:20) to 
act iv a t e d i 1 u t e ( l : 2 ) , fa c t or I I de ! i c ! e ~ t p l3 s ::a 
supple!teated vi.th 1.25 ug/ml of each test fraction. p-NA 
release from a thrombia specific substrate was compared to 
deteroioe the effects of the test fractions. At this 
cooceotratioa, mini:nal effects vere observed for all test 
fractions. 
Figure 15 
Effect of Molecular Weight 
on Plasma Concentration Time Course 
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Figure 15. Five primates were administered a 250 ug/Kg 
dose of the 23,000 M.W. fraction. Blood samples were taken 
at 5, 10, 15, 30, 60, 120 and 180 minutes post injection and 
plasma concentrations were determined using the Heptest 
heparin assay. Semi-log plots were generated using the mean 
plasma concentrations of the five primates at each time 
interval. The error bars represent the standard deviation. 
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Figure 16. 
Figure 16 
Effect of Molecular Weight 
on Plasma Concentration Time Course 
Conc1nt~1t1:n (ug/ml) 
4.00 
3.00 
2.00 
1. ;c O.:J 
c .e:i 
0.7:: ~ .50 
o.~o 
o . .:o 
0.30 
0.20 
8:6§ 
o.ce 
0.07 
o.oe 
0.0!5 
0.04 
0.03 
0.02 
-- ... ..,. !3. 300 
Intravenous 
• 
VO (l../i<g) • 0!5 i . 003 
t 1/2 !minl 34.!5 : 4.~ 
Cl !rnl/1111n/k;J 1. 12 :: . ! ! 
AUC (ug n~/mll 4.35 : .!5 
0.00 !50.00 100.00 1~0.00 
Time !m1nutesl 
200.co 
Five primates were administered a 250 ug/Kg 
dose of the 13,300 M.W. fraction. Blood samples were taken 
at 5, 10, 15, 30, 60, 120 and 180 minutes post injection and 
plasma concentrations were determined using the Heptest 
heparin assay. Semi-log plots were generated using the mean 
plasma concentrations of the five primates at each time 
interval. The error bars represent the standard deviation. 
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Figure 17 
Effect of Molecular Weight 
on Plasma Concentration Time Course 
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Figure 17. Five primates were administered a 250 ug/Kg 
dose of the 5,100 M.W. fraction. Blood samples were taken 
at 5, 10, 15, 30, 60, 120 and 180 minutes post injection and 
plasma concentrations were determined using the Heptest 
heparin assay. Semi-log plots were generated using the mean 
plasma concentrations of the five primates at each time 
interval. The error bars represent the standard deviation. 
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Figure 18. 
Figure 18 
Effect of Molecular Weight 
on Plasma Concentration Time Course 
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Five primates were administered a 250 ug/Kg 
dose of CY 216. Blood samples were taken at 5, 10, 15, 30, 
60, 120 and 180 minutes post injection and plasma 
concentrations were determined using the Heptest heparin 
assay. Semi-log plots were generated using the mean plasma 
concentrations of the five primates at each time interval. 
lbe error bars represent the standard deviation. 
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Figure 19. 
Figure 19 
Effect of Molecular Weight 
on Plasma Concentration Time Course 
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Five primates were administered a 250 ug/Kg 
dose of the unfractionated heparin. Blood samples were 
taken at 5, 10, 15, 30, 60, 120 and 180 minutes post 
injection and plasma concentrations were determined using 
the Hep test heparin assay. Semi-log plots were generated 
using the mean plasma concentrations of the five prioates at 
each time interval. The error bars represent the standard 
deviation. 
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Figure 20 
Effect of Molecular Weight 
on Plasma Concentration Time Course 
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Figure 20. 
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Five primates were administered a 1.0 mg/Kg 
dose of the 23,000 M.W. fraction. Blood samples were taken 
at 0, 2, 4, 6, 8, 10 and 12 hours post injection and plasma 
concentrations were determined using the Heptest heparin 
assay. Semi-log plots were generated using the mean plasma 
concentrations of the five primates at each time interval. 
1be error bars represent the standard deviation. 
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Figure 21. 
Figure 21 
Effect of Molecular Weight 
on Plasma Concentration Time Course 
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Five primates were administered a 1.0 mg/Kg 
dose of the 13,300 M.W. fraction. Blood samples ~ere taken 
at 0, 2, 4, 6, 8, 10 and 12 hours post injection and plasma 
concentrations were determined using the Heptest heparin 
assay. Semi-log plots were generated using the mean plasma 
concentrations of the five primates at each time interval. 
The error bars represent the standard deviation. 
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Figure 22 
Effect of Molecular Weight 
on Plasma Concentration Time Course 
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Five primates were administered a 1.0 mg/Kg 
dose of the 5,100 M.W. fraction. Blood samples were taken 
at 0, 2, 4, 6, 8, 10 and 12 hours post injection and plasma 
concentrations were determined using the Heptest heparin 
assay. Semi-log plots were generated using the mean plasma 
concentrations of the five primates at each time interval. 
The error bars represent the standard deviation. 
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Figure 23 
Effect of Molecular Weight 
on Plasma Concentration Time Course 
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Five primates were administered a 1.0 mg/Kg 
dose of CY 216. Blood samples were taken at 0, 2, 4, 6, 8, 
10 and 12 hours post injection and plasma concentrations 
were determined using the Heptest heparin assay. Semi-log 
plots were generated using the mean plasma concentrations of 
the five primates at each time interval. The error bars 
represent the standard deviation. 
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Figure 24, 
Figure 24 
Effect of Molecular Weight 
on Plasma Concentration Time Course 
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Five primates were administered a 1.0 mg/Kg 
dose of the unfractionated heparin. Blood samples were 
taken at 0, 2, 4, 6, 8, 10 and 12 hours post injection and 
plasma concentrations were determined using the Heptest 
heparin assay. Semi-log plots were generated using the mean 
plasma concentrations of the five primates at each time 
interval. The error bars represent the standard deviation. 
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Fl"gure 25 Effect of Molecu ar Weight on PCC/RVV 
Activated Stasis Thrombosis 
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Figure 25. Male rabbits were anesthetized and segments of 
both jugular veins surgically exposed. Each test fraction 
was administered to five rabbits and allowed to circulate 
for five minutes. A thrombogenic challenge of prothrombin 
complex concentrate and Russells viper venom was given. 
After 20 seconds both jugular veins were ligated for exactly 
10 minutes and the jugular vein segments removed and 
evaluated for degree of clot formation. With the exception 
of the 5,100 M.W. fraction, all agents produced significant 
inhibition of clot form~.tion compared to control (p • .001). 
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Figure 26 
Effect of Molecurar Weight on PCC/RVV 
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Figure 26. Male rabbi ts were anesthetized and segments of 
both jugular veins surgically exposed. Each test fraction 
was administered to five rabbits and allowed to circulate 
for fh·e minutes. A thrombogenic challenge of prothrocbin 
complex concentrate and Russells viper venom was given. 
After 20 seconds both jugular veins were ligated for exactly 
10 minutes and the jugular vein segments removed and 
evaluated for degree of clot formation. All fractions 
produced significa~t antithrombotic actions compared to 
control. 
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Figure 27 
Effect of Molecular Weight on PCC/RVV 
Activated Stasis Thrombosis 
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Figure 27. Male rabbits were anesthetized and segments of 
both jugular veins surgically exposed. Each test fraction 
was administered to five rabbits and allowed to circulate 
for five minutes. A thrombogenic challenge of prothrombin 
complex concentrate and Russells viper venom was given. 
After 20 seconds both jugular veins were ligated for exactly 
10 minutes and the jugular vein segments removed and 
evaluated for degree of clot formation. All fractions 
produced significant antithrombotic actions compared to 
control. Tile unfractionated heparin was the only agent to 
.. 
produce complete inhibition in all five animals. 
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Effect of Molecliirew~~ght on PCC/RVV 
Activateo Stasis Thrombosis 
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Figure 28. Male rabbits (N • 5) were given subcutaneous 
injections of the test fractions at a dose of 1.0 mg/Kg. 
After four hours the rabbits were anesthetized and segments 
of both jugular veins surgically exposed. A thrombogenic 
challenge of prothrombin complex concentrate and Russells 
viper venom was given. After 20 seconds both jugular veins 
were ligated for exactly 10 minutes and the jugular vein 
segments removed and evaluated for degree of clot formation. 
With the exception of the 23,000 M.W. fraction, all agents 
produced significant antithrombotic effects compared to 
control. Error bars represent standard deviation 
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APPENDIX I 
conceptual Representation of the Molecular Diversity in Heparin 
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APPENDIX II 
The Chemical Structure of Heparin 
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APPENDIX I II 
HUMAN COAGULATION PROTEINS 
Clotting Factors 
Name Molecular Weight Plasma Cone. Active Form 
Factor XII 80,000 30 ug/ml serine protease 
Prekallikrein 80,000 50 ug/ml serine protease 
High Molecular 
Weight Kininogen 120,000 70 ug/ml cofactor 
Factor XI 160,000 4 ug/ml serine protease 
Factor IX 57,000 4 ug/ml serine protease 
Factor VII/ 
von Willebrand 
factor 2,000,000 7 ug/ml cofactor 
Factor VII 47,000 1 ug/ml serine protease 
Tissue Factor 45,000 0 cofactor 
Factor x 59,000 5 ug/ml serine protease 
Factor v 330,000 5 - 10 ug/ml cofactor 
• 
Factor II 70,000 100 ug/ml serine protease 
Fibrinogen 340,000 250 mg/dl clot structure 
Factor XIII 300,000 10 ug/ml transaminase 
Regulatory Factors 
Antithrombin III 64,000 29 mg/dl Inhibitor 
Protein c 62,000 .5 ug/ml Serine protease 
Protein s 65,000 ? Regulates Protien C 
Thompson and Harker, 1983 
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Conceptual Representation of the Coagulation Network 
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Analysis Of The Unfractionated Heparin And 
A Low Molecular Weight Heparin (CY 216) 
Unfractionated 
Heparin 
Lot number ................ . 
Description ............... . 
Color ..................... . 
Origin, Intestinal Mucosa .• 
Molecular Weight 
Chemical Data 
USP Potency, as is 
AXa Potency, as is 
Loss on Drying ....••. 
Residue on Ignition •• 
Nitrogen Content ..... 
Heavy Metals ••••••••• 
pH @ 1 % ••••••••••••• 
Protein Content ••••.. 
Solubility @ 20,000 
U /ml ................ . 
Absorbance @ 20,000 
U/ml at 400 nm ..••.•• 
Uronic Acid (%) 
So3-/coo- (meq) 
Pyrogen DY LAL ..••.•• 
H-410 
Powder 
White 
Porcine 
12,500 
160 U/mg 
154 U/mg 
3.1 % 
38.7 % 
2.2 % 
< 10 ppm 
6.94 
Negative 
Clear 
0.015 
24.5 
2.44 Neg. 
Negative 
• 
Low Molecular 
Weight Heparin 
XH 46 
Powder 
White 
Porcine 
5,400 
58 U/mg 
96 U/mg 
2.9 % 
29 % 
• 2.3 % 
< 10 ppm 
6.86 
Negative 
23.9 
2.23 Neg. 
Negative 
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APPENDIX VI 
Method for Prothrombin Time Assay 
Principle 
The prothrombin time (PT) is a screening test for the 
extrinsic pathway of coagulation (factors VII, X, V, II, 
I) and for the monitoring of coumadii therapy. It is 
based on the measurement of time to clot after plasma has 
been activated by tissue thromboplastin and CaCl2. 
Reagents 
1. Thromboplastin-calcium reagent (Dade, Miami, FL). 
Reconstituted according to manufacturer's instructions. 
2. Citrated test plasma (platelet poor) 
3. Normal plasma control 
Procedure 
Incubate 100 ul plasma at 370 C in fibrometer* for 3 
minutes. 
Add 200 ul of pre-warmed 
immediately record time 
activator. 
(370 C) throm~oplastin-C and 
to clot upon addition of 
* The fibrometer is a electro-mechanical device used to 
detect clot formation. It utilizes a probe arm which 
drops into a reaction vessel and alternately descends and 
rises in a sweeping motion to sense the formation of a 
clot. When the reagents are in a fluid phase, an electric 
current is transmitted. As clotting begins, the 
electrical conductance is reduced, the electrode and 
mechanical timer stop and the clotting time is read from 
the digital readout. 
APPENDIX VII 
• 
254 
APPENDIX VII 
Method for Activated Partial Thromboplastin Time Assay 
Principle 
The activated partial thromboplastin time assay is a 
screening test for the intrinsic pathway of coagulation 
(factors XII, XI, IX, VIII, X, V, II, I) and for 
monitoring heparin therapy. It is based on the time for 
plasma to clot after activation by a platelet substitute 
(phospholipid) activator and CaCl2. 
Reagents 
1. APTT reagent (General Diagnostics, Morris Plains, NJ) 
containing phospholipid and micronized silica is 
reconstituted as directed by the manufacturer. 
2. CaCl2 (0.025 M) 
3. Citrated test plasma (platelet poor) 
4. Normal plasma control 
Procedure • 
Add 100 ul of APTT reagent to 100 ul of plasma. 
at 370 C for 5 minutes in fibrometer well. 
Incubate 
Add 100 ul of prewarmed (370 C) .025 M CaCl2 and record 
time to clot immediately upon adding the CaCl2. 
APPENDIX VIII 
• 
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APPENDIX VIII 
Method for Heptest Heparin Assay 
Principle 
The heptest assay is a clot based test for determining 
heparin concentrations in plasma. Inhibition of factor's 
Xa and Ila is accelerated by hep•rin bound to 
antithrombin-III. The amount of factor Xa/IIa activity 
neutralized during a specific time period is directly 
proportional to the concentration of heparin in the 
reaction mixture. 
Reagents 
1. Factor Xa (supplied by manufacturer) reconstituted in 
2.0 ml distilled water. The factor Xa is kept at room 
temperature. 
2. Recalmix (supplied by manufacturer) containing 
phospholipid and fibrinogen is reconstituted in 2.0 ml 
distilled water. The recalmix must be pre-warmed to 370 C 
for at least 10 minutes before using. 
Procedure 
• 
100 ul of plasma is pre-warmed in the fibrometer for 3 
minutes. 
100 ul of factor Xa is added to the plasma and incubated 
for exactly 2 minutes. 
After the 2 minute incubation, 100 ul of recalmix is added 
and the time to clot is recorded from this point using the 
fibrometer. 
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APPENDIX IX 
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APPENDIX X 
Calibration Curve for 
Toluidine Blue Assay 
Abs 606 
0.30 
0.20 
0 .10 
0 . 00 ___.__.__...__.__.._~~.._._.__.~~_.._~.._ 
0.00 50.00 100.00150.00200.00 
Heparin Cone. ug/ml 
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Reference Standards For GAG Molecular Weight Determination 
Reference Standard 
Hyaluronate 
CH-6-S 
CH-2-S 
Choay Stnd.#1 (heparin) 
Barlow Stnd. #2 (heparin) 
CH-4-S 
Barlow Stnd. #3 (heparin) 
Choay Stnd. #3 (heparin) 
Barlow Stnd. #5 
Choay Stnd. #5 
Octodecasaccharide 
Hexadecasaccharide 
Tetradecasaccharide 
Dodecasaccharide 
Decasaccharide 
Octosaccharide 
Hexasaccharide 
Pentasaccharide 
Tetrasaccharide 
Disaccharide 
Molecular Weight 
230,000 
45,000 
29,000 
22,900 
16,500 
15,000 
13.280 
12,600 
7,700 
7,570 
5,706 
5,~72 
4,438 
3.804 
3' 170 
2.336 
1.902 
1,585 
1,268 
634 
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APPENDIX XII 
GPC TSK 2000 
Log molecular weight 
4 
!5 7 
Retention time 
APPENDIX XIII 
• 
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APPENDIX XIII 
GPC TSK 3000 
Log molecular weight 
4 
!5 6 7 9 
Retention time 
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HPLC-GPC Profile of Unf r?ctionated Heparin 
Column TSK 2000 
AcQu1s1t1on m•tnod 
Un 1 ts 
r Chann•l 
; In J •ct 1 on 
, P.un tim• 
InJ•c:t1on volum• 
Irit•rnal standard Amt 
Mode 
V•rs1or-. 
tiirscr1pt1on 
COLO~#~E: TSK 2000Si-i VI 
~.403 
'=a~t!ZG02 
20C.u9 
1 
l 
l~.00 min 
20 uL 
Anal vs is 
RE'.'O~.O 
Detector UV 205 
17:4:'.a:17 
Q~ant1tat1on m•tnDd 
S·Jst•m numo•r 
V1 ;ol 
Total in)•ct1ons 
S;imcl• rat• 
Same!• amount 
S::a.o• factor 
Fl•tPons• factors 
Chann•l to cal1brat• 
9a~t:£C:GC:~ 
1 
l 
l 
2 p•r sec 
SOL.VANT: t~a2S04 0, ~ DETECTEUF: W 
cum :; 
~C• 1 
I 
60 i 
I 
70 "". 
! 
Hl -
I 
~c 1 
•0 1 
~a ... 
/\__ '.: j 
1!.250 ~~..::.;.c:::::::::..:.~.:.;.:~~!.l:~~~~.!..!,.;.;..;~:.:.:.;::::::::;::i=::.'~' -----'~;;;;:;;::;;;;;;;;;;,;;; 
10 11 
49.~6 
12 
CUlll :. I 
I 
Q" ""'! 
.• I 
I 
~" ... I 
I 
:-~ i 
60 -: I 
!O i 
·"~ -
:o ~ 
: 
zo 1 
10 -
14. 64e -1====-.::::.-====~::::::======~=::::::::::::::======::::-_;I 
e 
W•19ht Av•ra43• 
Z Avera43• 
Viscosity AveraQ• 
Z + l Av•r•'3• -
M: / l"o..I 
12487 
16723 
12487 
33376 
.l .33~ 
10 
Numb•r Avera43• 
Disp•rsivity 
Intrinsic Viscosity 
P•ak Mol W•i 43nt 
M:Tl / Mw 
927'!5 
1.346 
o.ooo 
13108 
2.673 
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APPENDIX XIV a 
Frequency Distribution of Molecular Weight Components 
Column TSK 2000 
Unfractionated heparin 
Ret. time Mal. Wt. Cum. % Slice area 
S.'!~O ~2:.€3 0.217 4947 
'!. €vo 453:?7 0.467 1c:.:.9 
5. :-:c 3992? 0.663 16:;47 
'! .Ei:O 3~2::: 1.434 22~€1 
~.=-Jo 31~77 2.!~; 30630 
6 .C·CO z-:i1 ire ..... __ 3.206 411 ~3 
E.lCO 2'!4'.;7 4.~~= ~477~ 
6 ·''"" 
2:::::1 6.~~3 70€16 
. ::co 2!.!E3 e.~!.~ 901:03 
6.4:;C 1:!'47€ 11.223 112439 
6 .5:0 18021 14.639 1363'!3 
6.6vo 16760 18.'!67 1ca•cQ 
6. :-:o 1'!662 22.99'! 179456 
6.S~C 147C l 27.760 :.939€9 
6.?~Q 13856 32.747 202'!'!4 
7.c:o 13108 37.782 204'!48 
7.:.co 12443 42.739 201339 
7.2:0 1:.849 47.!!!. 1~3=~~ 
7.:::o 11312 '!2.C47 164263 
7. 4~0 10826 S6.33c 174206 
7.'!:0 10382 60.333 162332 
7.6~:; ~~74 64.CS~ 1~!~42 
7. :-:o 95:04 67 .'!:.3 140302 
7.SOO 9239 70. 710 12?'346 
:'.~~a 8902 73.666 120076 
0. c:i:; 9591 76.339 110609 
'!! .:.:o 8271 78.891 101Ei2 • 
e.z~~ 79"0 81.:.77 92923 
0.:::0 7674 93.269 84942 
S.4CO 7392 s5.:.s7 77?60 
8. '!:o 7091 86.948 71'!33 
8.0~0 6800 e0.s.:;.; 65750 
a. ;-~c 6507 90.043 ~~~63 
8.SOQ 6-·-, ... , 91.355 54SC9 
8.?')0 ~~!~ ?2.602 4:-437 
S-. CCiJ 5614 93.:"CO 44~:?9 
9. :.:o ~~10 94.cSS 40042 
~.::: 5004 ~s.:~6 3~~~6 
? . :::J 46?6 :!'6.:::.1 30Eo.O 
:a. ~.Jc 4388 96 • .?47 25934 
~.~:; 4080 ~7 . .;61 20660 
!l.6CC 3"'"' .. '. ~ 97.65'! 1~9:16 
~. :-:o 3473 99.:.40 llCU7 
!'.SOC .3177 98.;';34 7S7S 
9. si·~c zsae !'9 . ..:67 5407 
10.~C~ .2609 ~9.!:'4 43·H 
lo.~;J 2340 99.ti90 4665 
lo.:oo 2094 99.828 5625 
10.300 1943 98.973 5969 
10.4.JO 1616 9~.l!' ~674 
10.'!~0 1406 ~si.::2g ~!~2 
10 .6il0 1213 99.376 5603 
lo.:-:o 1037 99.!01 5070 
l0.<:00 87S 9?.u49 ~~~4 
10.~!)0 
__ .,. 
I.;,' l00.000 14259 
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APPE~DIX XIV b 
HPLC-GPC Profile of the 23,000 M.W. Fraction 
Column TSK 2000 Solvent NazS04 0.5 M Deteo: tor t;'; 205 
683HH1 
~ccu1s1t1on m•t~oa 
Un 1 ts 
ct-.ann•l 
Ir.' •Ct 1 on 
F.un t 1m• 
In1•<:t1on Yolum• 
Ir.t•rn•l stanaerc ._,.,t 
Moc• 
t.'•rs1on 
O•s-:.r1i;.tton 
4/£'/86 
9;~aO:E02 
2o"u9 
1 
1 
i:..oo min 
20 uL 
Analysis 
P.E'J03. 0 
18:0010~ 
'Jia.l. 
Tot•.l. 1r.1•-:t1or.s 
Sill!ID.l.• r•t• 
Serr.ole amount 
S=a.l.e factor 
i:: .• £oor.se f ectors 
Channe.l. to <:al!brat• 
:. 
COLOt.NE: TSK 2~oos;... VI SOL'.IANT: Na2S04 0, ~'1 DETECiELJP.: W 20'!5 
8'?.681 -
,j} 
~Z.033 
; ~ i 111 
·I ' 
v1 11 
1 
• 
JI I I,. 
Y: I Ii Ii /1· 1!!1:111111 14.19.0 
~ 
S9.SS1 
... 
I 
l-l•19ht Avera43e 
Z AYeT"aQ• 
Viscosity Avera43• 
Z + 1 Av•r•A• 
Hz / Hu • 
~ 
24299 
28624 
24299 
49348 
1.178 
; 
~ 
111nut•s 
1e 11 
10 
Numoer Av•ra43• 21'!511 
Disoers1v1ty 1.130 
Intrinsic Viscosity 0.000 
Peak Hol ~•143ht 23131 
H:~l / l1w 2.031 
12 
eurn .• I 
I Q" i 
. . I 
se 1 
;e -, 
I 
t:~t -
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Frequency Distribution of ~olecular Weight Components 
Column TSK 2000 
23,000 M.W. Fraction 
Ret. time Mol. Wt. Cum. % Slice area 
5.500 52169 1.002 20658 
5.600 45397 2.201 38042 
5.700 39829 4.579 75479 
5.800 35219 9.280 149182 
5.900 31377 17.156 249970 
6.000 28155 28.219 351078 
6.100 25437 41.601 424715 
6.200 23131 55.774 449774 
6.200 21163 68.936 417723 
6.400 19476 79.643 339809 
6.500 18021 87.245 241242 
6.600 16760 92.082 153521 
6.700 156c2 94.931 90412 
6.200 14701 96.565 5186~ 
6.:000 13856 97.513 30091 
7.000 13108 98.087 18216 
7.100 12443 98.446 11371 
7.200 11848 98.682 7505 
• 
APPENDIX XIV c 
HPLC-GPC Profile of the 17,450 M.W. Fraction 
Column TSI: 2000 
683HH2 
~cou1s1t1on m•t~cc 
un 1 ts 
Ct".anne.I. 
Rur. time 
InJecuon uo.l.ume 
Ir.terr:a.I. star.o•ro 6mt 
Mooe 
1 
... '•"' 11 on 
Oescnption 
CCLOt·ll'<E: TSK 200CSi-l VI 
p.72? 
13.345 
!: 
94.113 
~3.667 
l 
13.Z.S.:. I 
0 
Weic:iht Auerac:ie 
Z A~era'3e . 
Viscosity Auer•'3• 
Z + 1 Auer•'3• 
H:z: / Hw 
6 
4/~/96 
gagtsZEv2 
2COug 
l 
l 
i:.oc• n'\1n 
20 uL 
Ar.alus1 s 
REvo:;.o 
Detector UV 205 
19116:4~ 
Ouant1t•t1on methcc 
S11stem numoer 
V1iil 
Total inJect1ons 
Samele rate 
SillYlple ~ount 
Scale factor 
Resoonse factors 
Channel to calibrate 
~·~-::s,CO~ 
l 
3 
1 
2 PH sec 
SOL1.iANT: Nii2S04 0, :M CCTEC~E:.JF: w 20: 
I 
17559 
19439 
17559 
27466 
1.107 
; 
!: 
---------
• 
9 9 10 11 
M1nute:r 
iw I I 
11 1 :~1 
t: 
k 
r 
1iil l 11 Jl!!!,l1 L 
10 Minute!' 
NumOer Au•r•'3• 
Oispersau1ty 
Intrinsic Viscosity 
P•ak Hol Wea ght -
H:z:+l / Hw 
16106 
1.090 
0.000 
16760 
1.564 
~~j 
so 
70 
60 
!:ll 
40 
~o I 
2e 1 
10 ~ 
I 
1, 
cum :, I 
"'' -I 
90 1 
::-e i 
I 
60 1 
~13 i 
·~ ., I 
"0 -I ~ I 
"', 
I 
1£1 ; 
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APPENDIX XIV c 
Frequency Distribution of Molecular Weight Components 
Column TSK 2000 
17,450 M.W. Fraction 
Ret. time Mol. Wt. Cum. % Slice area 
5.500 52169 0.168 2862 
5.600 45:397 0.367 7100 
5.700 39829 0.752 13742 
5.800 35219 1.288 19158 
5.900 31377 2.099 28954 
6.000 ")Q, C'C' '--•w-.1 3.590 53240 
6.100 2=437 6.459 102451 
6.200 23131 11.489 179593 
6.300 21163 19.265 277679 
6.400 19476 29.794 375964 
6.500 18021 42.395 449951 
6.600 16760 55.834 479893 
6.700 15662 68.605 456014 
6.800 14701 79.392 385161 
6.900 138=6 87.432 287099 
7.000 13108 92.744 189697 
7.100 12443 95.974 111748 
7.200 11848 97.523 58888 
7.300 11312 98.332 28893 
7.400 10826 98.718 13771 
7.500 10382 98. 903 • 6632 
7.600 9974 99.001 3486 
APPE~DIX XIV d 
HPLC-GPC Profile of the ~5,000 M.W. Fraction 
Column TSK 2000 
G83HH3 
Uri 1 t~ 
ci-.ann•.i. 
lnJ•~t1on 
P.un t!m• 
lnJ•ct1on uolum• 
lnt•rr1al 5tanoarc amt 
Mode 
Ve-rs1on 
O••cr Ult l on 
COLOrl"E: TSK 20002:~ VI 
9e.239 
90.239 
51.273 
1~.308 
e 
Solvent NazS04 0.5 M Detector DV 205 
1.8: :::3: :38 
9a9u2602 
C!OCug 
1 
1 
1:.00 min 
::O UL 
An1olvs1s 
RE"J03.0 
Q~antltilt!On ~•t"OC 
S·;~t•m numt.er 
l.'1 •l 
iota! l~l•~~~~n• 
S•mp.le T'ate 
Samo le amount 
S::al• factor 
P•soons• factors 
Chann•.i. to ca.i.1brat• 
SOLVANT: Na~S04 0, :0'1 
5 
M1nut•s 
19 
11 
9a~tsZ.OOZ 
1 
4 
1 
Z p•r sec 
cum :: j 
Q0 -
. i 
so ~ 
I 
i'O i 
E-£1 J I 
! 
5() i 
40 ; 
I 
:;o i 
I 
~e ~ 
I 
10 
CUID ~; I 
~0 i 
sol 
ro j 
:: ~ 
I 
"~~ -
:o -
Hl -
I 
Hol•cular We19ht Oi5tr1bution Averages 
Wei9ht Auera9e 
Z Auera9• 
Vi•cos1ty Auera9e 
Z + 1 Average 
H::: / t'\.I 
14~44 
17701 
14644 
43573 
1. 20!' 
Number Average 
Oi•oers1u1tY 
lntr1ns1c Viscosity 
P•ak Mo! We19ht 
H:+l / t'\.I 
136!'!' 
1.069 
o.ooo 
13856 
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APPENDIX XIV d 
Frequency Distribution of Molecular Weight Components 
Ret. time 
5.700 
5.800 
5. '.?00 
6.000 
6.100 
6.200 
6.300 
6.400 
6.500 
6.600 
6.700 
6.800 
6.900 
7.000 
7.100 
7.200 
7.300 
7.400 
7.500 
7.600 
7.700 
7.800 
7.900 
Mol. Wt. 
39829 
35219 
31377 
28155 
25437 
23131 
21163 
19476 
18021 
16760 
15662 
14701 
13856 
13108 
12443 
11848 
11312 
10826 
10382 
9974 
9594 
9239 
8902 
Column TSK 2000 
15,000 M.W. Fraction 
Cum. % 
0.354 
0 .541 
0.806 
1.160 
1.692 
2.650 
4.455 
7.669 
12.944 
20.739 
31. 093 
43.400 
56.464 
68.875 
79.384 
87.331 
92.686 
95.953 
97.770 
98.722 
99.130 
99.408 
99.509 
Slice area 
4030 
6616 
9370 
12558 
18805 
33930 
638i5 
113782 
186710 
275864 
366484 
435626 
462415 
4392E1 
371957 
291302 
189518 
115641 
64329 
33707 
16566 
7665 
~c:.,~ 
..;-..it -
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APPENDIX XIV e 
HPLC-GPC Profile of the 1,3,300 M.W. Fraction 
Column TSK 2000 
0 S3HH4 
~cau1s1tion m•tnoa 
units 
Char.n•.I. 
In J •c ti on 
"un t 1m• 
JnJ•Ct1on 1.10.l.um• 
lnt•rna.1. stanaard amt 
l"toa• 
1.,••r~1on 
~•scr1pt1on 
CCLCl'JNE: TSK 2000S .. VI 
83.916 
12.C04 
=: 6 
83.916 
47.928 
11.949 
e 
Solvent NazS04 0.5 M Detector UV 205 
sasu2602 
200u9 
1 
1 
1~.oo min 
20 UL 
Anah·s1s 
RE'.103.0 
7 
19150126 
Cuant1tat1on m•thod 
Svst.in numb•r 
Via.I. 
Tota.I. inJ•ct1on~ 
SMno.I.• rat• 
Samo.I.• amount 
Sea.I.• factor 
R•scons• factors 
Chann•.I. to ca.l.ib~at• 
9•9tsC:6C2 
1 
OE:ECTEUR: lN 20:5 
8 
Plinut•s 
5 
PlinutH 
9 1e 
( 
11 12 
CUlll :; I 
90 ., 
I 
60 ~ 
I 
70 i 
i 
60 1 
"'0 ...: 
: . .J 
- I 
' 
Ho.1.ecu.l.ar We19nt Oistr1but1on Averages 
Wei9nt Aueraqe 
Z Au•rage -
Viscosity Aueraqe 
Z + 1 A1.1era9e -
Hz / Hw 
12843 
1:5804 
12843 
42894 
1.231 
Number Avera9• 
Oiso•rs1111ty 
lntr1ns1c Viscosity 
P••k Ho.1 W•19nt 
H:~l .' Hw 
11841 
1.os::s 
o.ooo 
12443 
:LZ40 
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APPE~DIX XIV e 
Frequency Distribution of Molecular Weight Components 
Column TSK 2000 
13,300 M.W. Fraction 
Ret. time Mal. Wt. Cum. % Slice area 
6.000 28155 0.601 6119 
6.100 25437 0.857 9842 
6.200 23131 1.263 15619 
6.300 21163 1.939 21:'C.QIC' ...,)- _, "'111 
6.400 19476 3.128 45718 
6.500 18021 5.191 79370 
6.600 16760 8.549 129147 
6.700 156€2 13.608 194574 
6.800 14701 20.603 269035 
6.900 13856 29.484 341548 
7.000 13108 39.815 397349 
7.100 12443 50.881 425614 
7.200 11848 61.815 420512 
7.300 11312 71.792 383733 
7.400 10826 80.231 324561 
7.500 10382 86.831 253857 
7.600 9974 91.617 194094 
7. 700 9594 94.814 122956 
7.800 9239 96.792 76045 
7.900 8902 97.910 43028 
8.000 8581 99.47! 21764 
8.100 8271 98.731 9814 
8.200 7970 98.836 4044 
8.300 7674 98.867 1174 
APPENDIX XIV f 
HPLC-G?C Profile of the Jl,750 M.W. Fraction 
Column TSK 2000 
683HH~ 
Acqu1s1t1on m•thoo 
Un 1 ts 
Cl".ann•.l 
Ir•J•ctton 
Run tim• 
In J •cti on 1o10J. um• 
lnt•rna.l standard amt 
Moo• 
• ... ••rt1on 
C'•scr1ption 
COLOt.Jt~E: TSK 2000Si-l VI 
69.062 -
6 
69.Bt.2 
48.075 
9•~ts26~2 
C:OOus 
1 
1 
1:.oo min 
20 uL 
7 
Detector UV 205 
19:07:09 
Ouantitat~on m•thoo 
S11stl'l!I numo•r 
Vial 
Total 1nJ•ct1ons 
SamoJ.• rat• 
Sarno!• a1noun t 
Seal• factor 
R•srions• factors 
Chann•.l to calibrat• 
ga~u26u2 
1 
6 
1 
2 P•r s•c. 
DETEC7EWR: UV 20~ 
6 - 9 10 11 
l'linut.s 
12 
euna % I 
:: i 
:~ ~o ~ 
I 
•e 1 
30 1 
~0 1 
11.css ~======-=:::::i=---='~======:=!:~==--...;;;;..~:;;;:;~!O!!!!:.i.' _1_0...;j 
e 
l-l•iQht A1o1eraQ• 
Z A~ua43• . 
Viscosity A1o1era43e 
Z + 1 A1o1er a43e 
Mz / Mw 
11393 
14026 
11393 
44130 
1.231 
5 
l'ltnutH 
10 
Number A1o1erase 
Oisoers11o11ty 
Intrinsic Viscos1ty 
Peak Mo.l We143ht 
H:z:+l / l'tJ 
1066~ 
1.060 
o.ooo 
10826 
3.873 
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279 
APPENDIX XIV f 
Frequency Distribution of Molecular Weight Components 
Column TSK 2000 
11,750 M.W. Fraction 
Ret. time Mol. Wt. Cum. % Slice area 
6.200 23131 0.806 11050 
6.300 21163 1.241 16166 
6.400 19476 1.901 24476 
6.500 18021 2.897 36957 
6.600 16760 4.412 56231 
6.700 15662 6.679 84120 
6.800 14701 9.929 120599 
6.900 13856 14.374 164942 
7.000 13108 20 .159 214659 
7.100 12443 27.256 263349 
7.200 11848 35.477 305065 
7.300 11312 44.451 332978 
7.400 10826 53.717 343850 
7.500 10382 6~.801 337085 
7.600 9~74 71.258 313800 
7.700 9594 78.709 276507 
7.800 9239 84.921 230495 
7.900 8902 89.822 181876 
8.000 8581 93.450 134593 
8.100 8271 95.966• 93370 
8.200 7970 97.581 59920 
8.300 7674 98.552 36030 
8.400 7382 99 .114 20873 
8.500 7091 99.416 11217 
8.600 6800 99.569 5681 
~. 700 6507 99.641 2662 
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HPLC-GPC Profile of the lp,400 M.W. Fraction 
Column TSK 2000 Solvent ~azS04 0.5 M Detector UV 205 
663HH6 
~cou1s1t1on m•tMod 
l,tr, • t ! 
C!"l•nn•J. 
Ir,,•~~1on 
Run t1m• 
In;•c~1on "'olum• 
:n~•"nal star.dare amt 
Moc• 
O•scr1pt1on 
' co:..OtlNE: TSI'. 2COCSl-I l..'l 
69.3!4 
~E.'.eee 
10.646 
6 
69.3:54 -
39.859 
10.362 
e 
4/~/66 
:agu.<cC.2 
cOOug 
l 
l 
15.00 min 
20 uL 
Analysis 
RE\.'03.0 
Cuent1tat1on m•tMoo 
S·1tt•m "•UrT•tl•r 
•,,,11 a.l. 
Total inJ•ct1on1 
Sarr.oJ.• rat• 
Soi:noJ.• amount 
Seal• fector 
P•soons• factors 
Chann•l to cal1crat• 
i 
SOL•JANT: Na2S04 o.~ oe::e:crnF: w 20s 
------- y 
· \ 
1.,; Ir 
i 
I . ~ . I~ I i I• 
.J i I· 
, 1 
1il11 
11111 
g 
lhnui•s 
5 
Minu\•s 
11 • 
9 10 11 
Hl 
1c 
CUDI }; I 
I 
:: ~ 
70 i 
60 1 
!0 .., 
I 
4e l 
:: ~ 
10 
Mol•cular W•19ht Oistritlut1on A"'•rag•s 
W•1cirit A"'•raQIP 
Z A~ua9• -
Viscosity A"'•r•9• 
Z + l A"'•ra9• 
Hz / l"'Y 
10220 
14933 
10220 
63165 
1.461 
Numb•r A"' •r •9• 
Oiso•rs1v1ty 
Intrinsic Vi1co1ity 
P•ak Mol W•19ht 
Mz+l / """' 
9359 
1.092 
o.ooo 
9239 
6.190 
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HPLC-GPC Profile of the 9,000 M.W. Fraction 
Column TSK 2000 Detector UV 205 
69:3HH7 
Acau1s1t1on m•tnod 
Ur• I ~S 
ci-.ann•.L 
Ir·J•ction 
Pur. t 1m• 
In1•ct1on uo.Lum• 
Int•rna.L stanoard Amt 
Mooe 
V•rs1on 
Oescr1pt1on 
COLQ:'.,.~E: TSK 2000$1.1 VI 
65.3~4 
37.611 
9.Ec9 
6 
65.3!4 
37.610 
s.sc.c. 
e 
4/9./96 
c:ac:a2G02 
200ug 
1 
1 
l~.oo rr.1n 
20 uL 
1~:40142 
o~ant1tat1cn metnco 
s.stem numo•r 
Via.I. 
Tota.I. in1ect1cns 
Samo.I.• ritt• 
SA.'Tlo.l.e amount 
Sea.i.e factor 
Resoonse factors 
ChanneJ. to caJ.ibrate 
ga<:t!2G02 
l 
e 
1 
2 per s•c 
DCTECTEUR: t.JJ 20~ 
5 
l'hnut•s 
10 
12 
Ho.Lecu.Lar We1gnt Oistr1bution Auerages 
Weight Auerag• 
Z Auerage 
Viscosity Auerag• 
Z + 1 Au•rag• 
Mz / '"'-' 
!.'074 
14647 
9074 
787!.'1 
1.614 
Numoer Auerage 
Oisoersivity 
Intrinsic Viscosity 
Peak Mo.L W•ight 
Mz~l / '"'-' 
8187 
1.1oe 
o.ooo 
76i4 
S.683 
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APPENDIX XIV h 
Frequency Distribution of Molecular Weight Components 
Column TSK 2000 
9,000 M.W. Fraction 
Ret. time Mol. Wt. Cum. % Slice area 
Oo'+UU l. ::::i'+ l'b 0.671 10111 
6.500 18021 1.043 18331 
6.600 16760 1.642 29495 
6.700 15662 2.51~ 43013 
6.800 14701 3.699 58342 
6.900 13856 5.214 74603 
7.000 13108 7. 063 91098 
7.100 12443 9.2::4 107~::2 
7.200 11848 11.799 12540:: 
7.300 11312 14.709 143338 
7.400 10826 18.010 162612 
7.500 10382 21. 749 184225 
7.600 9974 25.920 20::46a 
7.700 9594 30.546 2-:"_0__,0 -1-"--
7.800 9239 35.661 251962 
7.900 8902 41.262 27::944 
8.000 8581 47.318 298347 
8.100 8271 53.750 316880 
8.200 7970 60.409 328089 
8.300 7674 67 .103 329742 
8.400 7382 73.60$ 320286 
8.500 7091 79.663 298499 
8.600 6800 85. 034 264603 
8.700 6507 89.528 221412 
8.800 6212 93. 058 173993 
8.900 5915 95.642 127314 
~.000 5614 97.393 86275 
9.100 5310 99.491 54074 
9.200 5004 99 .122 31097 
9.300 4696 99.457 16490 
9.400 4388 99.619 7994 
9.500 4080 99.685 3249 
APPENDIX XIV i 
HPLC-GPC Profile of the.7,400 M.W. Fraction 
Column TSK 2000 
6S:3HHS 
~eou111t1on m•thoa 
Un 1 t I 
Cnar.n•l 
Ir., •et1 on 
Run tim• 
In)•c:non uolum• 
Int•rnal stanoaro •~t 
' Hoo• 
V•r11on 
O•sc:r1pt1on 
COLOt,,.~E: TSK 2000S;.< VI 
57.ess 
9.299 
6 
57.SSS 
33.516 
9.144 
e 
Detector UV 205 
4/9/S.6 191~7:32 
cia-=~ 12€02 
z:>o'"s 
l 
1 
l:.oo min 
20 uL 
Anal1111 s 
RE'J03.0 
Quant1tat1on m•thod 
S111t1tm numc•r 
VtaJ. 
Total 1n1•ct1ons 
Samc.i.• rat• 
Samol• amount 
ScaJ.• factor 
R•1oons• factors 
Cnann•J. to caJ.ibrat• 
9a9a.<:Gu:2 
1 
9 
l 
2 p•r s•c 
SOLVANT: Na2S04 O,:M OE'TEC7EUR: lN 205 
7 8 
l'hnut..s 
5 
M1nut•s 
9 10 11 12 
lEl 
Hol•cular W•19ht Oistr1but1on Av•r•9•s 
W•19ht Av•r•<g• 
Z Av•r•C1• 
Viscosity Av•ra<g• 
Z + 1 Av•r•C1• 
Hz / ~ -
7459 
10166 
7459 
45552 
1.:;63 
Numcer Av•ra9• 
Oi11P•ruv1ty 
Intr1ns1c Visco111ty 
Pea11. Hol W•19ht 
H:+l / ~ 
6:S48 
1.139 
o.ooo 
5~l:S 
i::.1ne 
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Frequency Distribution of Mo~ecular Weight Components 
Ret. time 
6.700 
6.800 
6.900 
7.000 
7.100 
7.200 
7.300 
7.400 
7.500 
7.600 
7.700 
7.800 
7.900 
8.000 
8.100 
s.200 
8.300 
8.400 
8.500 
8.600 
8.700 
8.200 
8.:?00 
9.000 
9.100 
~.200 
9.300 
9.400 
9.500 
9.600 
9.700 
9.800 
9.900 
10.000 
10.100 
Mol. Wt. 
15662 
14701 
13856 
13108 
12443 
11848 
112.12 
10826 
10382 
9974 
95?4 
8902 
8581 
8271 
7970 
7674 
7392 
7091 
6800 
6507 
6212 
5915 
5614 
5310 
5004 
4696 
4398 
4080 
3775 
3473 
3177 
2898 
2609 
2340 
Column TSK 2000 
7,400 M.W. Fraction 
Cum. % 
1.093 
1.630 
2.380 
3.384 
4.671 
6.250 
8.119 
10.270 
12.687 
15.355 
18.249 
21.357 
24.664 
28.179 
31. 910 
35.891 
40 .157 
44.741 
49.663 
54.906 
60.41t 
66. 071 
71.738 
77.230 
82.357 
96.918 
90.765 
93.818 
96.082 
97.630 
98.612 
99 .182 
99.489 
99.643 
99.715 
Slice area 
18368 
27368 
38251 
51204 
65603 
80503 
95265 
109636 
123239 
135999 
147558 
158441 
168574 
179186 
190234 
202938 
217494 
233707 
250898 
267269 
280662 
288549 
288882 
279995 
261398 
232500 
196150 
155629 
115427 
78910 
50039 
29092 
15620 
7654 
3654 
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HPLC-GPC Profile of the .?.100 M.W. Fraction 
Column TSK 2000 Detector UV 205 
663HH9 4/10/.86 91"2~110 
~c:ul!ltion m•t~OC 5agt!2€02 
~Rlt! 200ug 
c~-~n•i 1 
I~;•c~:on 1 
Run t:m• 1:.00 min 
:ft;•ction volum• 100 uL 
!nt&•n•L st•no•rc •mt 
~oc& An•ivsis 
V&•s1on REV03.0 
C'&sc'!'1ption 
Ouantitat1Cft m•thoo 
S·1st•m n11mc•r 
'Ji al 
Total in;•c~ions 
S.mple rat• 
Samole 9/llount 
Scai• l'actor 
R.•sc.onte factors 
Chann•l to calibrate 
cc~:·i~~E: TSI< 2000Si-I VI SOL'JANT: Na2S04 0, :iH 
:"0.632 
f~.091 
7 
;"0.6JZ 
8 
l'linuus 
I 
I, 
I 
10 11 
~-~t!~C~: 
l 
1 
1 
2 P•"' sec 
CUlll % I 
90 ~ 
eo ~ 
I 
l~ 
;e -I 
60 ., 
I 
.. 0 -
:e ~ 
I 
zo ~ 
i 
~: ~ IS.1~ -l-------~~~~..L~~--~~~~~~================== 
e s 
Minut•s 
10 
Holecular Weight Distribution Av•rages 
Weight Averag• 
Z Av•rage 
Viscosity Av•r•g• 
Z + l Av•rag• 
H: / """ 
ssoo 
12381 
ssoo 
7'9276 
2.:.s1 
Numoer Averag• 
Oisp•rsiuity 
Intrinsic Viscosity 
Peak Ho! W•igl'\t 
H:+l / ~ 
436S 
1.:!60 
o.ooo 
4080 
14 .:!32 
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Frequency Distribution of Mol~cular Weight Components 
Column TSK 2000 
5,100 M.W. Fraction 
Ret. time Mol. Wt. -.SuE!. % Slice area 
7.200 11848 1.194 5031 
7.300 11312 1.340 6950 
7.400 10826 1.540 9322 
7.::oo 10382 1.815 12864 
7.600 9:<74 2.200 18021 
7.700 9594 2.735 25060 
7.800 g23~ 3.465 34135 
7.900 8902 4.427 45042 
8.000 8581 5.669 58118 
8.100 8271 7.223 72736 
8.200 7970 9.120 88789 
6.300 7674 11.396 106489 
8.400 7382 14.063 124847 
s.::oo 7091 17 .140 144012 
8.600 6800 20.628 163203 
E:.700 6507 24.519 182095 
8.8(:0 6_,-, ..::. ..... 28.813 200~90 
8.:?00 5915 33.526 220549 
9.000 5614 38.689 241671 
9.100 52.10 44.333 264142 
9. 2C'0 5004 50.475 • 287425 
='.300 4€?6 57. 055 307980 
9.400 4388 63.940 322186 
9.500 4080 70.861 322~30 
~.600 3775 77.438 307796 
~.700 3473 63.264 272680 
9.800 3177 89.041 223552 
9.900 2888 91.684 170503 
10.000 2609 94.294 122131 
10.100 2340 96.100 84541 
10.200 2084 97.349 58441 
10.300 1843 98.240 41712 
10.400 1616 98.984 30150 
10.500 1406 99.342 21419 
10.600 1213 99.655 14667 
10.700 1037 99.670 10048 
10.800 878 99.982 5234 
10.900 737 100.000 651 
Column TSK 2000 
2162 
~ccu111t:on m•t~oc 
Uni ts 
C!",ann•l 
lnJ•c:t1on 
~.un t 1m• 
InJ•C:t1on uolw:ne 
Int•Tnal stencaTa amt 
Moc• 
Version 
C••se~1ot1on 
CCLO"-'~E: TS!'. ZCGGSW VI 
~.!14 -
e 
APPENDIX XIV k 
HPLC-GPC Profile of CY 216 
Detector UV 205 
11117127 
c:•c:ni:602 
200uc: 
1 
1 
1:;.00 min 
C:O uL 
Analo,11 I I 
R£1.'C~.O 
Ouant1tat1on m•t~oc 
5)1 st em r1 UlroC•r 
V1a.1 
Total 1n)•ct:on1 
Samo.Le Tat• 
S9moJ.e amount 
So:a.1• factor 
Re1c;ons• factc.rs 
Chann•.1 to c:a.11brat• 
9ac:u.260Z 
1 
1 
. 
. 
CE7£C'r£UJ:.: W 20:; 
:s 
Minutes 
CUlll :~ I 
,0 ., 
I 
ee l 
iEl "'I 
60 ~ 
"'0 J 
- I 
413 j 
30 i 
20 ... I 
Hi i 
Molecular W•asht OistT1bution AY•T•~•s 
W•19ht Auera9• 
Z A11eTa9e 
Viscosity AU•T•S• 
Z + 1 AYeTa9e 
Mz / Mw 
:5399 
10799 
:5399 
86436 
2.000 
NumbeT AY•T•S• 
Disp•TsiYi ty 
IntT1nsic Viscosity 
.P•ak Ho.1 Weight 
H:+l / Mw 
4391 
1.230 
o.ooo 
4308 
16.010 
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Frequency Distribution of Molecular Weight Components 
Column TSK 2000 
CY 216 
Ret. time Mol. Wt. Cum. % Slice area 
7.000 13108 0.631 30S8 
7.100 12443 0.753 3870 
7.200 11848 0.931 5638 
7.300 11312 1.173 7665 
7.400 10826 1.497 10281 
7.500 10382 1.944 14168 
7.600 9974 2.522 18341 
7.700 9~~4 3.2:s 22317 
7.900 9239 4.175 29087 
7.900 8902 5.309 35941 
8.000 6581 6.688 43749 
8.100 8271 8.~44 52500 
8.200 7970 10.315 62478 
S.300 7674 12.636 73598 
8.400 7382 1:5.336 85610 
8.500 7091 18.444 98543 
8.600 6800 21.987 112363 
8.700 6507 25.~99 127194 
8.800 6-, "") .::._ .... 30 • .:l.67 141668 
8. '.?00 5915 35.398 156348 
9.000 S614 40.758 169946 
9.100 5310 46.507 • 182283 
9.200 5004 :2.=65 192086 
9.300 4696 58.914 198146 
9.400 4388 65.104 1994.:J.3 
9 .. 500 4080 71.244 194673 
•9. 600 3775 77.037 183686 
9.700 3473 82.302 166?35 
9.800 3177 EG.850 144189 
9.:?00 28:::8 :?O • i;o S 1:=-·157" 
10.000 2609 :-2.~so ?4226 
10.100 2:::40 95.809 706.?0 
10.200 2084 97.402 50~22 
10.300 1843 98.481 34203 
10.400 1616 99.187 22386 
10.500 1406 99.610 1 "'':"OIOI .,j~-·-
10.600 1213 99.829 6956 
10.700 1037 99.893 2043 
10.800 878 99.917 740 
10.900 737 100.000 2637 
APPENDIX XV 
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APPENDIX XV a 
HPLC-GPC Profile of the unfractionated heparin 
Column TSK 3000 
Acau1!1t1on m•thoc 
ur. i ti> 
ci-.ar.n•l 
lr.Ject:cr. 
Run tim• 
! n J •e~ ion voL1me 
Internal stancard amt 
ModE 
Ver!ion 
Descrii;.tion 
COLOMNE: TSK 3000S:..I l I l 
47,041 -
31..071 
47.041 
., 
Solvent NazS04 0.5 M Detector UV 205 
4/10/96 
s•?~s3303 
2~0 ... 9 
l 
l 
::.cc min 
2C UL. 
i:.rial ·;sis 
PE'JOZ. 0 
19149:1::: 
Ouantitation ~•thod 
S·;stem numoer 
'Jial 
Total inJee~:~ns 
S.:.mclli rat& 
Samele .vnour.t 
Sea.le factor 
P.1uponse factors 
Channel to calibrate 
Replace 
1 
SOL'JANT: NA2S04 0, SM DETEC7EUR: VJ 205 mn 
r r 
Jo" 6.0 s.5• 9.0 
1e 
I 
90 -: I 
S0 1 
I 
70 ~ 
I 
60 -; 
I 
I 
~o -
I 
40 -' 
10.0 10.5 
CUhl ;, 
?9 : 
so -: 
"linute~ 
Molecular Weight Distribution Averages 
Weight Average 
Z Averaq• 
Viscosity Average 
! Z + l Average 
Hz / r-t.i 
i:z,;.;o 
14877 
12660 
1702:3 
1.17~ 
Numcer Average 
Dispersivity 
Intrinsic Viscosity 
Peak Mol Weight . 
Mz+l / f't.I 
100S9 
1.261 
o.ooo 
14011 
1. :34~ 
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Frequency Distribution of Molecular ~eight Components 
Ret. time 
:i.uuu 
: .:.ci:i 
~-~OG 
~.400 
.. ,.. .. 
-·--~ 
: . i·~C 
~.'.?CIC 
b.:.cc 
6.:.:o 
6.:~c 
6.::o 
6.400 
6.!~IJ 
e . .;«;:: 
6. ;-.;c 
6.aoc 
6. :·:c 
7.:JCO 
- .... ,. , ..... ... 
7.2:C 
I• .;1,,. U 
7.41JO 
7.!:C 
~ .~.:c 
7.:i:o 
7. :?00 
s.occ 
e.:.:c 
e . .:~c 
e.:;,c 
s • .;:;o 
e. !·:ei 
s.cc~ 
e. ;-.: : 
a.:~:: 
:- .. .::c: 
!I' ........ 
=' • .:: : 
:1 • .::= 
~ • .;.:.o 
?. :-oo 
~.soc 
?.:?00 
10 .uOO 
lO .:.:o 
io • .:oo 
:.o.:oo 
10 ... oo 
10.!00 
10.uOO 
10. 700 
10.zoo 
10.:?00 
11.000-
ll.!OO 
ll.~00 
Mol. Wt. 
44432 
41E=O 
~74!'32 
3!4~$ 
21oa7 
'6ea7 
~!:GE 
24~Z,4 
23!46 
ZZ6Z7 
~!i€Z 
2C~,j~ 
zo:.7:. 
H 14::! 
1Ei34 
lEQG.: 
17'1Z:! 
16co: 
16Zl0 
1!6!! 
1!07? 
14!.~3 
140:.:. 
li4?9 
12='£'6 
1~~·::4 
1ZC2~ 
l!'!il? 
11054 
10GZ7 
10177' 
?7::4 
?2:?~ 
ESG? 
S447 
&o::: 
:c~.; 
__ ,..._..,, 
. -....-.;:. 
~7J! 
!J.;:-
:oo:: 
40_;0 
43.;3 
403l 
~730 
3442 
3167 
2?0:5 
2G5G 
2420 
21?8 
1?!0 
17?4 
1612 
1443 
Column TSK 3000 
Unf ractionated heparin 
Cum. % 
0.039 
a.on 
O.J?:> 
CJ .1::. 
0.2Z6 
0 .::::: 
0.473 
0.6!!' 
o.e~:: 
l.~E7 
1.!~! 
z.o,:i 
4.:.c.; 
:.204 
6.4!~ 
i.~:6 
!'.i!:' 
11.a~= 
14.~~4 
1;.z::: 
20 .4'!:> 
~/ •' c.-. 
~!. ;-3:: 
!?.?!t 
4'3.~~~ 
47.:?£': 
~: . .:c;: 
~=-~~' 
~~.:_44 
6,.~~~ 
6:.:-.:~ 
oc.:-:? 
7:. .c.;;! 
74.~i!:: 
~::.~~c 
=~.~~: 
S'~ • .:s: 
::ao • .::.:. 
!'7 .01: 
S'7.0?2 
~9.Z~!l 
98. ;;;;1 
98.969 
S'~.!S9' 
~!.3~Z 
99 • .;97 
~~.616 
9!.:'46 
99.97: 
100.000 
Slice area 
--7~7- -
976 
16.;: 
'44Z 
3431 
4831 
63!3 
6437 
106.;? 
1 ""'"'Q 16;;.;; 
21::'.70 
,6:03.l 
31!26 
3?0l:. 
471 E7 
:67C:~ 
601:::: 
8li42 
97160 
1:::'~' 
12~71 :l 
14:4~~ 
1:~S~! 
1 ~~ .. ., .. 
ieo:.:..; 
le,;.;.::; 
1s:;c6 
ie1:::: 
17~·~1;: 
l66.S~!' 
l6iC::? 
1:~7.:.7 
14~S7? 
13'.:"C! 
130::~4 
1Z2~~3 
!! ~St:l 
..... -.- .. 
•lol• -.:i ... 
:.c:::.;~3 
-·:--·": 
.,;.:; : : . 
!3C':.! 
~==!·J 
47~=~ 
.1C:C:: 
~i:; .. eo 
::06a2 
24641 
1?134 
14004 
7396 
6113 
:s6o 
:~17 
• 
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HPLC-GPC Profile of the 23,000 M.W. fraction 
Column TSK 3000 Solvent Na2S04 0.5 M Detector UV 205 
683H1 4/10/86 
~~:~1s1t:on metnoc 3~~t!3203 
Un1~s ~OOus 
Ch~nn•l l 
l~Jec::on l 
~un time 1e:.oo min 
lnJec:t1on vol~me 20 uL 
lr.terr.•.l £tar.ca.re: ~t 
Moc:e Analvs15 
Ver!1on RE!O!.O 
Desc:r1pt1on 
19:04153 
Ou~nt!~~t:on ~•,Mod 
$v!tem numoel" 
To~i.i. :n)ec:tions 
Same.lot "ate 
Samo l • .,.,,oun ~ 
S.::a.le f•c-:or 
Resoon!e f•c:tors 
Channel to calibrate 
9ag~£33C3 
l 
2 
1 
2 per sec: 
C~LCtlNE: TSK :;ooos:~ I I I SOL'.'ANT: NA2SC4 0, ~ OETEC7EUR: lJJ 205 mn 
SL e:11 
48.805 
l 
4.0 
si.e:11 .... 
10.0 Hl.S 
0 s 
Minute~ 
ia 
Molecular ~eight Distribution Averages 
Wei9ht Average 
i Z AV1l'ra9e 
Viscosity Av!l'rage 
Z + 1 Avll'ragll' 
Mz / l"\.I 
21691 
22527 
21691 
23509 
1.039 
Numoer Average 
Di spersivi tv 
Intrinsic: Viscosity 
Peak Mel Wtu ght 
Mz+l / l"\.i 
20354 
l.066 
o.ooo 
20945 
1.084 
' ~0 
' so i 
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Frequency Distribution of Molecular Weight Components 
Column TSK 3000 
23,000 M.W. Fraction 
Ret. time Mol. Wt. Cum. % Slice area 
5.200 39558 0.596 6522 
5.300 37438 0.863 9652 
5.400 354'.?t 1.190 11771 
S.500 33712 1.595 1461~ 
5.600 3202~ 2.135 19486 
5.700 30~7~ 2.947 29308 
5.800 ---01 ~'="~ "- - ' - 4.267 47E20 
5.:?00 
__ ,...f*"._ 
~.· c: =' ,' 6.421 776C:S. 
6.000 -.---- -::. .,..,~ 11:?647 c;.'.:·•:·C·,. 
- • i ~, 
6.100 2:.si.::= 14.520 172512 
6.200 ""4 C' ::: .. 1 c:. ·--. 20.~~3 232072 
6. 20 Ct 23'::4,,: 2:?.047 291993 
6.400 ~"'"='-="':·-c.._.,_._. 38.598 344543 
6.500 21.762 49 .122 37'.?~94 
6.600 20:?4:. C' ·=i 0. C' C' ....J- ._._;_ 3:?0422 
6.700 2017:. 70.197 36.?464 
6.800 1942':: 79.028 318577 
6.900 18734 85.910 248222 
7.000 18064 90.737 17414? 
7.100 17422 93.816 
• 
111061 
7.200 16205 95.654 66200 
7.300 16210 o- ..,., 0 -~·'""-- 38423 
7.400 156;::. '?7.3=.5 """"':·i::I~? c::.~- -'-
7.500 1507? c.- ..,~~ -1.' ._,, 144?2 
- -
APPE~DIX XV c 
HPLC-GPC Profile of the 17,450 M.W. fraction 
Column TSK 3000 Solvent NazS04 0.5 M Detector UV 205 
693H2 4/10/96 1~:21:37 
Acau1s1t1on metnoo ga?t!3303 
Ltn1a ;;oousi 
Channe~ 1 
!n3ec~;on l 
P.un nme l:.oo min 
In1ec~1on volume 20 uL 
Interna~ stanoaro amt 
Mooe Anal~s1s 
1Jers1on RE'J03.0 
Cesc!'1C:t1on 
COLOtl'JE: TSK 3000$!.-< I I I 
52.776 
1 
Ouant1tat1on methoo 
S·111 tem r.umcer 
V1a.l. 
Total 1n3ect1ons 
Sample rate 
S..-nole amount 
Sea.le f •c~or 
Re!pcnse- factors 
Channe.l. to calibrate 
.,,a~a3302 
1 
l 
OETEC7E1JR: IJ.J 2C:i mn 
I . 
I 90 ., I 
80 .J I 
70 ., 
i 
60 i 
I 
'.:'-1 -
I I I 2e ~ 
16.4139 ~...;._------~..;.;..;..;..;..;..;.;.,;1..;.;.l ..;..;.I .;..;..;.;;;;, ______ 1_0 1 
•.0 4.S S.0 
99.0631 
0 s Minutes 10 
Holecu.l.ar Weight Oistr1but1on Avera~es 
Weight Average 
Z Averac:ie 
Viscosity Average 
Z + l Average 
H:z: / Hw 
17348 
17996 
17~48 
19493 
1.032 
Number Avera<!!• 
Oisoersivi tv 
lntr1ns1c Viscosity 
Peak Ho.1. i..le1 ght 
H:z:+l / Hw 
16399 
l .OS9 
o.ooo 
1690:i 
l.066 
~UtD :. 
Q~ -
. - ' 
so ~ 
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Frequency Distribution of Molecular Weight Components 
Ret. time 
;) • :>UU 
5.600 
5.700 
5.800 
5.:?00 
6.000 
6.100 
6.200 
6.300 
6.400 
6.500 
6.600 
6.700 
6.800 
6.:?00 
7.000 
7.100 
7.200 
7.300 
7.400 
7.500 
7.600 
7.700 
7.800 
7.900 
8.000 
13.100 
8.200 
Mol. Wt. 
:3:3718 
32022 
30572 
2917'.? 
.-.-,-_c-
t!ld·.;l 
26c27 
2=::c:.a 
24~24 
235~6 
226~7 
21762 
2094'! 
2017"'1 
1S'42:. 
187S4 
18064 
17422 
16205 
16210 
15635 
1507:? 
14~~3 
14011 
13498 
12::?6 
12504 
12022 
11549 
Column TSK 3000 
17,450 M.W. Fraction 
Cum. % 
0.164 
0.268 
0.425 
0.620 
0.81S 
1.061 
1.286 
1.S74 
2.626 
4.060 
6.31:? 
14.904 
21. 740 
40.22~ 
50.97? 
61.7~8 
71.752 
80.280 
86.932. 
91.674 
94.759 
96.614 
97.660 
gs.226 
("4Q t::~C" 
-·-·-"--· 
Slice area 
2253 
4121 
62~? 
3227S 
~40:;=: 
20213? 
271824 
340~'.?4 
39S,?O 
427~19 
422733 
397504 
339211 
264~75 
1e::e30 
122665 
73806 
41585 
22505 
118S'6 
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HPLC-GPC Profile of the 15,000 M.W. fraction 
Column TSK 3000 Solvent NazS04 0.5 M Detector UV 205 
6S~H:3 4/10/86 19:~8:16 
Aeau1s1t1on method 9a9~s3303 
1Jn1 ts 200u9 
Channel l 
lnJeetion 1 
Run time l~.oo min 
ln1ection volume 20 u~ 
Internal stanoard 91llt 
Mooe 
Version 
Description 
Aniil'.'SlS 
RE'J03.0 
Ouantitation ~ethoo 
System n urnc;er 
Total lnJect10~~ 
Samele rate 
Semc.i.e 2mount 
Sca.i.e fac~or 
Response factors 
Channel to ca.i.icrate 
s•s~s~:?03 
1 
4 
1 
COLONNE: TSK 3000SW III SOL\.'A~JT: NA2S04 0, 5:-1 DE'iEC7EUR: lN 20~ mn 
87.592 
=52.116 
1\ 
I l 
· ..... , i 
90 ., 
60 J J i0 I 
6il ... I 
I 
so -
I 
413 
I 
?O -
I 2e I 
10 ... I 
I 16. 639 _.,_ _____ ii&illl ___ .......,--..;.~.;...".;...1.;..;. -===-------
4.0 
52. 116 ..J 
I 
' 
16.639 
0 
6.<l e..s ".0 Mir.utes 
s Minutes 
- ... , ·~ a.a 
Ho.i.ecu.i.ar Weight Distribution Avera9es 
We19ht Averase 
Z Averase 
Viscosity Averase 
Z + 1 Average 
Mz / """ 
15273 
16133 
15273 
17!'48 
1.056 
Numoer Auerase 
Oisoers1v1ty 
Intr1ns1c Viscosity 
Peak Mol ~~e1 ght 
H::+l /""" 
9,0 
14464 
1.0:56 
o.ooo 
1507!' 
1.17:5 
9.! 10.0 lt). 5 
cum .. 
i 
'?O -
I 
80 -
7:Y -
-': .. _, 
::J -
... "3 -
:.; -
,i(l .., I 
10 J I 
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Frequency Distribution of Molecular Weight Components 
Ret. time 
6.100 
6.200 
6.300 
6.400 
6.=oo 
6.600 
6.700 
6.200 
6.900 
7.000 
7.100 
7.200 
7.300 
7.400 
7.~00 
7.600 
7.700 
7.800 
7 . .?00 
S.000 
8.100 
8.200 
8.200 
e.400 
e.=eio 
.e. 60 0 
8.700 
~:.200 
2.900 
Mal. Wt. 
25568 
24524 
23546 
2262i 
21762 
20945 
20171 
19435 
18734 
18064 
17422 
16805 
16210 
15635 
1=079 
145;::s 
14011 
13498 
12996 
12504 
12022 
11549 
11084 
10627 
10177 
9734 
~2.?8 
S869 
Column TSK 3000 
15,000 H.W. Fraction 
Cum. % 
0.989 
l.161 
1.350 
1.598 
1.$461 
2.536 
3.486 
= .034 
7.478 
11.143 
16.356 
23.308 
31.942 
41.953 
52.6?0 
63.334 
72.058 
el.241 
67.572 
~2.093 • 
~= .082 
96.935 
98. 018 
~e.627 
98. $465 
99 .160 
??.221 
QC, ':·OO 
-- . -"-'-
Slice area 
5687 
6706 
7358 
9706 
14138 
22520 
36984 
60404 
Sl5382 
143035 
203423 
271280 
336915 
390649 
419002 
415348 
379441 
319326 
247071 
176417 
116658 
72261 
42284 
23751 
13208 
7602 
4730 
4223 
~C:~? 
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HPLC-GPC Profile of the 13,300 M.w. fraction 
Column TSK 3000 Solvent NazS04 0.5 M Detector UV 205 
683H4 
Accu1s1t1on met~oc 
Units 
Charin el 
lnJec~:or1 
Pun time 
lnJe~t1on volume 
Internal stancarc amt 
Hoce 
Ver:1or. 
Oesc~ 1 p t1 on 
COLOt.t•E: TSK 30 0 0 S>• I I I 
83.!53 -
se.037 
1 
I 
16.~~! 
4/10/66 1.9:5~:03 
=ac:its.2303 
206u9 
1 
1 
1:.00 run 
20 uL 
Analvs1s 
P.E'JO'?. 0 
Ouant1tat1on methoc 
S·Jstem nurncer 
Vial 
Tot al 11'• J •ct 1 on s 
Samele rate 
Samele amount 
Scale factor 
Resoonse factors 
Channel to calibrate 
9a9a3303 
1 
1 
2 per sec 
Reolace 
1 
SOLVANT: NA2S04 O,~ OETEC7EUP.: W 20:; mn 
.... 
.... 6.il 
~i 
- .. 
... w ~.0 
Minutes 
}: 
1 I 
11 
~ .. 
'•w 
y 
! ti 
I \ 
: I 11\ 
, .I. I 1111 
"I 
1 , I I, I 1 
• 8.0 a.~ 9.0 9.5 10.0 
i 
00 ..., 
~0 J I 
70 -
60 ~ 
\ 
~2 -: 
I 
4H -
i 
30 .. 
20 -
10 -
! 
10.! "·6 4.5 s.e 
SJ. 5;'.:l -; i:un % 
16.413 I 
' 
s 10 
M1nu~s 
Molecular We19ht Distr1but1on Avera9es 
We19ht Average 
Z Average 
Viscosity Average 
Z + l Avera9e 
Hz / l"W 
13707 
146c5 
13707 
16840 
1.070 
Numo•r Average 
Dispersivity 
Intrinsic Viscosity 
P•ak Hol Weight 
Hz+l / Mw 
13053 
1.050 
o.ooo 
13498 
1.~2~ 
90 -
S0 ~ 
; 
70 -
I 
60 -: 
I 
~o ""'. 
-'') -
:.) -
,;(' -
10 -: 
.........._ 
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Frequency Distribution of Molecular Weight Components 
Ret. time 
6.200 
6.300 
6.400 
6.500 
6.£00 
6.700 
6. eoo 
6.900 
7.000 
7.100 
7.200 
7.300 
7.400 
7.600 
7.700 
7.800 
7.900 
8.000 
8.100 
8.200 
8. 300 
e. 400 
s.::oo 
8.600 
8.700 
~. 800 
c.9oo 
:?.~!QO 
::: .. ::. 00 
Mol. Wt. 
24524 
23546 
22627 
21762 
20945 
20171 
19435 
18734 
18064 
17422 
162.0 5 
16210 
1563':: 
15079 
1453:3 
14011 
13498 
12996 
12504 
12022 
11549 
11084 
10627 
10177 
9734 
9298 
826? 
~447 
:::o 21 
762'1 
Column TSK 3000 
13,300 M.W. Fraction 
Cum. % 
0.988 
0.969 
1. 091 
1 .265 
1.515 
1.887 
2.451 
3.324 
4.680 
6.726 
9.707 
13.852 
19.316 
2€ .133 
34.160 
43.071 
52.402 
61.623 
70.220 
77. 821 • 
84 .152 
89 .125 
92.804 
95.371 
97.061 
98.113 
~8.742 
99.112 
Slice area 
1687 
3474 
7416 
10660 
1586? 
24065 
37260 
57836 
87265 
127161 
176a2s 
233074 
2.:10800 
342436 
380149 
398038 
3933:;4 
3615741 
324259 
270102 
212131 
156923 
10'.?535 
72062 
44901 
26219 
300 
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HPLC-GPC Profile of the 11,700 M.W. fraction 
Column TSK 3000 Detector lN 205 
68:3H5 
Acau1s1t1on metMoc 
Un 1 ts 
Cl":anne.i. 
lnJECtlOn 
P.un time 
InJecuon vol.ume 
Interna.i. stancaro amt 
Hoce 
Version 
Descr1pt1on 
CCLOt.NE: TSi'. 300CS._. I I I 
71.6';oS 
43.7:i2 
l 
4/10/86 
ga~~s3203 
200u'!I 
l 
l 
l~.00 mir. 
20 UL. 
Analvs1s 
RE')03.0 
20111146 
Ouant1tat1on m•thoc 
Svstem numoer 
Vi el. 
Total 1n)ect1ons 
Samol.e rate 
Samo.i.e amount 
Sca.i.e fac~:ir 
F.esponse factors 
Channel. to calibrate 
ga9a3303 
l 
6 
1 
2 per sec 
P.eolace 
1 
SOL'J~NT: NAZS04 0, !:1 CE!ECTEWP.: VJ 205 mn 
2e ~ 
I 
10 -: 
I 
4.0 
71.695 ~ 
s.e t-.s -.0 7.::: a.0 e.::: ~.0 3.::: 10.0 10.::: M1,.,1.1tes 
s Minutes 
Hol.ecular Weight Distribution Averages 
Weight Auer age 
Z Auerag• 
I Viscosi tY Auer age 
! Z + 1 AueraC1• I • 
H:z: / Hw 
120~1 
12937 
12091 
14501 
1.070 
Numb•r Au er ;,ge 
Oispersiui ty 
Intrinsic Viscesity 
Feak Hol W•i gnt 
H:+l / Hw 
11439 
1.057 
o.ooo 
11549 
1.!99 
:io -
i 
80 ..; 
70 -: 
I 
60 ~ 
I 
so -: 
I 
301 
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Frequency Distribution of Molecular Weight Components 
Ret. time 
6.:500 
6.600 
6.700 
6.800 
6.?00 
7.000 
7.100 
7.200 
7.200 
7.400 
7.500 
7.600 
7.700 
7.800 
7.900 
s.ooo 
8.100 
8.200 
8.300 
9.400 
8.500 
8.600 
8.700 
s.200 
8.900 
.~. 0 0 0 
9 • .:.oo 
9.200 
9.300 
9.400 
9.500 
Mol. Wt. 
21762 
20945 
20171 
19425 
18734 
1S064 
leo05 
1i:~10 
15J5~= 
1::o7? 
14528 
14011 
124?8 
12996 
12=04 
12022 
11549 
11084 
10627 
10177 
9734 
886? 
E447 
8021 
7624 
722~: 
64-l7 
6071 
Column TSK 3000 
11,750 M.W. Fraction 
Cum. % 
0.908 
1.025 
1.220 
1.:12 
1 . :?34 
2.542 
3.412 
4.649 
6.389 
8.783 
11.982 
16.107 
21.227 
27.~21 
34.300 
41.936 
49 • .956 
58.042 
65.866 
73.132 
79.602 
95.104 
00 """"0 
··- • ...,;-1,,.J 
Q "":i 0'7,.· -'-·-'~ 
~7.1.29 
98.207 
CIC ~""C 
- .._ • W'•··~ 
99.492 
99.632 
• 
Slice area 
2535 
4759 
7988 
11885 
17246 
24821 
3~506 
50502 
71004 
97712 
1~0595 
168360 
209014 
249146 
284492 
311628 
327256 
330085 
319358 
296613 
264093 
224581 
181 S24 
1 "'0.0:.0~ ---~-
100E7:: 
4 -:-·::ioc: 
_._ - ·.J 
26:;7:; 
1601 ;' 
9846 
5745 
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APPENDIX XV g 
HPLC-GPC Profile of the 10,400 M.W. fraction 
Column TSK 3000 
693H6 
AcQu1s1tion methoo 
Un1~s: 
Ch11nne.L 
lnJect1on 
Run time 
ln3ect1on Yo.Lume 
lnterna.L st11no11ro amt 
Mooe 
Version 
Oescr1pt1on 
COLONNE: TSK 3000S'-' 111 
~.643 
Solvent NazS04 0.5 M Detector UV 205 
4/10/96 
9al'?t£3303 
200u9 
1 
1 
:.!.CO min 
20 uL 
Ana.Lys1 s 
RE'J03.0 
20129133 
Ou11nt1tat1on method 
S·1stem number 
V1 ill 
Tota.L inJect1ons 
Samp.Le r11te 
Sample amount 
Sca.i.e factor 
Resoonse f11ctors 
Channe.L to c11.Libr11te 
9119ts3303 
1 
7 
l 
2 per sec 
SOL'JANT: NA2204 0, :H OETECTEUP, : l>J 20 ~ mn 
.... I •• I 
90 1 
80 i 
70 J 
60 ' 
I 
~0 1 
40 ., 
i 
"'0 ., 
w i 
29 i 
1~.844 .,l-__ .;.. ______________ ..,..r;;;,.s;;;;;;.;...;.;..:..:..:.~..:..:..w..;..:..:..:..;..!..J..:..~.:.:::== ..... --10 .... i 
4.0 4.~ 5.0 
73.442 i 
44.643 
-
I 
s.s 6.~ 6.5 ~.a 7.s e.e e.~ 
l"llnuws 
e 10 
Molecular We19ht Distribution AYera9es 
Wei9ht AYera9• 
Z Auera9• 
Viscosity Auera9e 
· Z + 1 Auer119• 
Mz / Mw 
1o=ss0 
11638 
10,88 
14,9=s 
1.119 
Number AYer119e 
Oispersiui ty 
Intr1ns1c Viscosity 
Peak Mo.L We19ht 
Mz+l- / ~ 
9692 
1.094 
o.ooo 
9734 
1.379 
10 • ., 10. ~ 
cum:; I 
~0 1 
se ~ I 
~a -~0 ~ 
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APPENDIX XV g 
Frequency Distribution of Molecular Weight Components 
Ret. time 
6.500 
6.600 
6.700 
6.800 
6.900 
7.000 
7.100 
7.200 
7.300 
7.400 
7.500 
7.600 
7.700 
7.800 
7.900 
8.000 
8.100 
8.200 
8.300 
8.400 
8.500 
8.600 
8.700 
8.800 
8.:?00 
9.000 
<9.100 
9.200 
9.200 
9.400 
?.:'.80 
:?.GOO 
9.700 
9.800 
9.900 
10.000 
Mol. Wt. 
21762 
20945 
20171 
19435 
18734 
19064 
17422 
1680= 
16210 
15635 
15079 
14538 
14011 
13498 
12996 
12504 
12022 
11549 
11084 
10627 
10177 
9734 
9298 
8869 
8447 
80 ::·1 
7624 
7223 
6831 
6071 
5705 
534:? 
5003 
4668 
4343 
Column TSK 3000 
10,400 M.W. Fraction 
Cum. % 
0.686 
0.761 
1.090 
l.38E: 
1.802 
2.38~ 
3.:. 66 
4.205 
~.e-13 
7.172 
11.74~ 
14.SOZ 
18.463 
22.761 
27. 697 
33.264 
39.382 
45.943 
52.810 
59,799• 
66. 656 
73 .181 
7~. :4:~ 
8'1 I 382 
88. 7~7 
92. 21 s 
~4. so 3 
S'6'. 61 = 
97 I 20 s 
:?8. 544 
:?8.981 
9~.230 
99. 375 
99. 463 
Slice area 
1815 
36:?~ 
631.C 
9896 
14618 
20648 
28415 
33376 
51071 
64334 
81536 
100856 
1242.24 
150091 
179982 
211313 
242711 
273710 
300777 
322598 
337635 
343108 
337665 
320217 
293397 
215057 
170169 
127094 
89082. 
=~.6~.;; 
26~·:16 
2.1468 
12242 
7155 
4318 
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APPENDIX XV h 
HPLC-GPC Profile of the 9,000 M.W. fraction 
Column TSK 3000 
693H7 
Ac:quis1t1on metnod 
Un 1 ts 
Ch•nr.e.l 
lnJec:t1on 
Run time 
lnJec:tion vo.lume 
Interna.l stanoarc amt 
Mooe 
Version 
Description 
4/10/96 
9a~a3303 
200ug 
1 
1 
lS.00 m1n 
20 uL 
Ana.LYS1tl 
REl.'03. 0 
Detector UV 205 
2014~113 
Quant1tat1on metnod 
S·1 st em n umcer 
Via.L 
Tota.L inJeetions 
Samo.Le rate 
Sample amount 
Sc:a.Le factor 
Resoonse fioc:t~r• 
Channel to c:a~ibrate 
ga~u3303 
1 
8 
1 
2 per sec: 
COLON'~E: TSK 3000SW III SOL1JANT: NA2S04 O,~ OE7ECTEUR1 l.JJ 205 mn 
74.308 -
44.971 
1 
90 j' 8  
70 
60 
50 1 
40 ~ 
30 ~ 
~: 1 
15.634 1 .+---:~~~~~~--...,:;;,;...::~:...:..i..:....:...:..;:...:..:...:~.%ll~...;....:_;,...l...:...l..!...W.:i::::::o........; 
i 
4.0 4.S 
74.308 -
44.924 
15.541 
0 
.
1
, Ho.lecu.lar Loole19ht 
Weight Average 
Z Average 
: Viscosity Average 
: Z + 1 Average 
Hz / l1w -
5.~ 5.S 6.0 6.5 7.0 f'linui.s 
- .. , ,. , a.a s.s 9.0 
8999 
1006:5 
8999 
11 :so:s 
1.118 
I I 
s Mtnuws 
10 
Number Average 
Oispersivity -
Intrinsic Viscosity 
Pea11. 1'10.1 Wei gnt 
Hz+1 / l1w 
8079 
1.114 
o.ooo 
7624 
1.278 
10.0 10.5 
-:~j 
S0 I 
70 i 
60 1 
I 
~c ~ 
I 
40 1 
30 ~ 
' I 
20 ~ 
I 
10 "". 
. I 
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APPENDIX XV h 
Frequency Distribution of Molecular Weight Components 
Ret. time 
6.500 
6.600 
6.700 
6.800 
6.'.?00 
7.000 
7.100 
7.200 
7.300 
7.400 
7.500 
7.600 
7.700 
7.800 
7.:?00 
8.000 
8.100 
8.200 
8.300 
8.400 
8.500 
8.EOO 
2.:-00 
;:;,~OO 
8.~00 
'.?.000 
?.100 
:?.200 
:?.200 
:? . ..:.o 0 
9.::oo 
9.600 
9.700 
9.800 
9.900 
10.000 
10.100 
10.200 
10.300 
10.400 
Mol. Wt. 
21762 
20945 
20171 
19435 
18734 
18064 
17422 
16805 
16210 
15635 
15079 
14538 
14011 
13498 
12="96 
12504 
12022 
11549 
11084 
10627 
10177 
St734 
c;..-,oc 
- '-- 'wJ 
8869 
8447 
8031 
7624 
7222 
6C:~:l 
i~447 
6071 
5705 
5349 
5003 
4660 
4343 
4031 
3730 
3442 
3167 
Column TSK 3000 
9,000 M.W. Fraction 
Cum. % 
0.156 
0.195 
0.262 
0.370 
0. 54'.? 
0. :?17 
1.207 
1.75<1 
2.483 
3.413 
4.563 
~.~4~ 
7.56? 
9.447 
11. 5:?8 
14.043 
16.802 
l'.?. 899 
23.36'.? 
27.242 
31. 54~. 
36.307 
41.5~0 
47.180 
52.210 
5:?.480 
6~.834 
72.070 
77.962 
S3.2~1 
87.869 
~1.!.83 
94.407 
96.423 
97.768 
98.623 
99.147 
99.464 
99.660 
99./~R 
Slice area 
1170 
2143 
---~ .. ,.., 
.:> ( ... .:; 
5946 
9859 
14847 
21516 
301'.?1 
4026? 
51345 
63535 
76~2~ 
89€71 
103739 
118753 
135058 
152327 
171037 
1916~1 
213685 
237874 
26274'.? 
287299 
312:36 
"91~~~ecQ 
.:>-----
346Z46. 
350?23 
34.!.!06 
32::236 
2?4315 
252E5~ 
205090 
15~940 
111353 
74252 
47259 
28910 
17507 
10842 
7n&:CI 
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APPENDIX XV i 
HPLC-GPC Profile of the 7,400 M.W. fraction 
Column TSK 3000 
683HS 
Accu1s1tion methoo 
Un I~ s 
Channe.i. 
InJect:on 
Run time 
!nJecti.on 'JOl.ume 
Internal. stanoarc 6/nt 
Mooe 
'.Jers1on 
Oescl"1pticn 
COLONNE: TSK JOOOSW III 
68.8S6 
42.019 
~-~· l 
I 
I 
i 
Detector UV 205 
4/10/86 ~l.:02:00 
:.;,?~'S2303 
200J'i' 
1 
. 
.. 
~naj,·,;Sl $ 
f<.E'.'02 .C 
Cuant:tat1on met~od 
S11stem number 
Vi6.i. 
Totiol 1nJections 
S&mol.e rate 
S-oJ.e ilTIOUnt 
Sc:a.l.e factor 
l'esoonse fectors 
Channel. to c•l.i~rate 
'i'a~•s.;::o:: 
l 
SOL';ANT: NA2S04 0, ~ DE!EC~EWR: 'J.J 20S mn 
~-~ 6.e ~-~ ~.e Minutes 
5 
Minutes 
7.S S.0 a.s 9.0 9.S 
10 
10.ti 10.:: 
cum ;; 
'?0 ... J se i 
/t.l -
I 
6e ; 
I 
Mol.ecul.ar We19ht Distribution Mvera9es 
: Wei 9ht Aver as• 
' Z Average 
Viscosity Average 
Z + l Average 
Mz / Mw 
7285 
8927 
7285 
1156? 
1.~2s 
Number Average 6009 
Disoersivity l.~12 
Intrinsic Viscosity 0.000 
Peak Mol. Weight S349 
M:+l / Mw 1.!88 
.· 
307 
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APPENDIX XV i 
Frequency Distribution of Molecular Weight Components 
Column TSK 3000 
7,400 M.W. Fraction 
Ret. time Mol. Wt. Cum. % Slice area 
7.100 17422 0.938 8758 
7.200 16805 1.053 12252 
7.200 16210 1.360 1756>3 
7.400 1563~ 1.784 24177 
7.::oo 15079 "" "jC'-c:. .... ..., .;; 32486 
7.600 14522 3. 078 41352 
7.700 14011 "':) o--...., • - 1.:; 51044 
7.eOO 13498 ~. 06? 62:~3 
7.900 129:?6 6.382 74923 
8.000 12504 7.921 877:?5 
6.100 12022 9.687 100783 
8.200 11549 11. 680 113733 
8.300 11084 1~.901 12E709 
8.400 10627 16.340 1392.1.4 
8.500 10177 18.::088 151063 
8.600 9724 21.842 162829 
8.700 9~'=i0 "'-- .. 24.90= 1747S4 
8.800 886? 2E .180 186890 
8.900 8447 31.688 200203 
e.coo 8031 3~.45S 215141 
9.100 7624 3?.:2e 
• 
2322.;;.s 
9.200 7223 4-: 0:,")1 
-. - "-- 25070E 
9.300 6831 48.664 270E'38 
9.400 6447 53.744 2898153 
9.500 6071 59.109 306177 
.9. 600 5705 64.661 316787 
9.700 534? 70.265 3197:?3 
9.eoo 5003 i=.747 3122~2 
9.?00 46158 80.904 2.?4271 
10.000 4343 85.541 264606 
10.1.00 4031 6:?.495 22=656 
10.200 3730 92.679 181708 
10.200 3442 ~5.0:?6 137925 
10. 400 3167 96.808 97668 
10.500 2905 97.939 64517 
10.600 2656 98.654 40844 
10.700 2420 99.096 2=211 
10.800 2198 99.384 16413 
10 . :?00 1990 99.591 11831 
APPE~DIX XV j 
HPLC-GPC Profile of the 5,100 M.W. fraction 
Column TSK 3000 
683H9 
Accu1s1t1on m•tnoo 
Ur11 t ! 
c~.an,.,e.l. 
In J e-c ~ 1 on 
P;..:r1 t:.me 
!n~ec~1on volume 
!nte~n•l stanc•rc amt 
Mooe 
1;e,..'! 1 on 
De'!C!' l ct: on 
cc:..ONNE: TSi', 3000SW I I I 
-1.0 
:"Q.S61 .., 
43. ~~5 
We1<;1ht Average 
'Z Average 
Viscosity Average 
Z + 1 Average 
M:: / Mw 
Detector tN 205 
4/10/86 21:19:39 
9agu3303 
~o o ... c: 
l 
l 
:.~.oc min 
l:JW UL.. 
Anal·J~l ~ 
RE'i03.0 
.. .. 
-·-
4741 
61:50 
4741 
~871 
1.zg7 
Ouant1tat1on metnod 
Sy!tem numce~ 
'Ji al 
•otai.i. 1nJeet1ons 
Samele rate 
Same.le amount 
S::ol.e- f ac~cr 
Peic.onse fac~ors 
C~annei tc calibrate 
9ag~s:=:31J3 
1 
10 
1 
2 per sec 
Reo.l.ace 
l 
DETEC7EUR: V~ 20~ mn 
e.: 7".~ 
M1r1Uti':i 
- .. 
··-
~ 
MinutE·S 10 
Number A1,1eraqe 
Di sper<s1v1 ty -
Intr1n<s1c Vi<sco<s1ty 
Peak Mo.l. W•1gnt 
M::+l / Mw 
3867 
1.Z26 
o.ooo 
3442 
2.0S2 
C<om :; 
.:..~ -
• • I 
i 
so -: 
! 
:.: -
-'·; -
:.) -
309 
310 
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Frequency Distribution of Molecular Weight Components 
Column TSK 3000 
5,100 M.W. Fraction 
Ret. time Mal. Wt. Cum. % Slice area 
t.uuu J. ~Ubq 0.230 1084 
7.100 17422 0.2:;9 1345 
7.200 16805 0.2~4 1657 
i.300 16210 0.243 2266 
7.400 15635 0.397 2540 
7.500 15079 0.466 3244 
7.600 145::.s 0.542 ~c,..::-~ 
....,"'-'--
7.700 14011. 0.6::~ 4229 
7.800 12496 0.737 4664 
7.900 12996 Q OC'O . '-'""""'-' 56QS' 
8.000 12504 1.010 i12:; 
s.:.oo 12022 1.199 es:::2 
8.200 11549 1.444 11461 
e.::oo 11084 1.764 149?1 
8.400 10627 2.189 1~910 
8.500 10177 2.7:: 26461 
S.600 g.734 3.4?3 34:;:;9 
8.700 9298 4.446 44622 
s. ~:o o 886.9 =.651 5i5•ll 7 
8.900 8447 7.150 70170 
?.000 8031 8.967 Ot::'l"':~.lt \.Jw\J._-r 
9.100 7624 11.146 • 102003 
? . .:c· o .,..,~~ ( c...-.- 12.706 11 :0962 
9.~co 6831 16.676 139053 
9.400 6447 20. 067 158717 
9.500 6071 23.8~0 178.975 
..:· .600 ~70~ 28.147 199285 
9.700 5349 22.864 220812 
:?.800 5003 ~2 .. 0 62 242315 
?.:?00 4'5C.C 43.77=: 267446 
:o.C:OG 4343 50.002 291=83 
10.lOO 4021. S6.626 212222 
1C1 • .:o 0 ·-=--:-~..-, 
- ' '-''-i 
~32. ~7~ ~~-:1 "':'O 
-'-• ---10.:=.oo 2442 ;";J,701 328987 
l G . .lO 0 3167 ~"";' .388 313003 t I 
10.!SOO 2;•05 83.330 278186 
10.600 2656 88.246 230130 
10.700 2420 Sl2.034 177325 
10.800 2198 94.805 129697 
10.900 1990 Sl6.779 92411 
11.000 1794 98.198 66459 
11.100 1612 99.237 48638 
11.200 1443 100.000 35710 
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Appendix XVIa 
Intravenous Time Course Determined Using the Anti Xa Assay 
Concentration ~;/~lJ 
4.00 
3.00 
2.00 I 
a:ss F= 
o.eo E 0 70
0.60 
0.50 
0.40 
o .3o I 
0.20 
8:AS 
0.08 
0.07 t-
o .06 r-
0.05 r-
0.0<4 1-
0.03 
0.02 
n - 5 
0.00 
* 
' + ' 
50.00 
' 
--W-- M. W. 23, 000 
· +· M.~. 13. 300 
--ff-M.W. e. 100 
' 
' 
' 
' ~~~~~: 
100.00 lSO. 00 
Time (rainutesJ 
200.00 
312 
Appendix XVIa 
Intravenous Time Course Determined Using the Anti Xa Assay 
Ccnc•ntrat1on ~;/ml) 
4.00 ~ 
I 
:::: ~ 
a.oo ~ g:~g ~~ 
0.60 
o.eo 
O.AO I 
0.30 I 
0.20 r 
8:62 b 
o.oa t-
o. 07 t-
0. 06 t 
0 .OS 
0.04 
0.03 
n • 5 
-M- Nat 1Ye Hacar 1n 
· +· CY 216 
• 
o. o 1 __ _.._ ___ -..J------1....----1----L 
o.oo 50.00 100.00 150.00 200.00 
Tlme (minutes) 
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Appendix XV!b 
Intravenous Time Course Determined Using the Anti Ila Assay 
Ccncantraticn ~g/mll 
I 
4.00 i-
i 
3.00 I-
I 
I 
2.00 ~ 
; . 
I 
j 
~.00 ~ 
u.90 !-
0. BO :...... 
0.70 ;.._ 
0 .so r-
o.eo ~ 
0.40 +--
i 
I 
0.30 i-
i 0.20 t-
i 
l 
s:as ~ 
o.oa F 
0.01 r 
0. 06 r-
1 
0 .05 r-
0 .04 ~ 
o.o3 L 
I 
I 
! 
0.02 t-
i 
~ .. 
I ' 
I * \ \ 
.... 
'~ ' 
'. ' \ ·~ \,. '\ 
'\+\ 
~-. \ 
\ . \ \ •\ 
' 
-"*- 23. 000 M. W. 
·+· i3.~00 M.W • 
-+i-5,100 M.W. 
. \ 
' 
' \ 
\ 
\ 
. ' 
' 
. ' 
\ 
\ 
I 
\ 
. \ 
' 
'\ 
'\ \ 
\ 
\ ., 
' \ 
\ 
\ 
\ 
'\ 
., 
.\ 
\ 
\ 
\ 
' \ 
\ 
j n .. s 
0. 01 l _ _._.l ___ _,_l __ J 
\, 
\ 
\ 
0.00 50.00 100.00 150.00 
Time (minutes) 
• 
~ 
200.00 
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Appendix XVIb 
Intravenous Time Course Determined Using the Anti !Ia Assay 
Concentr1t1on ~g/ml) 
I 
4.00 r-
1 3.00 L..-
1 
I 
2.00 L 
' a.oo !-0:~8 t: 
0.70 ~ 
0.60 ~ 
0.50 ~ 
I 
0.40 r 
I 
0.30 i--
1 
i 
I 
0.20 ~ 
i 
I 
I 
I 
8: AS t: 
0. 08 r-
0. 07 t-
0.06;..... 
0 .05 r--
0.04 r 
' 0.03 ~ 
I 
i 
0. 02 j--
'"""'*""-Native Hspal"1n 
· +· CY 216 
•• 
+ 
1 n - 5 
0. 01 .... 1--'-----~------']'--_ 
0.00 50.00 100.00 150.00 200.00 
T1:ne (minutes) 
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Appendix XVI c 
Intravenous Time Course Using A Dilute Prothrombin Time Assay 
Cancant~stian Cug/ml) 
' l 4.00 ~ 
I 
3.00 L.-
1 
I 
2.00 r 
I 
i a .co~ 
~ 
\ 
~ 
k 
· ...... 
-
~'\_, 
,,, 
--*- 2:3. 000 M.W. 
• +• ~:3. 300 M. W. 
~-5.100 M.W. 
.90 !""'9 
0.80 ~ 
0.70 !-
0.SO i 
o.5o I 
0.40 ~ 
\\~ 
,, 
. 
I 
o.~o ;,...._ 
l 
0.20 !--
I 
i 
I 
8. iO :...... .09 ~ 
0.08 ~ 
0. 07 !-
0. 06 r-
0. 05 r 
0.04 i 
. 
0 .03 :-
I 
0. 02 :-
' 
n • 5 
: L 
0. 0 !l ._ -4-------
0.00 50. 00 
\\ 
\\ 
\\ 
\ 
', \ 
\ 
\ \ 
\ \ \ \ 
\ \ 
• 
\ \ 
\ \ 
\ \ \ \ 
.. 
\ \ \ . 
\ \ 
\ \.: 
' '\~ 
-'* i00.00 i50.00 
Time (minutes) 
200.00 
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Appendix XVI c 
Intravenous Time Course Using A Dilute Prothrombin Time Assay 
Ccncentret1cn (u;/mll 
L 4.oo I 
3.00 r-
. 
! j 
2.00 r 
' I 
I 
LOO !:: 0.90 . 
o.so ~ 
0.70 r-
0.60 r-
t o.so ;-
' 0.40 I-
i 
0.30 r-
, 
0.20 r-
l 
I 
8. iO I-• 09 -0.08 ;_.. 
0.07 t 
O.OB I 
o .oe 1-
0 .04 L 
I 
0.03 !.-
1 
I 
I 
0.021 
·, 
* \'\ 
'\ + 
'\ 
\ 
\ 
\ 
~ 
" \ 
--*-Native l-fepal"1n 
· +· CY 216 
' 
' \ 
' 
. . 
+ 
UI -s o.o! ·---~---L ___ L _J, __  
0.00 50.00 i00.00 ~50.00 200.00 
Time (minutas) 
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Appendix XVI d 
Intravenous Time Course Using the Fibrinopeptide-A Assay 
Concsntration (ug/ml) 
, 
4. 00 i--
3. 00 ~ 
I 
2.00 t-
1 
I 
l 
1.08 t-0 .9 ~ 
o.ao ~ 
0.70 t--
0.SO I 
o.so r-
o .40 ;-
I 
0.30 ! 
I 
0.20 l 
I 
J 
l 
l 
8:6B F 
0. 08 .--
0. 07 r-
0.06 ~ 
0 .05;..... 
0. 04 r-
' 
o.os ;.._ 
I 
I 
0. 02 I--
I 
! 
\ 
' \ \ 
\ 
' \ 
-*"'- 23, 000 M.W. 
· +· i3, ~00 M. W. 
-*-5, 100 M.W. 
' 
' 
' 
' * 
\ 
\ 
'\ 
\ 
\ 
' 
\ 
\ 
\ 
+ 
• 
~ 
\ 
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Appendix XVI d 
Intravenous Time Course Using the Fibrinopeptide-A Assay 
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• 
Appendix XVIIa 
Subcutaneous Time Course Determined Using the Anti Xa Assay 
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Appendix XVIIa 
Subcutaneous Time Course Determined Using the Anti Xa Assay 
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Appendix XVIIb 
Subcutaneous Time Course Determined Using the Anti IIa Assay 
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Appendix XV II b 
Subcutaneous Time Course Determined Using the Anti Ila Assay 
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Appendix XVII c 
Subcutaneous Time Course Using A Dilute Prothrombin Time Assay 
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Appendix XVIIc 
Subcutaneous Time Course Using A Dilute Prothrombin Time Assay 
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Appendix XVIId 
Subcutaneous Time Course Using the Fibrinopeptide-A Assay 
Concentrat1an (ug/mll 
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Appendix XVI Id 
Subcutaneous Time Course Using the Fibrinopeptide-A Assay 
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APPENDIX XVIII 
• 
M.W. 
Parameter 
Weight 
Average 
z 
Average 
Viscosity 
Average 
Z+l 
Average 
MZ/ZW 
Number 
Average 
Dispersity 
Peak MW 
MZ+l MW 
IDLECUIAR WEIGH!' PROFILE OF TFST HEPARINS 
23,000 17,450 13,300 9,000 5,100 CT 216 
24,299 17,558 12,843 9,074 5,500 5,399 
28,624 19,439 15,804 14,647 12,381 10,799 
24,299 17,558 12,843 9,074 5,500 5,399 
49,348 27,466 42,894 78,791 78,276 86,436 
1.178 1.107 1.231 1.614 2.251 2.000 
21,511 16,106 11,841 8,187 4,365 4,391 
1.13 1.09 l•.00 1.10 1.26 1.23 
23,131 16,760 12,443 7,676 4,080 4,388 
2.673 1.654 3.340 8.683 14.232 16.010 
Hepar.!.n 
12,487 
14,877 
12,487 
17,023 
1.175 
9,275 
1.34 
13,108 
1.345 
~ 
~ 
~ 
H 
H 
w 
w 
0 
APPENDIX XIX 
• 
APPENDIX XIX 
Recovery of Fractions from Gel-Filtration Procedure 
Fraction Molecular Weight % Recovered 
I 23,000 5.0 
II 17,450 14.5 
III 15,000 11. 5 
IV 13,300 13.0 
v 11,750 12.5 
VI 10,400 11. 0 
VII 9,000 9.0 
VIII 7,400 • 10.0 
IX 5,100 2.0 
Total Recovery = 88.5 % 
Percent recovery was calculated by comparing the gravimetric 
yield of each fraction to the anticipated recovery of starting 
material. The percent of each fraction represents the percent 
of the total recovery. 
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APPENDIX XX 
• 
APPENDIX XX 
Comparative Potency of Various Heparin Fractions 
Agent APIT PI' Heptest Anti xa Anti IIa FPAGT 
0:2* 0:2* DJ** IC50+ IC50 IC50++ 
23,000 2.5 10.0 1.5 1.25 1.0 0.38 
17,450 2.0 11.0 1.1 1.25 1.1 0.70 
13,300 1.5 11. 7 0.7 1.20 1.2 0.70 
9,000 2.4 >20 1.0 2.65 2.0 1.20 
5,100 6.5 >20 2.0 6.20 6.25 7.50 
CY 216 2.5 >20 1.25 4.60 7.6 7.45 
Heparin 1.3 20.0 1.20 1.25 0.8 0.5 
* The concentration required to produce a doubling of the 
baseline time values. All values represent ug/ml concentrations. 
** The concentration required to produce a tripling of the 
baseline time values. All values represent ug/ml concentrations . 
• 
+ The concentration required to produce a 50 % inhibition 
in the activity of factor xa and IIa respectively. All values 
represent ug/ml concentrations. 
++ The concentration required to produce a 50 % inhibition 
of control FPA generation. All values represent ug/ml 
concentrations. 
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APPENDIX XX! 
• 
• 
A Comparison of Unfractionated and IJ::M Molecular Weight Heparin 
Heparin IJ::M Molecular Weight Heparin 
Molecular Weight 
Distribution 1,000 - 40,000 1,000 - 15,000 
Mean Molecular t Weight 12,500 5,000 Anti Xa/IIa 
Ratio 1.0 )> 2.0 ~-
Relative USP g 
Potency 
----
< Heparin 
Effect on Platelet 
.Aggregation < Heparin 
Half life 30 min. 60 min. 
Bleeding tendency < Heparin 
w 
w 
°' 
APPENDIX XXII 
• 
Apperdix XXII 
Description of HPI..C Elution Profile 
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Very slight changes in retention tiJne can cause large changes in the mean 
molecular weight of polymers. For this reason it is important to interpret 
molecular weight data determine:i by HPI.C relative to various parameters • 
• Peak Molecular Weight: In:Ucates the mlecular weight of the greatest portion 
of the elutirq material. 
Mz, K., an:! Mz•1: 'Ihese values are affected by variations in the high molecular 
weight reqion of the elutirq material. 'Ihus they characterize the high 
molecular weight o:xrponerrts. 
1-fn: 01aracterizes the low molecular W'eight portion of the elution curve. lb.is 
value is sensitive to a lorq tail of low molecular weight conp:ments. 
Dispersity: When the polymer is ~ of a wide ran;e of molecular weight 
components this value will be high. It indicates the ran;e of molecular 
weights in the material. 
* Taken from technical manual Waters 410 Chromatography 
system 
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